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General Introduction
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Figure 1. Model of the regulation of water permeability in renal collecting duct cells. Binding of 
vasopressin (AVP) to the V2 receptor (V2R) in the basolateral membrane activates adenylate cyclase 
(AC) and increases intracellular cAMP levels. This activates protein kinase A (PKA), which induces 
translocation o f AQP2 bearing vesicles to the apical membrane, rendering this membrane water 
permeable. In addition, cAMP can activate exchange protein directly activated by cAMP (Epac). Epac 
can increase cytosolic Ca2+, which may facilitate AQP2 translocation. cAMP signaling is abrogated by 
phosphodiesterase (PDE)-mediated degradation of cAMP. Epac might control PDE activity by 
inhibiting ERK5, which inhibits PDE. PKA also increases AQP2 synthesis by phosphorylation of the 
cAMP responsive element binding (CREB) protein and its binding to the AQP2 promoter. Possibly, 
Epac enhances AQP2 synthesis by inhibiting extra-cellular signal-regulated kinases 1 and 2. Water, 
entering the principal cell via AQP2, can leave the cell via constitutively expressed AQP3 and AQP4.
Introduction
Maintaining water homeostasis by controlling both the osmolality and intravascular 
blood volume is essential for terrestrial mammals to survive. Water is lost through 
breathing, sweating, defecation and urination, and is obtained through glucose 
metabolism, drinking, and urinary water conservation. While several of these processes 
occur autonomic in healthy individuals, body water homeostasis is tightly controlled by 
regulating both water intake (drinking) and urinary water excretion. Changes in 
intravascular blood volume are sensed by vascular volume- and baroreceptors, which 
regulate the release of the antidiuretic hormone arginine-vasopressin (AVP) (1). 
Changes in osmolality are sensed by osmoreceptors located within specific regions of 
the hypothalamus, the organum vasculosum lamina terminalis (OVLT) and the
8
Chapter 1
subfornical organ (SFO) (2;3). In states of hypernatremia these receptors are activated, 
which results in the sensation of thirst and subsequent water intake. Furthermore, 
neurons from the OVLT and SFO project to the supraoptic and paraventricular nuclei, 
where AVP is synthesized. These neurons project to the posterior pituitary from where 
AVP is released into the blood and sets out for the kidney where water excretion is 
governed (Reviewed in (2;4)). Approximately 90% of all water filtered by the 
glomeruli is reabsorbed constitutively in the proximal tubule and descending loop of 
Henle. Depending on the body’s needs, remaining water can be reabsorbed in renal 
collecting duct, defining the final urine concentration. The adjustment of water 
reabsorption mainly depends on the release of AVP. When reaching the kidney, AVP 
binds its vasopressin V2 receptor (V2R) in the basolateral membrane of principal 
collecting duct cells, initiating a signal transduction cascade that consists of activation 
of adenylate cyclase (AC) via the stimulatory G (Gs) protein, an increase in 
intracellular cAMP levels and activation of protein kinase A (PKA) (Fig.1). 
Subsequently, aquaporin-2 (AQP2) water channels are phosphorylated and translocated 
from intracellular storage vesicles to the apical plasma membrane, rendering this 
membrane permeable to water (5-8). Due to the increase in water permeability, water is 
able to pass the apical membrane passively through AQP2 along the osmotic NaCl and 
urea gradient and leaves through AQP3 and AQP4, which are constitutively expressed 
on the basolateral side of these cells. When isotonicity is restored, reduced blood AVP 
levels result in AQP2 internalization, leaving the apical membrane watertight again.
Activation of AQP2 translocation
Adenylate cyclase in the renal collecting duct
It is widely accepted that short-term AQP2 regulation, meaning AQP2 shuttling 
between intracellular storage vesicles and the apical plasma membrane, requires a 
functional AVP-AC-cAMP-PKA signaling cascade (Fig. 1). Upon V2R stimulation by 
AVP, membrane-bound AC is activated to synthesize cAMP from ATP. So far, nine 
mammalian AC isoforms have been identified. In the outer medullary collecting duct 
(OMCD), Ca2+-inhibitable isoforms AC5 and AC6  were detected by in situ 
hybridization (9). AC6  was found in principal cells, whereas both AC5 and AC6  were 
detected in intercalated cells. In inner medullary collecting duct (IMCD), AC2-7, and 
AC9 mRNA were observed by RT-PCR (10). So far, only AC3, a Ca2+-stimulated 
isoform, and AC6  proteins have been detected in IMCD (10). Their presence in 
principal cells suggests that one or both isoforms are responsible for the AVP- 
stimulated rise in cAMP. The contribution of each isoform to the cAMP increase, 




Activation of AC increases intracellular cAMP levels. Traditionally, the role of 
intracellular cAMP in AQP2 translocation was thought to be restricted to the activation 
of PKA. Previously, a novel target of cAMP was discovered, namely “the exchange 
protein directly activated by cAMP” (Epac) 1 and 2 (also known as cAMP guanine- 
nucleotide-exchange factor) (11). Epac1 and Epac2 activate specifically Rap1 and 
Rap2, monomeric G proteins of the Ras family, which are implicated in cellular 
functions like cell adhesion and cell-junction formation (reviewed in (12)). In addition, 
Epac has been associated with exocytosis, mitogen-activated protein kinase (MAPK) 
signaling, hormone gene expression, and phospholipase C-epsilon (PLC-e) activation 
(12). Recently, several studies demonstrated that Epac is also involved in the regulation 
of ion channel activity and, as such, Epac2 has been implicated in the release of Ca2+ 
from internal stores via ryanodine-sensitive Ca2+-channels (see also further) (13-16). 
Both Epac1 and Epac2 are highly expressed in kidney and might therefore be of 
interest in the regulation of AQP2. Yip provided the first evidence for a role of Epac in 
AQP2 regulation by demonstrating that activation of Epac with a specific agonist 
induces intracellular Ca2+ mobilization as well as AQP2 translocation (17). In both rat 
and human collecting duct, Epac1 is mainly located in intercalated cells of cortical 
collecting duct, principal and intercalated cells in outer medullary collecting duct 
(OMCD), and mainly AQP2-negative cells in IMCD (18). In contrast, Epac2 is mostly 
expressed at the apical and basolateral membrane in principal cells of cortical collecting 
duct, dispersed and apical in the OMCD, and in all cells of the IMCD (18). Possibly, 
both PKA-mediated phosphorylation and Epac-activated Ca2+ mobilization play a role 
in AVP-activated AQP2 translocation towards the apical membrane. To which extent 
this novel pathway contributes to the AVP-induced water reabsorption remains to be 
established.
Ca2+and A QP2-mediated water reabsorption
Ca2+ plays an important role in AQP2 regulated water reabsorption. While local 
increases in intracellular Ca2+ concentration are known to be of great importance for the 
fusion of vesicles with the plasma membrane (reviewed in (19;20)), the importance of a 
transient Ca2+ increase for AQP2 translocation is still controversial. AVP induces a 
transient increase in the intracellular Ca2+ concentration and sustained Ca2+ oscillations 
in microdissected rat OMCD and IMCD tubules (21-23). In perfused IMCDs, pre­
incubation with BAPTA, which buffers intracellular Ca2+, blocked the osmotic water 
permeability, indicating that intracellular Ca2+ is required for AQP2 membrane 
insertion (24;25). In addition, both ryanodine-sensitive Ca2+ stores and calmodulin are 
likely to be involved in the Ca2+-dependent translocation of AQP2, since ryanodine and 
calmodulin blockers were shown to inhibit AVP-mediated AQP2 trafficking and water 
permeability in IMCD cells (24). Lorenz et al., however, demonstrated that cAMP 
alone is sufficient to induce AQP2 shuttling, without the necessity of a cytosolic Ca2+
10
Chapter 1
increase in IMCD cells (26). Using Madin-Darby canine kidney (MDCK) cells stably 
transfected with AQP2 and stimulated with 1-desamino-8-D-arginine vasopressin 
(dDAVP), we found similar results (unpublished data). Combined, these data suggest 
that intracellular Ca2+, but not necessarily an AVP-induced increase in Ca2+, is needed 
for AQP2 translocation.
Phosphodiesterase in the renal collecting duct
Phosphodiesterases (PDEs) play an important role in the control of cAMP levels within 
specific cellular compartments. After its cAMP-induced activation and subsequent 
phosphorylation of PKA target proteins like AQP2, PKA signaling is abrogated by 
PDE-mediated cAMP degradation. The activity of PDE can have profound 
physiological effects because increased PDE activity was found to cause hereditary 
nephrogenic diabetes insipidus (NDI) in mice (27-29). Activated PKA directly 
phosphorylates and activates the PDE4D3 isoform, thereby confining its own activity 
(30;31). Additionally, activated Epac1 is able to inhibit extracellular signal-regulated 
kinase 5 (ERK5), which inactivates PDE isotypes, such as PDE3 and PDE4D3, thereby 
contributing to the control of cAMP signaling (32). The PDE superfamily consists of
11 gene families and several PDE transcripts are expressed along the nephron (33-35). 
In the collecting duct, the Ca2+- and calmodulin-dependent PDE1 and the cGMP- 
specific PDE5 were identified, as well as the highly expressed cAMP-specific PDE4 
(33).
During the last decade, it has become clear that intracellular cAMP levels are locally 
regulated, in which the so-called kinase anchoring proteins (AKAPs) play a crucial 
role. AKAPs bind PKA, PKA substrates, phosphatases, and PDEs, and due to their 
unique targeting domains, they target these proteins, and thus cAMP-induced signaling 
cascades to various subcellular compartments (reviewed in (36;37)). Indeed, in elegant 
studies, the Klussmann team identified AKAP185 as the important anchoring protein in 
AQP2 regulation in IMCD cells; because PDE4D was recruited by AKAP185 onto 
AQP2-bearing vesicles, AKAP185 and AQP2 were co-translocated to the apical 
membrane upon AVP stimulation, and the interaction between AKAP185 and PKA 
was abrogated by an increase in cAMP levels (38). Moreover, using fluorescence 
resonance energy transfer on a PKA phosphorylation-sensitive probe, they showed in 
vivo IMCD cAMP dynamics to occur on AQP2-containing vesicles.
The cGMPpathway
Formerly, AQP2 translocation was thought to be the result of cAMP increase only. 
However, compounds increasing cGMP levels, like the hormone atrial natriuretic 
peptide (ANP), nitric oxide donors, nitric oxide synthase substrate and cGMP 
phosphodiesterase inhibitors, also appear to stimulate AQP2 translocation to the plasma 
membrane (39;40). The exact pathway responsible for the cGMP-mediated AQP2
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effect, however, is not clear yet as it is unknown whether the activated cGMP-mediated 
protein kinase G (PKG) directly phosphorylates AQP2 and induces its translocation or 
whether the effect could be due to PKG- mediated PKA activation. Moreover, the 
physiological relevance of these findings remains unclear since the effects of an 
increase in cGMP (through ANP) in vivo are controversial. Some studies show that 
ANP inhibits AVP-stimulated water permeability and sodium reabsorption, whereas 
others do not (41-45). Consistently, ANP was demonstrated to inhibit AVP-induced 
cell swelling in primary cultured IMCD cells by reducing phosphorylation of AQP2 
and its localization in the plasma membrane (46). This effect was clearly reduced upon 
inhibition of PKG. In addition, Wang et al. demonstrated that ANP infusion induces a 
transient diuresis in rats (47).
Activation of AQP2 expression 
Hypertonicity
In addition to short-term AQP2 regulation, AVP also increases long-term AQP2 
expression in collecting duct cells, mediated through a cAMP-responsive element in 
the AQP2 promoter (48;49). However, recent studies reported that hypertonicity also 
increases AQP2 expression independent of AVP by activating two other pathways 
individually capable of increasing AQP2 transcription (50-52). First of all, 
hypertonicity activates the transcription factor tonicity-responsive enhancer binding 
protein (TonEBP) by increasing its nuclear targeting, transactivation, and transcription. 
Subsequent binding of TonEBP to the AQP2 promoter increases the transcription of 
AQP2 (52). Accordingly, TonEBP/NFAT5- deficient mice showed decreased AQP2 
expression (53). Secondly, activation of the nuclear factor of activated T cells c 
(NFATc) pathway can increase AQP2 expression in the collecting duct (51). A 
hypertonicity induced Ca2+ increase activates the protein phosphatase calcineurin that 
dephosphorylates NFATc. Subsequently, NFATc translocates to the nucleus to bind the 
AQP2 promoter and increases AQP2 transcription. Although both pathways 
independently increase AQP2 expression, cross-talk between these pathways might 
increases AQP2 expression even further (51).
MAPK signaling
Several studies also indicate a role for mitogen-activated protein kinase (MAPK) 
signaling in AQP2 transcription. The V2R is capable of both inhibiting and activating 
ERK 1 and 2 (ERK1/2) MAPK activity. In this context, inhibition of ERK1/2 
activation by V2R appears to be mediated by Gas and activation of PKA, whereas 
activation of ERK1/2 by V2R was shown to be independent of G-protein coupling but 
involves the recruitment of P-arrestin (54). Recently, the hormone insulin, which is 
known to play a role in renal water and sodium excretion, was shown to enhance AVP-
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induced AQP2 expression by increasing its mRNA levels (55;56). The effect of insulin 
on AVP-dependent AQP2 mRNA expression is mediated by both ERK1/2 and p38 
MAP kinase activation (55). Umenishi et al. demonstrated that inhibition of ERK 
blocked the AVP-induced AQP2 expression, whereas inhibitors of two other MAP 
kinases, p38 and JNK kinase, did not affect AQP2 expression, indicating a role for 
ERK in regulating AVP-mediated AQP2 expression (57). Interestingly, this ERK 
activation was induced by the Epac specific activator, 8CPT-2Me-cAMP. Together, 
these results suggest that AVP might initiate an alternative cAMP-Epac-ERK signaling 
pathway that contributes to the long-term AQP2 expression.
AVP-independent activation of AQP2-mediated water transport
While AVP plays a key role in the activation of AQP2-mediated water transport, there 
is emerging evidence for the existence of AVP-independent mechanisms, regulating 
both AQP2 trafficking and expression. Oxytocin has been demonstrated to induce 
AQP2 translocation, which could be prevented by blockage of the V2R, suggesting that 
oxytocin activates AQP2-mediated water transport via V2R signaling (58). It remains 
to be established, however, whether this also occurs at physiologically obtainable levels 
of oxytocin. Furthermore, in AVP-deficient Brattleboro rats, induction of 
hyperosmolality increased AQP2 expression and translocation, indicating the presence 
of an AVP-independent mechanism (59). Possibly, the hormone secretin might be 
involved in this. Secretin is a hormone traditionally involved in regulating the pH of 
duodenum content by controlling gastric acid release and bicarbonate secretion. 
Recently, however, it was found that secretin receptor knockout mice demonstrate mild 
forms of polyuria and polydipsia, as well as reduced levels of AQP2 (60). Also, in 
secretin receptor knockout mice, the effect of water deprivation on AQP2 translocation 
and expression was also clearly diminished. Moreover, in normal mice, secretin was 
able to induce AQP2 plasma membrane translocation, as well as AQP2 expression in 
inner medullary tubular cells. The exact way in which secretin changes AQP2 
expression remains to be defined.
Inhibition of AQP2-mediated w ater transport
Upon withdrawal of AVP, AQP2 is internalized from the membrane into intracellular 
storage vesicles, decreasing water reabsorption in the collecting duct. In addition, 




Fig. 2. Model of the inhibition of AQP2-mediated water reabsorption. Several hormones can 
antagonize AVP-induced water transport. Indicated are: AC: adenylate cyclase; ATP: adenosine tri­
phosphate; BK(2R): bradykinin (type-2 receptor); cAMP: cyclic adenosine monophosphate; D(R): 
dopamine (receptor); EGF(R): epidermal growth factor (receptor); EP: E-prostanoid receptor; ET: 
endothelin receptor; G«13: G protein involved in Rho family GTPase signaling; Gi: inhibitory G- 
protein; Gq: PLC activating G-protein; MChR: muscarinic cholinergic receptor; P2: purinergic 
receptor; PGE2: prostaglandin-E2; PKA: protein kinase A; PKC: protein kinase C; PLC: 
phospholipase C; Ub: Ubiquitin. For details see text.
Luminal A VP
In addition to the V2R, which is expressed at the basolateral membrane of principal 
cells, several studies suggest the presence of the V1a receptor (V1aR) in the apical 
membrane of the collecting duct, which, upon activation in the presence of basolateral 
AVP, reduce the V2R-mediated water reabsorption (reviewed in (61)). In the rabbit 
cortical collecting duct, luminal AVP was suggested to act via the V 1R and to increase 
intracellular Ca2+ levels (62-64). Others reported that V1aR activation stimulated the 
synthesis of prostaglandins, which reduce AVP-induced cAMP accumulation (see 
below; (65)). V1aR-mediated signaling might thus contribute to the inhibition of V2R- 
induced AQP2-mediated water reabsorption.
Prostaglandin E2
In the absence of AVP, prostaglandin E2 (PGE2) has been shown to stimulate water 
transport, but in its presence, PGE2  decreases water permeability (6 6 ). The differences 
in PGE2-mediated actions on water permeability might be explained by the presence of
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four E-prostanoid receptor subtypes, denominated EP1, EP2, EP3, and EP4, and the 
different G proteins they couple to (reviewed in (67)). The stimulatory effect of PGE2 
on basal water permeability was reported to be most likely mediated via the EP4 
receptor, which couples to Gs, thereby activating AC and increasing cAMP levels (6 8 ). 
The inhibitory effect of PGE2 on AVP-induced water reabsorption is most likely 
mediated by EP1 and/or EP3 receptors (66;69), as EP1 receptors couple to Gq and their 
activation by PGE2 increases intracellular Ca2+ levels, while the EP3 receptor couples 
to Gi, thereby inhibiting cAMP generation. The molecular mechanism that underlies 
the PGE2-mediated inhibition of water transport, however, is far from complete 
understanding. PGE2 was demonstrated to impair AVP- but not forskolin-induced 
water permeability, suggesting that PGE2 affects water permeability at a step between 
the V2R and AC (70). In other studies, PGE2 was shown to inhibit AVP-induced water 
permeability by activating protein kinase C (PKC), without affecting cAMP levels 
(71;72). A role for Ca2+ in mediating PGE2 action was also described (73). In addition, 
PGE2 counteracts AVP action by retrieving AQP2 from the plasma membrane (74;75). 
Furthermore, modulation of the cytoskeleton by PGE2 is an important factor. Tamma 
et al. demonstrated that AVP inactivates the monomeric G protein Rho, which results 
in the depolymerization of the actin cytoskeleton and is a prerequisite for AQP2 
translocation. Consistently, PGE2 binding to its EP3 receptor activates Rho, thereby 
inhibiting water permeability (76-78). In line with an inhibitory function on AVP- 
induced water uptake, inhibition of PGE2 production by indomethacin increases urine 
osmolality in wild-type mice but not in EP3-deficient mice, suggesting that PGE2 
indeed reduces AQP2 expression in the plasma membrane via the EP3 receptor (79). 
Interestingly, however, in untreated EP3-deficient mice, urine volume and osmolality 
do not differ from wild-type mice, suggesting that PGE2 action through the EP3 
receptor is not essential for the regulation of urinary concentrating mechanism under 
basal conditions (79). Like EP3, EP1 is expressed along the collecting duct and could 
therefore also mediate the PGE2 effects on water transport. Indeed, in EP1-deficient 
mice, urine osmolality was diminished upon water deprivation compared to wild-type 
mice (80). However, the defect in urine concentration could not be contributed to EP1 
expression in collecting duct because the EP1-deficient mice demonstrated normal 
collecting duct AQP2 expression and translocation. In stead, it was concluded that the 
lack of the EP1 receptor affected AVP production in the hypothalamus (80). 
Considering that AVP also increases AQP2 expression, this hypothesis is in conflict 
with the author’s data of normal AQP2 expression and translocation.
Bradykinin
Bradykinin also antagonizes AVP-induced water permeability. Indeed, in bradykinin 
receptor knockout mice, both water deprivation and administration of a V2R agonist 
results in more concentrated urine (81). The intracellular action of bradykinin is 
diverse. At first, bradykinin can act indirectly by stimulating PGE2 production (82).
15
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Directly, bradykinin has been shown to activate the bradykinin-2 receptor (BK2R), 
which couples to Gq and activates PKC (83). Furthermore, bradykinin, like PGE2, 
inhibits AQP2 translocation by activating Rho (84). This effect is independent of 
PGE2, since bradykinin also inhibits Rho-dependent AQP2 translocation in the 
presence of indomethacin, which blocks cyclo-oxygenase production and thereby 
prostaglandin synthesis.
Dopamine
Dopamine also decreases water permeability in the collecting duct by lowering cAMP 
production. In the cortical collecting duct, this effect is mediated by dopamine-induced 
activation of D4-like receptors (85;86). In the IMCD, the inhibitory effect of dopamine 
is mediated through a 2 -adrenoceptors, which can also be activated by catecholamines 
(87). Like PGE2, dopamine also causes AQP2 internalization from the plasma 
membrane into intracellular storage vesicles independent of AQP2 dephosphorylation 
at Ser256 (75). The mechanism, however, is unclear.
Endothelin-1
Collecting duct-derived endothelin-1 plays a key role in the regulation of systemic 
blood pressure and renal salt and water excretion (reviewed in (8 8 )). Direct evidence 
for endothelin- 1  functioning in renal water excretion originates from recent knockout 
studies. Collecting duct-specific endothelin-1 knockout mice showed reduced plasma 
AVP levels, but normal plasma renin activity and osmolality, urinary aldosterone 
excretion and osmolality, as well as normal urine volume (89;90). An acute, but not 
chronic, water load was eliminated less efficient in the knockout mice compared to 
wild-type mice, and upon V2R agonist infusion, knockout mice demonstrated increased 
urine osmolality, AQP2 phosphorylation and V2R expression (90). Also, in these 
knockout mice, AVP-induced cAMP levels are increased, as well as AC5/6 protein 
levels (91). Thus, collecting duct-derived endothelin-1 appears to inhibit AVP-induced 
actions. Endothelin-1 is reported to have opposite effects on sodium and water 
excretion in different parts of the kidney, which is most likely due to the fact that 
endothelin-1 can exert its effects via two distinct receptor subtypes, ETA and ETB (92­
94). Early studies suggested that endothelin-1 inhibits the AVP-induced water 
permeability in the renal collecting duct via activation of the ETB receptor through 
coupling to a Gi protein and inhibition of cAMP generation and through Gq protein 
coupling and activation of PKC (95-98). This is thus in line with the data on the 
endothelin-1 knockout mice. However, collecting duct-specifc ETB knockout mice 
showed no differences in water intake and urine volume during normal or high sodium 
diet compared to their control littermates (90;98-101). Surprisingly, collecting duct- 
specific ETA knockout mice demonstrated higher AVP plasma levels, accompanied by 
a slightly increased ability to excrete acute water load (102). Thus, signaling via the 
ETa receptor reduces endothelin-1 inhibition of AVP actions. Clearly, the exact
16
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mechanism responsible for the effects on AVP-mediated water reabsorption by the 
collecting duct-derived endothelin- 1  remains elusive.
Acetylcholine and epidermal growth factor
Acetylcholine exerts its effects by activating the muscarinic-type cholinergic receptors. 
Carbachol, an acetylcholine analogue, inhibits AVP-induced water flow, but not cAMP 
production, and mediates this effect by an increase in intracellular Ca2+ followed by 
PKC activation (103;104). Likewise, epidermal growth factor (EGF) inhibits AVP- and 
cAMP-stimulated water reabsorption through interaction with its EGF receptor, which 
also involves increased intracellular Ca2+ levels without affecting cAMP production 
(104;105). The exact molecular mechanism remains to be determined.
Extracellular purines
It has already been known for a long time that the extracellular purines, ATP and UTP, 
decrease AVP-induced water permeability by increasing intracellular Ca2+ levels, 
which is accompanied by activation of PKC (106;107). In addition, purines can also 
activate the Rho kinase pathway, which is involved in AQP2 trafficking, as described 
above (76;108). Extracellular purines can mediate their action via the ionotropic P2X 
receptors (P2Xi-7), as well as the metabotropic, G-protein-coupled P2Y receptors 
(P2Y1 246, 11-13) (109). Various P2X receptors have been identified in the collecting 
duct, including P2X3-6 receptors (reviewed in (110;111)). Clearest evidence for the 
involvement in AQP2 regulation has been found for the P2Y2 receptor. In principal 
cells, both P2Yi- and P2Y2-like receptors are expressed in the basolateral membrane, 
and mRNAs of P2Y4 receptor, as well as P2Y6 receptor, were found along the OMCD 
(reviewed in (111;112)). Furthermore, P2Y2 receptors were also localized to the apical 
membrane of collecting duct principal cells (112), although only basolateral ATP was 
shown to inhibit AVP-induced water permeability in perfused rat IMCD tubules (113). 
Moreover, circulating AVP levels were shown to affect the expression of P2 Y2 
receptors since in water-deprived rats, decreased expression of P2 Y2 receptors in 
IMCDs were found (114; 115). Clearest evidence came from recent studies on P2Y2 
receptor knockout mice. Although net urinary reabsorption was not different compared 
to wild-type mice, these knockout mice showed increased renal medullary expression 
of AQP2, as well as elevated urinary cAMP excretion. In response to the V2R 
antagonist SR121463, P2Y2 receptor knockout mice showed greater diuresis and lower 
urine osmolality compared to wild-type animals, suggesting that in the absence of 
P2Y2 receptor, AVP enhances cAMP formation and AQP2-mediated water 
reabsorption. This study provides the first evidence that under normal conditions, a 
continuous activation of the P2Y2 receptor by ATP exists, resulting in reduced cAMP 
formation and AVP-induced water reabsorption (116). Whether other P2 receptors 




There are also indications that ATP may affect AQP2-mediated water permeability 
indirectly. Hughes et al. showed that ATP also decreases the production of endothelin- 
1, thereby possibly affecting AVP-induced water transport through this hormone (117). 
Moreover, extracellular purines stimulate P2 Y2 receptor-mediated release of PGE2, 
which reduces water reabsorption as well (118).
Extracellular Ca2+
In addition to the hormones mentioned above, Ca2+ inhibits AVP-induced water 
transport by activation of the calcium receptor (CaR). Although the importance of a 
transient increase in intracellular Ca2+ levels for AQP2 trafficking is still controversial, 
extracellular Ca2+ exerts clear effects on AVP-mediated water transport. CaR agonists 
have been shown to inhibit AVP-induced water permeability in perfused IMCD tubules 
(119). In addition, extracellular Ca2+, acting through the CaR, was shown to antagonize 
forskolin-induced AQP2 trafficking in AQP2-transfected collecting duct cells (120). In 
vivo studies support these effects because in hypercalcemic rats, AVP was unable to 
increase the osmotic water permeability in the IMCD, and AQP2 protein levels were 
decreased (121). Similarly, Valenti et al. found that while in healthy children with 
normally increased nighttime AVP levels daytime urinary AQP2 levels were nearly 
half of the nighttime AQP2 levels, enuretic children with normal nocturnal AVP levels 
but with hypercalciuria displayed low nighttime urine AQP2 levels compared to 
daytime samples (122). Moreover, a low-Ca2+ diet given to these enuretic 
hypercalciuric children restored AQP2 excretion and relieved enuresis in 80% of these 
children (123). Although these findings suggest that high levels of Ca2+ in urine indeed 
contribute to the regulation of AVP-dependent water reabsorption, Raes et al. recently 
found that nocturnal polyuria in a group of hypercalciuric children coincided with 
nocturnal natriuresis, suggesting that the polyuria might be due to osmotic diuresis 
(124). It would be interesting to know whether the children from the Valenti study 
showed the same differences in daytime-nighttime sodium excretion and whether the 
nocturnal enuresis in the patients from Raes et al. would be diminished when these 
children would receive a low-calcium diet.
Molecular regulation of AQP2 translocation
AQP2 Phosphorylation
As mentioned, a prerequisite for AVP-mediated apical translocation is the 
phosphorylation of AQP2 at Ser-256 by PKA (5;6;125). Although each AQP2 
monomer forms a functional water channel, AQP2 is expressed as a homotetramer, and 
phosphorylation of at least three out of four monomers is required for apical membrane 
localization (126). The role of other putative phosphorylation sites in AQP2, three 
putative casein kinase II sites (Ser-148, Ser-229, and Thr-244), and one PKC site (Ser-
18
Chapter 1
231) was also investigated but could not be associated with AQP2 trafficking (6 ). 
Recently, three novel phosphorylation sites were identified in the C-terminus of AQP2, 
Ser-261, Ser-264, and Ser-269, which are of potential importance in AVP-induced 
AQP2 trafficking (127). While AVP treatment increases the phosphorylation of Ser- 
256 of AQP2, Hoffert et al. demonstrated that phosphorylation of Ser-261 in the AQP2 
C-terminus is reduced upon AVP treatment (128). Also, the subcellular localization of 
these phosphorylated proteins is distinct: While AQP2 phosphorylated at Ser-256 is 
predominantly expressed in the apical membrane, AQP2 phosphorylated at Ser-261 
localizes subapically and gives a punctuate staining (128). These findings suggest a 
role for Ser-261 phosphorylation in the trafficking of AQP2. Further investigation is 
required to establish a role of Ser-261 phosphorylation in AQP2 trafficking and to find 
out to what extent phosphorylation of Ser-264 and Ser-269 might contribute to AQP2 
trafficking, translocation, and water permeability.
Calcineurin, a Ser/Thr phosphatase, might also be involved in AQP2 trafficking. 
Calcineurin, also known as protein phosphatase 2B, was found in a complex with 
AQP2 and could dephosphorylate AQP2 in vitro (129). Paradoxically, mice lacking the 
a  isoform of calcineurin A subunit were unable to concentrate their urine in response to 
dDAVP (130). Accordingly, these mice showed a decrease in phosphorylated AQP2 
levels in response to AVP and AQP2 appeared to be retained in an intracellular 
compartment. While these data indicate that phosphatase activity of calcineurin might 
be required for apical AQP2 translocation, its role in AQP2 regulation thus seems to be 
more complex than just a phosphatase that may dephosphorylate AQP2 at Ser-256.
AQP2-associated proteins
To date, only four proteins are known to directly interact with AQP2. Noda et al. 
identified two AQP2 interacting proteins, actin and signal-induced proliferation- 
associated protein 1 (SPA-1) (131 ;132). Translocation of AQP2 to the apical plasma 
membrane is associated with the depolymerization of the actin cytoskeleton (see 
below), and binding of AQP2 to actin might therefore be a key step for AQP2 
translocation. SPA-1 is a specific GTPase-activating protein for Rap1 whose activity is 
required for AQP2 translocation to the apical membrane (131). Interestingly, Epac 1 
and 2 also activate Rap1 and have been shown to be involved in AQP2 translocation 
(see above). At present, however, it is unclear whether SPA-1 is involved in the Epac 
signaling cascade. Secondly, AQP2 interacts with heatshock protein 70 (Hsc70), which 
is part of the endocytotic machinery that regulates clathrin-mediated endocytosis (133). 
In addition to Hsc70, AQP2 also interacts with other components of the clathrin- 
mediated endocytotic machinery, such as clathrin, dynamin, and the clathrin adaptor 
protein AP2. This is consistent with previous reports demonstrating that AQP2 is 
internalized via clathrin-mediated endocytosis (134-136). Finally, a recent study by 
Kamsteeg et al. demonstrated that AQP2 interacts with myelin and lymphocyte- 
associated protein (MAL). MAL is constitutively expressed in the collecting duct
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apical membrane and was shown to increase AQP2 phosphorylation and decrease its 
internalization, thereby enhancing its apical membrane expression (137). The 
interaction between AQP2 and MAL increases the apical membrane expression of 
AQP2 by decreasing AQP2 endocytosis. It will be interesting to determine whether 
AQP2 ubiquitination is involved and whether exocytosis from recycling endosomes is 
affected as well.
The microtubular network
Besides AQP2 phosphorylation, the microtubular network and cytoskeleton also play 
an important role in the trafficking of AQP2 bearing vesicles to the apical membrane. 
Intracellular trafficking requires a microtubular network and microtubule-associated 
motor proteins like dynein and dynactin of which several have been identified in 
AQP2-bearing vesicles (138-140). The motor protein myosin Vb and its vesicular 
receptor Rab11 are involved in protein recycling and, recently, these proteins have been 
shown to play a role in AQP2 trafficking (141;142). Myosin Vb was shown to 
colocalize with AQP2 in principal cells of rat kidney slices. Upon expression of a 
dominant-negative myosin Vb mutant in AQP2-expressing CD8  cells, forskolin- 
induced AQP2 translocation to the apical membrane was abolished (141). Similarly, it 
was demonstrated that Rab11 family interacting protein 2 (Rab11-FIP2), a protein that 
mediates interaction between myosin Vb and its vesicular receptor Rab11, plays a role 
in the trafficking of AQP2. A dominant-negative Rab11-FIP2 mutant, which disrupts 
Rab11-dependent recycling, impaired forskolin-induced AQP2 translocation to the 
apical membrane (141). Thus, myosin Vb and Rab11-FIP2 play a role in the 
translocation of AQP2 to the membrane.
The cytoskeleton
Upon translocation to the apical plasma membrane, AQP2-bearing vesicles finally need 
to fuse with the membrane. This fusion is likely mediated by soluble A-ethylmaleimide 
sensitive fusion factor attachment protein receptors (SNARE) proteins. Several 
SNARE proteins like syntaxin-4 and synaptosome-associated 23-kDa protein have 
been found in collecting duct principal cells and are enriched in AQP2-bearing vesicles 
(143-146). Moreover, Gouraud et al. demonstrated that the vesicle-associated 
membrane protein 2 is required for AVP-induced AQP2 translocation (147).
Before being able to fuse, however, these vesicles have to pass the cytoskeleton. In 
mammalian collecting duct and toad bladder, vasopressin-induced AQP2 translocation 
to the plasma membrane is associated with depolymerization of the actin cytoskeleton 
(148;149). In this process, the small GTPase RhoA plays an important role in AQP2 
translocation by modulating the actin cytoskeleton conformation. Inhibition of RhoA 
activity by PKA-mediated phosphorylation induces partial depolymerization of the 
actin cytoskeleton, thereby facilitating the translocation of AQP2-bearing vesicles to 
the apical membrane (76;78;150;151). AQP2 translocation also requires the Ezrin-
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Radixin-Moesin (ERM) protein moesin. ERM proteins play an important role in the 
regulation of F-actin cytoskeleton by cross-linking actin filaments with proteins in the 
plasma membrane. Tamma et al. demonstrated that functional moesin is required for 
AQP2 trafficking to the apical membrane (152). ERM proteins function both upstream 
and downstream of the Rho GTPases and could therefore be affected by RhoA 
signaling or affects RhoA activity itself. In addition, ERM proteins might affect AQP2 
trafficking by mediating the interaction of actin with AQP2.
AQP2 internalization
Upon AVP withdrawal, AQP2 is internalized from the plasma membrane and 
accumulates in intracellular vesicles (8;153). In addition, activation of PKC by the 
phorbol ester 12-tetradecanoylphorbol-13-acetate causes internalization of AQP2 (6 ). 
While phosphorylation of Ser-256 is essential for AVP-induced AQP2 translocation to 
the plasma membrane, dephosphorylation of AQP2 does not seem to be required for its 
internalization (6 ). Retrieval of AQP2 from the plasma membrane was demonstrated to 
occur via clathrin-mediated endocytosis (134;154). Inhibition of clathrin-mediated 
endocytosis resulted in AQP2 accumulation at the plasma membrane (136).
The molecular mechanism underlying the internalization of AQP2 was not known. 
Recently, however, Kamsteeg et al. demonstrated that AVP removal or PKC activation 
by phorbol esters induces short-chain ubiquitination of AQP2, followed by endocytosis 
and subsequent sorting to multivesicular bodies (155). While AQP2 has three putative 
attachment sites for ubiquitin (cytosolic lysines) at positions Lys-228, Lys-238, and 
Lys-270, analysis of cells expressing AQP2 mutants in which these lysines were 
replaced by arginines revealed that only Lys-270 is a substrate for ubiquitination. 
Consistently, AQP2-K270R was delayed in its internalization, demonstrating the 
importance of ubiquitination in AQP2 endocytosis (155). However, although delayed, 
AQP2-K270R was still internalized, which indicated that there are other mechanisms 
involved in AQP2 endocytosis.
AQP2-associated pathologies
AQP2 has been demonstrated to play a role in the pathophysiology of several diseases 
associated with a disturbed water balance. Congestive heart failure (CHF), liver 
cirrhosis, and pre-ecclampsia are characterized by excessive water reabsorption. In 
these conditions, increased AVP levels, resulting from arterial underfilling and 
“suggestive” hypovolemia, induce excessive water uptake, often leading to 
hyponatremia. Consistently, in CHF rat models, increased AQP2 levels and clear apical 
plasma membrane expression were found (156;157). In liver cirrhosis, increased 
plasma AVP levels have been suggested to be responsible for impaired water excretion 
(reviewed in (158)). However, there are still some discrepancies between the various
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animal models. In several rat models of liver cirrhosis, increased AQP2 levels were 
found (159;160). In another study, however, total AQP2 levels were not changed, but 
an increase in plasma membrane expression of AQP2 was observed (161). Moreover, 
other rat models of liver cirrhosis displayed decreased AQP2 levels and impaired water 
reabsorption (162-164). An explanation for the differences found between these rat 
models is at present lacking.
In contrast to the conditions mentioned above, NDI is characterized by polyuria due to 
an AVP-induced impaired water reabsorption, and, consequently, polydipsia (reviewed 
in (165)).
Acquired NDI
NDI can either be acquired or present from birth (congenital). Acquired NDI was 
reviewed in detail recently and will only be discussed here briefly (158; 165). Acquired 
forms of NDI result from various conditions. NDI is a common side effect in 10% to 
20% of patients treated with lithium, the drug of choice to treat bipolar disorders. In 
rats, lithium was demonstrated to induce polyuria and a downregulation of AQP2 
expression, which is, at an early stage, likely mediated by a lithium-induced inhibition 
of cAMP production (166-168). At later stages of disease development, lithium also 
induces a loss of principal cells (167). Other causes of NDI are hypokalemia and 
hypercalcemia. Like lithium therapy, hypokalemia and hypercalcemia decrease AQP2 
expression in rats (169;170). Also, urinary tract obstruction, accompanied by decreased 
AQP2 expression, can cause urinary concentration problems because after removal of 
the obstruction, AQP2 levels are still downregulated (171;172). Finally, acquired NDI 
is also seen in acute and chronic renal failure. Several studies demonstrated decreased 
AQP2 expression and polyuria in rat models suffering from renal failure (173-175). 
Patients with chronic renal failure have severe problems with water reabsorption, 
regardless of vasopressin plasma levels (176).
Congenital NDI
Congenital NDI can be due to mutations in the A VPR2 gene, encoding the V2R (X- 
linked NDI) or mutations in the AQP2 gene (autosomal recessive or autosomal 
dominant NDI). More than 90% of all congenital NDI patients suffer from X-linked 
NDI. Mutations in the A VPR2 gene result in disturbed receptor signaling, rendering the 
renal principal cells insensitive to AVP, which results in a severe urine concentration 
defect. The molecular mechanisms underlying X-linked NDI can be divided in five 
different classes. The most common is misfolding of the protein and retention in the 
endoplasmic reticulum (ER; class II) (177;178). Others include (I) defective processing 
or unstable mRNA, (III) diminished binding of the Gs protein, (IV) reduced affinity for 
AVP and (V) misrouting of the V2R to different organelles in the cell (179-184). These 




Of all patients diagnosed with autosomal NDI, more than 90% suffers from recessive 
NDI. Most mutations found in recessive NDI are located in the core region of the 
AQP2 protein, which encompasses six transmembrane domains and five connecting 
loops. These mutations result in misfolded proteins that are retained in the ER and 
degraded rapidly (185-189). The healthy parents of recessive NDI patients express both 
mutant and wild-type AQP2 proteins. Since the mutants do not tetramerize with the 
wild-type AQP2, as was shown for the AQP2-R187C mutation (190;191), only 
homotetramers of wild-type AQP2 will be expressed on the apical membrane of the 
parents, allowing sufficient water reabsorption. The least occurring form of NDI, 
autosomal dominant NDI, is caused by mutations in the C-terminal tail of AQP2. These 
AQP2 mutants form heterotetramers with wild-type AQP2 and are, due to the mutation, 
missorted to other cellular organelles (190-193). Since wild-type AQP2 is retained in 
mixed tetramers and missorted, water reabsorption is severely affected, explaining the 
dominant inheritance of NDI in these patients.
Recent mouse models reveal that the mechanisms underlying congenital NDI in vitro 
also apply to the in vivo situation. Complete AQP2 knockout mice, as well as recessive 
NDI AQP2-T126M knockin mice, die within a few weeks after birth due to severe 
urinary concentration problems and hydronephrosis (194;195). Although cortical 
collecting duct-specific AQP2 knockout mice also demonstrated growth retardation and 
10-fold increased urine production, these mice survived (195). Several of the in vivo 
studies confirmed our current thoughts on congenital NDI. The AQP2-T126M knockin 
mice displayed a similar ER-glycosylation pattern as observed for the human mutant 
expressed in cells, demonstrating that ER retention also underlies recessive NDI in vivo 
(187;194;196). Furthermore, in the first mouse model of dominant NDI, the AQP2- 
763-772del knockin mouse, mutant AQP2 formed heterotetramers with wild-type 
AQP2 and was missorted to the basolateral plasma membrane, as described for the in 
vitro situation (190;191;197).
However, different NDI mice models also provided new information on AQP2 
regulation in NDI (195;197-200). Several studies already suggested that the relative 
strength of the wild-type and mutant sorting signals determine the final destination of 
the tetramers and whether NDI is inherited as a recessive or dominant trait (201;202). 
In two families with recessive NDI, patients appeared to be heterozygotes for AQP2 
mutations of which one, AQP2-P262L, was located in the AQP2 C-tail. Mutations in 
the AQP2 C-tail usually cause dominant NDI (201). In line with mutants in dominant 
NDI, in vitro studies demonstrated that AQP2-P262L was unable to interact with 
AQP2-R187C and did interact with wild-type AQP2. In contrast to mutants in 
dominant NDI, however, wild-type AQP2 rescued the misrouting of AQP2-P262L and 
directed the complex to the apical plasma membrane, thereby explaining the healthy 
phenotype of parents of the patients (201). Interesting in this respect is that an S256L 
mutation in AQP2 causes recessive NDI in mice, whereas the R254L mutation, causes 
dominant NDI in humans (199;203). As both mechanisms result in the lack of PKA to
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phosphorylate AQP2 at Ser-256, these data may be another indication that recessive or 
dominant NDI phenotype is determined by the strength of the apical sorting signal in 
wild-type AQP2 versus the strength of the missorting signal in the mutant.
Another surprising novelty from the mouse models was that mutations in the core 
region of AQP2 can lead to a variable level of misfolding and severity of NDI. While 
AQP2-T125M knockin mice die due to the lack of functional AQP2, mice with an 
F204V mutation in AQP2 have recessive NDI, but do survive. This suggested that 
these mice had some residual water transport ability (198). Indeed, while most AQP2- 
F204V was localized throughout the cytoplasm, some reached the membrane. 
Similarly, humans suffering from recessive NDI caused by a V168M mutation also 
demonstrate less ER retention and a less severe phenotype compared to other mutants 
in recessive NDI (204). Surprisingly and in contrast to another mutant in recessive 
NDI, AQP2-R187C, AQP2-F204V also forms heterotetramers with wild-type AQP2 
and is rescued to the plasma membrane in the heterozygote (198;202). As only AQP2- 
R187C is tested thoroughly in vitro, it may be that some AQP2 mutants causing human 
NDI are also less misfolded, interact with wild-type AQP2 and are transported to the 
apical membrane in parents of the patients with autosomal recessive NDI.
Scope of the thesis
The role of the AQP2 water channel in vasopressin-regulated water reabsorption has 
been studied intensively since its original discovery in 1993. Although tremendous 
efforts increased our knowledge of hormone-induced AQP2 shuttling to and from the 
apical plasma membrane and its underlying molecular mechanisms, many parts of the 
AQP2 regulation are still to be defined. The general aim of this thesis was to gain more 
insight into the regulation of hormone-induced AQP2 trafficking and expression. First, 
to identify proteins that interact with the C-terminal tail of AQP2, we employed yeast 
two hybrid assays in chapter 2. This resulted in the identification of LIP5 as a binding 
partner of AQP2. GST pull-down, co-immunoprecipitation, and immunohistochemistry 
analyses confirmed the specific interaction between AQP2 and LIP5. Furthermore, co- 
immunoprecipitation experiments demonstrated the absence of effects of 
phosphorylation and ubiquitination of AQP2 on LIP5 binding. Finally, the function of 
LIP5 in AQP2 regulation was investigated using RNA interference-mediated 
downregulation of LIP5. In chapter 3, the binding between AQP2 and LIP5 was 
further characterized. Yeast two hybrid assays, GST pull-down experiments, and co- 
immunoprecipitation were used to identify the domains within AQP2 and LIP5 
involved in the interaction. Furthermore, by applying various mutations in the AQP2 
C-tail, the amino acids, which are crucial for its interaction with LIP5, were identified. 
C hapter 4 describes the localization of LIP5 in several tissues.
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As outlined, binding of several hormones, such as ATP, dopamine, carbachol, and 
endothelin-1, activate the PKC pathway and reduce the AQP2-mediated water 
reabsorption. C hapter 5 reports how paracrinergic ATP regulates AQP2, using 
mpkCCD cells as a model of the collecting duct epithelium. Cell surface biotinylation 
and immunocytochemistry experiments demonstrated the effect of ATP on AQP2 
expression and localization. Furthermore, the expression of the various P2 receptors in 
mpkCCD cells was determined by immunocytochemistry. The P2 receptors that could 
mediate the effects of ATP on AQP2-mediated water permeability were identified by 
co-expressing these receptors with AQP2 in Xenopus oocytes and measuring water 
permeability upon P2 receptor activation. In chapter 6 , the pathways involved in the 
inhibition of AQP2 mediated water transport by ATP and dopamine were investigated. 
The effects of dopamine and ATP on AQP2 expression, localization degradation, 
ubiquitination, cAMP production, and Ser-261 phosphorylation were examined.
As described above, X-linked NDI is caused by mutations in the V2R gene, which 
prevents activation of the V2R-cAMP-PKA pathway in response to AVP, resulting in 
the inability to concentrate urine. Initiation of AQP2 translocation, while 
circumventing the V2R-cAMP-PKA pathway has been suggested as a putative therapy 
for these patients. In chapter 7, we determined the effects of the cGMP pathway 
activators atrial natriuretic peptide (ANP), L-arginine and 8 -bromoguanosine 3’,5’- 
cyclic monophosphate (8 -Br-cGMP) on AQP2 translocation and expression in 
mpkCCD cells.
Finally, a general discussion and summary is presented in chapter 8 .
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LIP5 Interacts with Aquaporin 2 and Facilitates Its Lysosomal Degradation
Abstract
Vasopressin binding to the V2 receptor in renal principal cells leads to activation of 
protein kinase A, phosphorylation of aquaporin 2 (AQP2) at Ser256, and the 
translocation of AQP2 to the apical membrane, resulting in concentration of the urine. 
In contrast, phorbol ester-induced activation of protein kinase C pathway leads to 
ubiquitination of AQP2 at Lys270 and its internalization to multivesicular bodies, 
where it is targeted for lysosomal degradation or stored for recycling. Because little is 
known about the regulation of AQP2 trafficking, we used the carboxy-terminal tail of 
constitutively nonphosphorylated AQP2 (S256A) as a bait for interacting proteins in a 
yeast two-hybrid assay. We isolated lysosomal trafficking regulator-interacting protein 
5 (LIP5) and found that LIP5 interacted with the proximal carboxy-terminal tail (L230- 
D243) of AQP2 in vitro but not with AQP3 or AQP4, which are also expressed in 
principal cells. Immunohistochemistry revealed that LIP5 co-localized with AQP2 in 
principal cells. LIP5 binding occurred independent of the state of Ser256 
phosphorylation or Lys270 ubiquitination. LIP5 has been shown to facilitate 
degradation of the EGF receptor; here, LIP5 seemed to bind this receptor. Knockdown 
of LIP5 in mouse renal cells (mpkCCD) reduced the phorbol ester-induced degradation 
of AQP2 approximately two-fold. In summary, LIP5 binds cargo proteins and, 
considering the role of LIP5 in protein sorting to multivesicular bodies, plays a role in 
the degradation of AQP2, possibly by reducing the formation of late endosomes.
Introduction
Tight regulation of the translocation of aquaporin 2 (AQP2) water channels to and from 
the apical membrane of renal collecting duct cells by the antidiuretic hormone arginine 
vasopressin (AVP) is fundamental for water homeostasis. Upon hypernatremia or 
hypovolemia, binding of AVP to its type 2 receptor (V2R) increases intracellular 
calcium and cAMP concentrations, which activate and tether protein kinase A (PKA) to 
AQP2-containing vesicles, resulting in phosphorylation of AQP2 and other proteins (1­
7). Consequently, these vesicles dock and fuse with the apical membrane, rendering 
principal cells water permeable. Regulated translocation of AQP2 to and from the 
apical membrane suggests the existence of proteins interacting with cytosolic segments 
of AQP2. Only the amino-terminal and carboxyl-terminal tails (N- and C-tails, 
respectively) of AQP2 extend well into the cytosol, and the C-tail of AQP2 has been 
shown to have an important role in its apical sorting: First, Ser256 in the AQP2 C-tail 
is phosphorylated in vivo by AVP stimulation, and studies in both cell and animal 
models revealed that this phosphorylation event is essential for AQP2 translocation to 
the plasma membrane (8-13). Second, all AQP2 mutants encoded in families with a 
dominant inheritance of nephrogenic diabetes insipidus (NDI), a disease in which the
40
Chapter 2
kidney is unable to concentrate urine in response to AVP, are missorted as a result of 
mutations in the C-tail (12; 14-19) In addition, the AQP2 C-tail is mono-ubiquitinated 
at Lys270 upon AVP removal or PKC activation, which enhances endocytosis and 
degradation of AQP2 (20). So far, the Rapl GTPase-activating protein Spal, heatshock 
protein 70, and Myelin and Lymphocyte Associated Protein (MAL) are the only 
proteins known to bind the AQP2 C-tail, potentially playing physiologic roles in AQP2 
trafficking (21-23); therefore, to gain more insight in the proteins and mechanisms 
involved in the regulation of AQP2, we used yeast two-hybrid assays to screen a mouse 
kidney cDNA library for proteins interacting with the C-tail of AQP2. We found the 
lysosomal trafficking regulator (LYST) interacting protein 5 (LIP5; Swiss-Prot entry 
Q9CR26; corresponding gene name DRG-1) to interact specifically with AQP2. 
Interestingly, LIP5 is reported to function in multivesicular body (MVB) formation 
(24), although a direct interaction of LIP5 with MVB cargo proteins has never been 
reported. Subsequent analyses revealed the LIP5-binding region within AQP2 and the 
role of LIP5 in AQP2 regulation.
Materials and Methods
Yeast Two-Hybrid
cDNAs encoding wild-type and mutant AQP2 C-termini starting at amino acid Phe224 
were generated by standard PCR reactions using AQP2-C-EcoRI (5’- 
GATCGGAATTCCCGCCAGCCAAGAGCCT-3’) as a forward primer and AQP2-C- 
XhoI as a reverse primer. As templates, pCB6-wtAQP2, pCB6-AQP2-S256A, and 
pCB6-AQP2-S256D (8 ) were used. cDNAs encoding truncated AQP2 C-tail proteins 
were generated similarly using AQP-C-EcoRI as a forward primer and AQP2-L230X 
(5’-GATCCTCGAGCTAGCTCTTGGCTGGCGGT-3’), AQP2-D243X (5’- 
GATCCTCGAGCTACGGCTCCAGGCCCTTCAG-3’), AQP2-R252X (5’- 
GATCCTCGAGTCACACCTCGCGCTCCTCCC-3’) or AQP2-Q263X
(GATC CTCGA GCTACGGCGAGTGCAGCTCCAC-3 ’) as a reverse primer (in all 
mutagenesis primers introduced, mutations are underlined and restriction sites are in 
italic). The obtained fragments were digested with £coRI and XhoI and cloned into the 
£coRI and SalI sites of pBTM116 (25). The C-terminal tails of AQP3 (amino acids 
M264-I292) and AQP4 (amino acids V251 through V323) were cut from pGBT9- 
AQP3 and pGBT9-AQP4 (26) using £coRI and PstI and cloned into the corresponding 
sites of pBTM116. For all constructs, introduction of only the desired mutation was 
confirmed by DNA sequence analysis.
To identify AQP2 interacting proteins, we screened a GAL4 cDNA library of adult 
mouse whole kidneys (MATCHMAKER, Clontech, Palo Alto, CA) against a bait of 
the AQP2-S256A C-terminal tail. For this, L40 yeast cells (MATa, trpl, leu2, his3, 
LYS2::lexA-HIS3, URA3::lexA-lacZ) were transfected with the pBTM116-S256A
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construct. After 3 d, colonies were picked, grown in medium, pelleted, and analyzed for 
their LexA-C-tail expression using AQP2 and LexA immunoblot analysis. For library 
screening, four independent colonies expressing LexA-AQP2-S256A were grown to 
A546 >2 at 30°C, 260 rpm in 100 ml of SD-Trp medium and used to inoculate 1 L of 
YPDA to 0.2 A600. At 0.8 A600, the cells were collected by centrifugation at 4200 x g at 
4°C for 15 min, washed twice with sterile distilled H2O, pelleted at 1300 x g (10 min, 
4°C), and transfected according to Gietz et al. (27) using 50 ^g of Library DNA. After 
incubation for 30 min at 30°C and a 30 min heat shock at 42°C, cells were harvested by 
centrifugation at 1900 x g for 3 min, washed with distilled H2O, resuspended in 20 ml 
of distilled H2O, and plated on 25 selective SD-Trp-His-Leu dishes of 245 x 245 mm. 
After 5 d, colonies were tested for b-galactosidase expression by a colony lift assay 
(28). For this, colonies were transferred onto 3-mm Whatmann filters, permeabilized in 
liquid N2, and overlaid with 0.2 mg/ml X-gal in TBSY (150mM NaCl, 50 mM Tris- 
HCl [pH 7.4], and 0.8% agarose). Colonies that turned blue were transferred to 
selective plates and rescreened for LacZ activity as already described. From colonies 
that remained positive after rescreening, DNA was isolated (29), electroporated to 
electrocompetent KC8  cells (2.3 kV, 25 ^F, and 200 W), and plated on M9-Leu plates. 
After checking insert sizes of DNA from three independent colonies by BglII digestion, 
L40 cells were retransformed with prey DNA in combination with either pBTM116 or 
pBTM116-AQP2-S256A to verify specificity of the isolated prey plasmid for binding 
to the AQP2-S256A C-tail by a colony lift assay. Prey plasmids giving rise to blue 
colonies when transformed with pBTM116-AQP2-S256A/D but not with pBTM116 
were subjected to DNA sequence analysis to identify the prey cDNA. Transformation 
of one or two plasmids to L40 yeast cells at a time was done by using 1 ^g of plasmid 
equivalents in a downscaled library transformation protocol and a selection for colonies 
on appropriate SD plates for 3 to 4 d.
Pulldown Assays
For the expression of wt-AQP2 C-tail as a GST fusion protein, a standard PCR was 
done using the forward primer AQP2-CtermFWD (5’- 
GGAATTCCCAGCCAAGAGCCTGTCG-3 ’) and the reverse primer AQP2-C-XhoI 
on a pBS-AQP2 template (30). The PCR fragment was digested with £coRI-XhoI and 
cloned into corresponding sites of pGEX4T-1 (Amersham Biosciences, Freiburg, 
Germany). For GST-AQP4 expression, we used a pGEX1 vector containing the C-tail 
of AQP4 (31). To make a GST-LIP5 expression construct, pACT2 clone 14b 
(identified from library screening) was cut with £coRI and XhoI, and the cDNA 
fragment encoding full-length LIP5 was isolated and cloned into the corresponding 
sites of pGEX6.1 (Amersham Biosciences, Freiberg, Germany).
GST, GST-AQP2, and GST-AQP4 production in BL21-DE3 bacteria was induced by 
IPTG and isolated with prewashed Glutathione- Sepharose 4B beads. LIP5 was 
produced by in vitro transcription/translation using the Riboprobe-T7 system
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(Promega, Leiden, Netherlands) in the presence of 35S-methionine/cysteine (Redivue 
Promix; Amersham Biosciences, Uppsala, Sweden) and incubated with the GST fusion 
protein beads, rotating overnight at 4°C. Bound LIP5 was eluted by boiling the samples 
in Laemmli sample buffer and analyzed by SDS-PAGE. Pulled-down LIP5 was 
visualized using a STORM phosphor imager (Amersham Biosciences, Uppsala, 
Sweden).
Cytosol of dog kidneys was prepared by crushing the tissue in a blender and 
subsequent homogenization in 20 mM HEPES, 100 mM NaCl, 5 mM MgCl2, 1 mM 
dithiothreitol, 1 mM PMSF, 5 ^g/ml leupeptin, and 5 ^g/ml pepstatin using a potter 
(PotterS, Braun Biotech, Melsungen, Germany). Cytosol was cleared by centrifugation 
at 33,000 rpm in a Ti45 rotor in a Beckman ultracentrifuge for 1 h at 4°C. The 
supernatant was preincubated for 1 h with glutathione-Sepharose 4B beads containing 
GST and subsequently incubated with GST, GST-AQP2, or GST-AQP4 glutathione- 
Sepharose 4B beads overnight at 4°C. After binding, the beads were washed with 25 
mM Tris (pH 7.5), 0.5 mM EDTA, and 1% Triton-X100, and bound proteins were 
eluted by shaking in 1.5 M NaCl, 25 mM Tris (pH 7.5), and 0.5 mM EDTA at room 
temperature for 1 h. Samples were desalted using Biospin columns (Biorad, Hercules, 
CA). Isolated proteins were analyzed by SDS-PAGE and immunoblotting.
Empty or transfected COS cells were lysed in 300 ^l of lysis buffer with 1% NP40. For 
LIP5 depletion, lysates were incubated for 2 h with 4 ^l of LIP5 antiserum and 40 ^l of 
protein A-agarose beads (Kem-En-Tec A/S, Copenhagen, Denmark). Lysates were then 
incubated with GST-AQP2 glutathione-Sepharose 4B beads and further processed as 
described already.
Expression in Eukaryotic Cells
For expression of LIP5 in eukaryotic cells, an EcoRI-XhoI fragment encoding full- 
length LIP5 was isolated from the pACT2 clone 14b, identified from library screening, 
and ligated into the corresponding sites of pCDNA3. Expression constructs encoding 
wild-type AQP2 or the S256A, S256D, K270R, and AQP2-Ub mutants were as 
described previously (7:20). pCDNA3-EGFR was provided by Prof. Y. Yarden 
(Department of Biologic Regulation, Weizmann Institute of Science, Rehovot, Israel) 
(32). HEK293 cells were maintained in DMEM (Biowittaker, Verviers, Belgium) 
supplemented with 10% FCS. For transient transfections, HEK293 cells were seeded at 
1.2 x 105 cells/cm2 in six-well plates. Four hours after seeding, cells were transfected 
using polyethylenimine (Polysciences, Eppelheim, Germany). A total of 3.5 ^g of 
circular DNA and 14 ^l of polyethylenimine (1 ^g/^l) were added to 80 ^l of 
OptiMEM medium (Life Technologies Europe, Breda, Netherlands), vortexed, and 
incubated at room temperature for 20 min. Subsequently, the mixture was added to the 
cells and incubated overnight. Three days after transfection, cells were lysed in IP lysis 
buffer (1% Triton X-100, 150 mM NaCl, and 25 mM HEPES [pH 7.4]) and incubated 
with rabbit anti-LIP5 antibodies, mouse anti-Xpress, or mouse anti-EGFR 528 (Santa
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Cruz Biotechnology, Santa Cruz, CA) immobilized on protein A-agarose beads (Kem- 
En-Tec A/S) overnight at 4°C. Immunoprecipitated proteins were analyzed by 
immunoblotting.
In Situ Hybridization
LIP5 cDNA templates with a T7 RNA polymerase promoter sequence (underlined in 
primer sequences) at the 5’ or 3’ end were used to generate LIP5 cRNA probes. These 
templates were made by a standard PCR reaction, using 5’-TAATACACTCACT- 
AT AGGGAGAGGCCCCTCTGCCGCCGCTGC-3 ’ or 5’-
CGTCCAGCTCGATCTTCATTGTCTGCATACA-3’ (sense) together with 5’- 
GGCCCCTCTGCCGCCGCTGC-3 ’ or 5 ’ -TAATACGACTCACTATAGG- 
GAGACGTCCAGCTCGATCTTCATTGTCTGCATACA-3’ (anti-sense) primers, 
respectively. 11-UTP dioxigenin (DIG)-labeled probes of these templates were made in 
vitro using T7 RNA polymerase (Roche Diagnostics, Almere, Netherlands). For 
preparation of mouse kidney sections, mice were transcardially perfused with ice-cold 
0.6% NaCl solution for 5 min, followed by Bouin’s fixative for 15 min. After 
dissection, kidneys were postfixed in Bouin’s fixative for 24 h. Then, kidneys were 
dehydrated in a graded series of ethanol and xylene and embedded in paraffin. Seven- 
micrometer sections were mounted on poly-L-lysine coated slides and dried for 16 h at 
37°C before they were rehydrated in a graded series of ethanol. Tissue penetration was 
enhanced by incubation in 0.1% pepsin in 0.2 M HCl for 15 min at 37°C, followed by 
fixation in 4% paraformaldehyde in PBS for 5 min and incubation in 1% 
hydroxylammoniumchloride for 15 min. After this, sections were dehydrated in ethanol 
and air dried. Hybridization took place for 1 h at 55°C in hybridization buffer (10% 
sodium dextran sulfate, 50% formamide, 4x salt and sodium citrate (SSC), 1x 
Denhardt’s and 200 ^g/ml yeast tRNA; 1x SSC = 0.15 M NaCl and 0.015 M sodium 
citrate) with 500 ng/ml DIG-labeled probe. After stringency washes in 2x SSC, 1x 
SSC, 0.5x SSC, and 0.1x SSC for 30 min at 37°C, sections were rinsed for 10 min in 
Tris-buffered saline (TBS), blocked in blocking solution (1% BSA and 2% normal goat 
serum in TBS) for 30 min, and incubated with alkaline phosphatase (AP)-conjugated 
sheep anti-DIG Fab fragments (1:500; Roche Diagnostics) in blocking solution for 16 h 
at 4°C. After three washes of 10 min in TBS and one wash of 5 min in AP buffer (100 
mM Tris and 100 mM NaCl [pH 9.5]), sections were stained in 350 ^g/ml 4-nitro blue 
tetrazolium chloride and 175 ^g/ml 5-bromo-4-chloro-3-indolyl-phosphate (Roche 
Diagnostics) in AP buffer until color development was sufficient. Then, sections were 
washed twice with distilled H2O and mounted in Mowiol. Alternating sections were 
used for AQP2 immunohistochemistry. After mounting of fixed sections on poly-L- 
lysine coated slides and rehydration in graded series of ethanol, sections were washed 
with TBS, incubated with 1% H2O2 in TBS for 15 min to quench endogenous 
peroxidase activity, rinsed with TBS, incubated with 1:100 diluted rabbit anti-AQP2 
antibodies in blocking buffer, washed three times with TBS, and incubated for 1 h in
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1: 100 diluted donkey anti-rabbit antibodies coupled to horseradish peroxidase (Jackson 
ImmunoResearch Laboratories, West Grove, PA). After washing three times in TBS, 
sections were incubated in diaminobenzidene until color development was sufficient. 
Then, sections were dehydrated in graded series of alcohol and ethylene and mounted 
in Entellan (Merck, Darmstadt, Germany). A sense LIP5 cRNA probe was taken along 
as a negative control for the specificity of the LIP5 mRNA hybridization.
mpkCCD Cells and shRNA Assays
MpkCCD cells (clone 14) (27) were grown in modified defined medium 
(DMEM:Ham’s F12 1:1 vol/vol; 60 nM sodium selenate, 5 ^g/ml transferrin, 2 mM 
glutamine, 50 nM dexamethasone, 1 nM triiodothyronine, 10 ng/ml EGF, 5 ^g/ml 
insulin, 20 mM D-glucose, 2% FCS, and 20 mM HEPES [pH 7.4]) at 37°C in an air 
atmosphere of 5% CO2 . The medium was replaced every 2 d. Exponentially growing 
cells (at approximately 70% confluence) were trypsinized and seeded at a density of 1.5 
x 105 cells/cm2 on semipermeable filters (Transwell, 0.4-^m pore size; Corning Costar, 
Cambridge, MA) of 1.13 cm2. The cells remained in culture for a total period of 8  d 
before being analyzed. The cells were treated for the last 96 h with 1 nM dDAVP to 
only the basolateral side to induce AQP2 expression maximally. TPA (0.1 ^M), 
cycloheximide (50 ^M), MG132 (20 ^M), and chloroquine (100 ^M) were 
administered to both the apical and the basolateral compartments for the indicated time 
periods.
To make pLV-CMV-GFP-shRNA-LIP5 constructs for the LIP5 shRNA assays, we first 
created the pTER-LIP5 construct. Phosphorylated LIP5-specific oligonucleotides (10 
^g) were annealed in 100 ^l of 25 mM KCl by incubating the mixture at 95°C for 2 
min and slowly cooling to room temperature. A total of 1 ^l of the mixture was ligated 
into the BglII- and HindIII-digested pTER vector (33). The following oligonucleotides 
were used: 5’-GATCCCCGACAATGACTCCTGTGTGGTTCAAGAGACC-3’, 5’-
CTTGAACCACACAGGAGTCATTGTCGGG-3 ’, 5’-
ACACAGGAGTCATTGTCTTTTTGGAAA-3 ’, and 5’-
AGCTTTTCCAAAAAGACAATGACTCCTGTGTGGTCT-3 ’ for pTER-LIP5-1;
5 ’ GATCCCCTGAAGATCGAGCTGGACGATTCAAGAGATC-3 ’, 5’-
CTTGAATCGTCCAGCTCGATCTTCAGGG-3 ’, 5’-
GTCCAGCTCGATCTTCATTTTTGGAAA-3’, and 5’-
AGCTTTTCCAAAAATGAAGATCGAGCTGGACGATCT- 3’ for pTER-LIP5-2. To 
generate the lentiviral LIP5 shRNA constructs, we inserted the PstI fragments from the 
pTER-LIP5 constructs containing the H1 promoter and LIP5 shRNA sequences into the 
corresponding site of pLV-CMV-GFP (34). MpkCCD cells were stably transfected 
with pCB6-AQP2 using the calcium-phosphate precipitation technique as described 
previously (35). Third-generation lentiviruses were produced by co-transfection of the 
packaging vectors pRSV-Rev, pMDL g/p RRE, and pMD2G (Tronolab, Lausanne, 
Switzerland) and the transfer vector pLV-CMV-GFP-shRNA-LIP5 into human
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embryonic kidney 293T cells as described previously (36). The titer was determined by 
a p24 HIV ELISA (Murex Diagnostics, Dartford, United Kingdom).
MpkCCD cells stably expressing AQP2 were infected with lentivirus immediately 
before being plated in the presence of Polybrene ( 8  ^g/ml) using a multiplicity of 
infection of 20. The next day, medium was replaced. Immunoblotting and 
immunocytochemistry were performed 4 d after infection. The half-life of AQP2 was 
determined on the basis of the best fitting model of regression.
LIP5 Antibodies
To obtain rabbit anti-LIP5 antibodies, we induced expression of soluble GST-LIP5 
with IPTG in DH5a bacteria transfected with pGEX6.1-LIP5 (made as described in the 
Pulldown Assays section) and isolated using glutathione-Sepharose 4B beads 
(Amersham Pharmacia Biotech, Uppsala, Sweden). After complete bleeding of the 
rabbits, anti-GST antibodies were removed by passing the serum over a GST-coupled 
Affi-gel 15 column (Amersham Pharmacia Biotech). Then, the flow-through was 
passed over a GST-LIP5-coupled Affi-gel 15 column, and the antibodies were eluted 
with 0.1 M glycine (pH 2.8), after which they were directly neutralized in 5x PBS (pH 
7.4).
Immunohistochemistry
Mice were perfused with 1% (wt/vol) paraformaldehyde-lysine-periodate (37). The 
kidneys were removed, cut into 2- to 3-mm sections, and incubated in 
paraformaldehyde-lysine-periodate for 2 h. After fixation, the kidneys were dehydrated 
and embedded in paraffin. Five-micrometer sections were cut, stretched in 37°C water, 
and dried on gelatin-coated object glass (Menzel Gläser, Braunschweig, Germany) for 
at least 1 h at 37°C. Then, the sections were deparaffinized with xylol; rehydrated 
subsequently with 100, 96, 90, 80, 70, and 50% ethanol and water; and mounted in 
mowiol. Immunocytochemistry was done as described for MDCK cells (38). For 
detection of LIP5 and AQP2, the sections were incubated with affinity-purified rabbit 
anti- LIP5 antibodies (1:25), goat anti-rabbit antibodies coupled to Alexa 594 
(Molecular Probes, Eugene, OR; 1:100), and, subsequently, with affinity-purified 
guinea pig anti-AQP2 (39) and goat anti-guinea pig antibodies coupled to Alexa 488 
(Molecular Probes; 1:100).
Immunoblotting
Immunoblotting was done as described previously (40). As antibodies, affinity-purified 
rabbit anti-AQP2 (1:3000) (39), rabbit anti-LIP5 (1:1000), rabbit anti-AQP4 (1:1500) 
(39), rabbit anti-GFP (1:5000; provided by Dr. B. Wieringa, UMC Nijmegen, 
Nijmegen, Netherlands), guinea pig anti-AQP2 (1:4000) (39), mouse anti-Xpress 
(1:5000), or rabbit anti-EGFR 1005 (1:1000; Santa Cruz Biotechnology) was used. As 
secondary antibodies, goat anti-rabbit, goat anti-guinea pig, or sheep anti-mouse
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antibodies coupled to horseradish peroxidase (Sigma, St. Louis, MO; 1:5000) were 
used.
Results
Screening for A QP2-Interacting Proteins
To isolate proteins involved in AQP2 regulation, we transfected yeast cells expressing 
(for clarity, expression refers to protein expression unless indicated otherwise) a fusion 
protein of LexA and the C-tail of AQP2-S256A with a mouse kidney cDNA library, 
grown under selective conditions and screened for b-galactosidase activity. 
Approximately 3.85 x 106 colonies were screened. Of the 22 initial positive clones, six 
remained positive after re-screening in combination with the AQP2-S256A bait 
construct but not with the empty bait plasmid. Sequence analysis of the positive clones 
revealed that all six clones encoded the same protein showing 1 0 0 % identity to a 
mouse RIKEN cDNA library clone annotated Mus musculus Vps20-associated 1 
homolog (Saccharomyces cerevisiae; Entrez GenelD 66201), encoding the mouse 
orthologue of human LIP5. A schematic representation and primary sequence of LIP5 
are depicted in Supplemental Figure 1. Among the six positive clones, four different 
positions for LexA-fusion were observed, all of them within the first eight N-terminal 
LIP5 residues, indicating that the product of several independent clones interacted with 
the AQP2 C-tail.
Supplemental Figure 1. Motifs 
in and sequence of LIP5. (A)
LIP5 contains three putative 
protein interacting motifs, being a 
microtubule interacting and 
transport motif 1 and 2 (MIT 1/2) 
and a C-terminal so-called VSL 
(Vta1/SBP/LIP5) domain
(underlined in Supplemental 
figure 1B). (B) Amino acid 
sequence of human LIP5. The 
amino acids corresponding to the 
motifs indicated in section A are 
underlined.
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Site and Specificity of the AQP2-LIP5 Interaction
To allow further characterization of the role of LIP5 in AQP2 binding and regulation, 
we generated antibodies directed against full-length LIP5. 
Immunohistochemical/cytochemical and immunoblot data (Supplemental Figure 2) and 
the immunoblot data from the LIP5 shRNA experiment reveal the specificity of our 
LIP5 antibodies.
Supplemental Figure 2. Specificity of the LIP5 antibodies. (A) Immunohistochemistry of mouse 
kidney sections (upper panel) and immunocytochemistry of mpkCCD cells (lower panel) demonstrate 
a dispersed specific staining when incubated with LIP5 antibodies (left column), but no staining when 
the LIP5 antibodies were pre-adsorbed with GST-LIP5 (right column). (B) Besides transfected LIP5 of 
around 44 kDa (right lane, lysate), our LIP5 antibodies also detect endogenous LIP5 of around 42 kDa 
(middle lane, lysate) in COS cells. GST-AQP2 pull down experiments of these samples revealed 
binding of endogenous and exogenous LIP5 to GST-AQP2 (upper panel). The absence of LIP5 binding 
to GST alone is shown in Fig. 1D. Immunoblotting of a sample of COS lysate that was partially pre­
cleared with LIP5 antibodies coupled to gluthation beads revealed no endogenous LIP5 of 42 kDa 
band anymore (lysate LIP5 depl), while a clearly reduced amount of endogenous LIP5 was observed 
after subjecting this sample to the AQP2 pull down assay (pull down, LIP5 depl).
To identify the LIP5-binding region in AQP2, we conducted yeast two-hybrid assays 
with truncated AQP2 C-tails. b-Galactosidase assays revealed that AQP2 C-tails 
truncated at Q263, R252, and D243 were still able to interact with LIP5, whereas 
interaction was lost with AQP2 truncated at L230 (Figure 1A), indicating that region 
230 to 243 of AQP2 is essential for LIP5 binding.
In the kidney, AQP2, AQP3, and AQP4 are expressed in the same cells (41; 42). For 
investigation of the specificity of the LIP5-AQP2 interaction, LexA-AQP C-tail fusion 
proteins of AQP2, AQP3, and AQP4 were expressed in yeast and tested for interaction 
with LIP5. b-Galactosidase assays revealed that LIP5 interacted with the C-tail of wt- 
AQP2 but not with the C-tails of AQP3 (M264-I292) or AQP4 (V251-V323; Figure 
1A). Yeast cells transfected with bait and empty pACT2 constructs revealed no staining
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(Figure 1A). Immunoblot analysis of the yeast cells confirmed expression of the bait 
and prey proteins (data not shown). For confirmation and further testing of whether 
LIP5 directly interacts with the AQP2 tail or requires additional proteins, 35S- 
methionine/cysteine-labeled LIP5 was synthesized in vitro and incubated with 
glutathione S-transferase (GST), GST-AQP2 , or GST-AQP4 coupled to glutathione 
Sepharose beads. Autoradiography of the eluted proteins showed that LIP5, running at 
approximately 42 kD, directly interacts with GST-AQP2  but, again, not with GST- 
AQP4 or GST (Figure 1B).
To investigate whether renal LIP5 would specifically interact with the AQP2 tail, we 
incubated dog kidney cytosol with GST, GST-AQP2, or GST-AQP4 coupled to 
glutathione Sepharose beads. LIP5 immunoblotting of the isolated interacting proteins 
showed a renal protein of approximately 42 kD specifically interacting with GST- 
AQP2 and not with GST or GST-AQP4 (Figure 1C). These results thus showed that 
LIP5 binding to the C-tail of AQP2 was specific in relation to the C-tails of AQP3 and 
AQP4.
LIP5 Interaction with the EGF Receptor
Our data reveal AQP2 as the first cargo protein identified to interact with LIP5; 
however, LIP5 has been reported to facilitate EGF receptor (EGFR) degradation and 
might therefore also interact with EGFR (24). For testing this, EGFR and Xpress 
tagged LIP5 were coexpressed in HEK293 cells. After EGFR immunoprecipitation, 
immunoblotting for the Xpress-tag indeed demonstrated that tagged LIP5 co­
precipitated with EGFR (in duplicate; Figure 1D, lanes 1 and 2), indicating that LIP5 
interacts with EGFR. Note that immunoblotting for LIP5 of the cell lysates shows 
endogenous LIP5 of approximately 42 kD, besides a strong and weak band of Xpress- 
tagged LIP5. Our data thus reveal that, besides AQP2, the cargo protein EGFR 
interacts with LIP5.
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Figure 1. Interaction of LIP5 
with AQP2, AQP3, AQP4, and
EGFR. (A) Yeast cells expressing 
LexA fused to the C-tail of wt- 
AQP2, AQP2-S256A, AQP2- 
S256D, AQP2-E258K, AQP3, or 
AQP4 proteins, all in combination 
with GAL4-LIP5 fusion proteins, 
were analyzed for interaction 
using b-galactosidase activity 
assays. Yeast cells expressing the 
C-tails of wt-AQP2, AQP2- 
S256A, AQP2-S256D, and 
AQP2-E258K but not those of AQP3 or AQP4 
show blue staining of the colonies and thus 
interaction with LIP5. Sequential stop mutants of 
the C-tail of AQP2 revealed that only upon 
deletion of region L230-D243, binding of the 
AQP2 C-tail with LIP5 is lost. Control yeast cells 
transfected with bait and empty prey constructs 
did not show any p-galactosidase activity. (B and C) GST or GST fused to the C-tails of AQP2 (GST- 
AQP2) or AQP4 (GST-AQP4) were incubated with in vitro translated LIP5 (B) or dog kidney cytosol 
(C) and subjected to GST pulldown assays. LIP5 was visualized by autoradiography (B) or 
immunoblotting (C). (D) For determination of whether LIP5 also interacts with the EGFR, Xpress- 
tagged LIP5 was expressed alone or together with the EGFR (in duplicate) in HEK293 cells, lysed, and 
subjected to EGFR immunoprecipitation. Subsequent immunoblotting of the precipitates using mouse 
anti-Xpress-tag antibodies revealed that Xpress-tagged LIP5 co-precipitated with the EGFR but was 
not precipitated when expressed alone (top). EGFR immunoblotting of the lysates revealed specific 
signals for the EGFR in lanes of cells transfected with EGFR constructs (bottom). LIP5 
immunoblotting showed Xpress-tagged (exo) and endogenous (endo) LIP5 in cells transfected with 
LIP5 constructs (third panel).
LIP5 Expression in the Kidney
For LIP5 to have a role in the regulation of AQP2 in vivo, it needs to be present in renal 
principal cells. We performed LIP5 in situ hybridization and AQP2 
immunohistochemistry on alternating mouse kidney sections. Microscopic analysis 
revealed that renal principal cells (positive for AQP2; Figure 2A, 2 and 4) indeed also 
contain LIP5 mRNA (Figure 2A, 1 and 3). Besides these cells, LIP5 mRNA was 
detected in epithelial cells of other renal tubules and collecting duct cells. A sense 
probe of LIP5 cRNA, which was taken along as a negative control, revealed no staining 
(Figure 2A, 5).
Next, AQP2 and LIP5 co-localization was determined. Immunohistochemistry for 
AQP2 and LIP5 on mouse kidney sections and confocal laser scanning microscopy
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revealed that AQP2 co-localizes with LIP5 in the apical region of renal principal cells 
(Figure 2B). Interestingly, in AQP2-negative tubules (arrows in Figure 2B) and 
intercalating cells (asterisks in Figure 2B), which are the AQP2-negative cells of 
collecting ducts, LIP5 showed a punctuate staining, suggesting a vesicular localization 
of LIP5 in these cells.
Figure 2.
Localization of LIP5 
in mouse kidney. (A)
Alternating mouse 
kidney sections were 
used to visualize the co­
localization of LIP5 
mRNA (by in situ 
hybridization; 1 and 3) 
and AQP2 (by 
immunohistochemistry; 
2 and 4). LIP5 mRNA is 
detected in most 
epithelial cells. In situ 
hybridization using a 
sense probe did not 
reveal any specific 
staining (5). (B) Renal 
sections of mice 
receiving water ad 
libitum were subjected 
to
immunohisto chemistry
for LIP5 (red) and AQP2 (green). In renal principal cells, which express AQP2, LIP5 shows similar 
localization to that of AQP2 (middle). In intercalating cells (*) and epithelial cells of other tubules 
(arrows), LIP5 staining is more punctuate.
1/ C
LIP5 AQP2 Merge
Effect of Physiologic Modification in the AQP2 C-Tail on Its Interaction with LIP5 
In vivo, redistribution of AQP2 from intracellular vesicles to the apical membrane 
coincides with phosphorylation of AQP2 at Ser256 (10; 11). Subsequent studies in 
MDCK cells showed that phosphorylation at Ser256 is essential and sufficient for 
apical membrane localization of AQP2, because AQP2-S256A, which mimics 
nonphosphorylated AQP2, is localized in intracellular vesicles, whereas AQP2-S256D, 
mimicking phosphorylated AQP2, is localized in the apical membrane (8 ). Also, AQP2 
mutants in dominant NDI have missense or frame-shift mutations in the C-tail, one of 
which is AQP2-E258K (15; 16). For determination of whether LIP5 binding to the 
AQP2 C-tail depends on the AQP2 phosphorylation state and whether binding is lost
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with AQP2 mutants in dominant NDI, the C-tails of AQP2-S256A, AQP2-S256D, and 
AQP2-E258K were expressed with LIP5 in yeast and tested for interaction. b- 
Galactosidase assays revealed a positive signal for the S256A, S256D, and E258K C- 
tails (Figure 1A), suggesting that LIP5 binding is independent of the AQP2 
phosphorylation state and is maintained in the AQP2-E258K mutant. Using HEK293 
cells, transiently-expressing AQP2-S256A or AQP2-S256D, co-immunoprecipitation 
assays confirmed that interaction of LIP5 with AQP2 is independent of AQP2 
phosphorylation state (Figure 3A).
Besides phosphorylation, AQP2 is subject to mono-ubiquitination at Lys270, which 
enhances endocytosis and degradation of AQP2 (20). To determine whether LIP5 
interaction with AQP2 depends on the ubiquitination state of AQP2, wt-AQP2, AQP2 
that cannot be ubiquitinated (AQP2-K270R), or constitutively ubiquitinated AQP2 
(AQP2-Ub) were expressed in HEK293 cells and tested for interaction. Co- 
immunoprecipitation assays and subsequent immunoblotting revealed that LIP5 binds 
both AQP2-K270R and AQP2-Ub, indicating that LIP5 binding to AQP2 is 
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Figure 3. LIP5 interaction with physiologically modified AQP2. (A) For determination of whether 
LIP5 binding to AQP2 depends on the phosphorylation state of AQP2, LIP5 was expressed together 
with wt-AQP2, AQP2-S256D, and AQP2-S256A in HEK293 cells; lysed; and subjected to LIP5 
immunoprecipitation. Subsequent immunoblotting of the precipitates demonstrated that wt-AQP2, 
AQP2-S256D, and AQP2-S256A co-precipitated with LIP5 (top). Immunoblotting of the lysates 
revealed similar signals for AQP2 in lanes of cells transfected with AQP2 protein constructs (middle) 
and for endogenous (endo) and exogenous (exo) LIP5 in cells transfected with LIP5 constructs 
(bottom). (B) For determination of whether LIP5 binding to AQP2 depends on the ubiquitination state 
of AQP2, LIP5 was expressed together with wt-AQP2, AQP2-K270R, and AQP2-Ub in HEK293 cells. 
Subsequent cell lysis and LIP5 immunoprecipitation followed by immunoblotting showed that wt- 
AQP2, AQP2-K270R, and AQP2-Ub co-precipitated with LIP5 (top). Immunoblotting of the lysates 
revealed equal signals for AQP2 in lanes of cells transfected with wt-AQP2, AQP2-K270R, and 
AQP2-Ub constructs (middle) and for endogenous (endo) and exogenous (exo) LIP5 in cells 
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Figure 4. TPA induces 
internalization and lysosomal 
degradation of AQP2 in mpkCCD 
cells. (A) TPA induced internalization 
of AQP2. For testing whether phorbol 
esters also induce internalization of 
AQP2 in mpkCCD cells, a monolayer 
of polarized mpkCCD cells stably 
expressing exogenous AQP2 
(mpkCCD-AQP2) was stimulated with 
forskolin for 45 min followed by 
stimulation with forskolin only (-TPA) 
or together with TPA (+TPA) for 45 
min. Subsequent
immunocytochemistry and confocal 
laser scanning microscopy 
demonstrated internalization of AQP2 
upon TPA treatment. (B) TPA induces 
lysosome-mediated degradation of 
AQP2. MpkCCD-AQP2 cells were 
stimulated with forskolin for 45 min, 
followed by incubation with forskolin 
alone or together with cycloheximide.
Moreover, cells treated with forskolin 
and cycloheximide were additionally 
treated with or without TPA alone or TPA together with the proteasome blocker MG132 or the 
lysosome blocker chloroquine. All treatments after stimulation with forskolin were for 2 h, after which 
the cells were lysed. Immunoblotting for AQP2 revealed that co-incubation with chloroquine but not 
MG132 counteracted the TPA-induced increase in AQP2 degradation. Immunoblotting was performed 
in at least two independent experiments performed in triplicate. Quantification of AQP2 levels showed 
significant effects (two-tailed t test; *P <0.05, **P <0.01). (C) TPA reduces the half-life of existing 
AQP2. MpkCCD-AQP2 cells were grown and stimulated to induce AQP2 expression as described in 
A. Cells were then treated with cycloheximide alone or together with TPA for the indicated periods. 
Cells were then lysed and analyzed using Western blotting using AQP2 antibodies (top), followed by 
semiquantification using densitometry. The data are plotted as a percentage of the control (mpkCCD 
cells grown 4 d in the presence of dDAVP). Quantification of AQP2 levels showed significant effects 
(two-tailed t test; *P <0.05).
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Role of LIP5 in AQP2 Abundance
LIP5 is implicated in sorting of proteins to the internal vesicles of MVBs after 
endocytosis, from where proteins are targeted for lysosomal degradation (24), and LIP5 
knockdown decreases lysosomal degradation of EGFR (24). In polarized MDCK cells, 
AQP2  is also degraded through the lysosomal pathway. In addition, activation of the 
protein kinase C (PKC) pathway by the phorbol-ester 12-tetradecanoylphorbol-13- 
acetate (TPA) counteracts the AVP-induced translocation of AQP2  to the apical 
membrane by inducing AQP2 internalization and degradation (8 ; 20). To test whether 
LIP5 has a similar function with regard to AQP2, we tested whether mpkCCD cells 
(murine collecting duct cells that yield expression of endogenous AQP2 protein upon 
treatment with dDAVP [43; 44]) show internalization of AQP2 upon TPA treatment. 
Immunocytochemistry and confocal laser scanning microscopy analysis showed 
presence of endogenous AQP2 in the apical membrane with dDAVP, which was 
redistributed to intracellular vesicles upon 45 min of TPA treatment (Figure 4A). 
Furthermore, immunoblot analysis showed that 2  h of TPA treatment in the presence of 
the protein synthesis inhibitor cycloheximide significantly increases the degradation of 
existing AQP2, which was partially blocked by the proteasomal inhibitor MG132 and 
completely blocked by chloroquine, which inhibits lysosomal degradation (Figure 4B). 
To investigate the effect of TPA on the half-life of AQP2, we incubated vasopressin- 
stimulated mpkCCD cells for various periods with or without TPA in the continuous 
presence of cycloheximide and immunoblotted for AQP2 (Figure 4C). After 60 min of 
TPA treatment, AQP2 levels were significantly (P<0.05) decreased for TPA-treated 
versus control cells. Calculations revealed that TPA reduced the half-life of AQP2 from
234.5 ± 32.7 to 66.2 ± 14.3 min.
To investigate whether LIP5 plays a role in AQP2 degradation, we made lentiviruses 
driving the expression of two different murine LIP5 (LIP5-1/2) shRNAs or a random 
sequence (mock). For recognition of infected cells, the viral DNA also encoded 
cytomegalovirus (CMV) promoter-driven GFP. Testing the viruses in untransfected, 
dDAVP-stimulated mpkCCD cells revealed that most cells had lost the shRNA 
constructs at the time of appropriate AQP2 abundance (at 4 d of dDAVP treatment 
after 4 d of cell polarization); therefore, mpkCCD cell lines stably expressing AQP2 
were generated. To perform experiments with physiologically relevant AQP2 protein 
levels, we selected clones that express AQP2 at a similar or lower level than 
endogenous AQP2 after stimulation with 1 nM dDAVP by immunoblotting (data not 
shown). After infection of mpkCCD-AQP2 cells with shRNA viruses, 
immunocytochemistry showed a strongly decreased LIP5 abundance in cells infected 
with the LIP5-specific shRNAs (LIP5-1, LIP5-2; Figure 5A), whereas cells infected 
with a virus encoding the mock shRNA (Figure 5A) showed no difference in LIP5 
protein abundance compared with uninfected cells. This indicated that LIP5-specific 
shRNAs but not viral infection itself affects LIP5 protein abundance. Unfortunately, we 
did not succeed in co-staining for LIP5 and AQP2 in the GFP background.
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To determine the effect of LIP5 knockdown on AQP2 degradation, we treated cells 
with cycloheximide in the absence or presence of TPA for 2 h and lysed them. 
Consistent with immunocytochemistry, subsequent immunoblot analysis for LIP5 
revealed that LIP5 shRNAs but not mock shRNA yielded significantly reduced LIP5 
protein levels (90 and 70% for LIP5-1 and LIP5-2, respectively; Figure 5, B and C). 
Upon TPA treatment, AQP2 levels were significantly higher with both shRNA virus- 
infected cells compared with mock virus-infected cells (Figure 5, B and C, +TPA). 
Assuming a similar half-life for AQP2 in non-TPA-treated cells as found for non-TPA- 
treated mpkCCD cells (Figure 4C), the reduced decrease of AQP2 with TPA in LIP5 
shRNA-expressing cells indicated that knockdown of LIP5 increased the TPA-induced 
half-life approximately 1.5- to 2.5-fold. Because Coomassie staining confirmed equal 
protein loading (Figure 5, B and C) and there was no effect on LIP5 or AQP2 
abundance levels in mpkCCD cells infected with mock shRNA virus (Figure 5A, 
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Figure 5. LIP5 silencing results in reduced lysosomal degradation of AQP2. MpkCCD cells stably 
transfected with AQP2 were infected with viruses expressing two different LIP5 shRNAs (LIP5-1, 
LIP5-2) at a multiplicity of infection of 20. Four days later and after stimulation with forskolin for 45 
min, the cells were incubated with cycloheximide in the absence or presence of TPA for 2 h. (A) Cells 
were subjected to immunocytochemistry for GFP (left) and LIP5 (right). In mock shRNA-expressing 
cells, LIP5 abundance was not affected. LIP5 shRNA expressing cells showed decreased LIP5 
staining. (B) Cell lysates were immunoblotted for GFP, LIP5, and AQP2. Immunoblotting for GFP 
serves as a measure for infection efficiency, whereas Coomassie staining demonstrates equal protein 
loading. A representative immunoblot of two experiments is shown. (C) Quantification of the 
immunoblot signals of two independent experiments performed in triplicate. The signals were scanned, 
and the amounts of LIP5, AQP2, AQP4, and total protein were quantified in arbitrary units ±SEM. 
*Significant difference from mock-treated cells (two-tailed t test; P  <0.05).
Interestingly, mpkCCD cells endogenously express AQP4, which is not bound by LIP5 
(Figure 1). Analysis of AQP4 under all of these conditions revealed that AQP4 
abundance is not affected by LIP5 knockdown (Figure 5, B and C), indicating that the 
effect of LIP5 is specific for AQP2.
Discussion
LIP5 Specifically Interacts with the Proximal Region o f the AQP2 C-Tail Independent 
of AQP2 Phosphorylation or Mono-ubiquitination
We identified LIP5 to interact with the C-tail of AQP2-S256A in yeast two-hybrid 
assays. Whereas AQP2 is coexpressed with AQP3 and AQP4 in renal principal cells 
and all have a similar gross architecture, yeast two-hybrid and GST pulldown analyses 
revealed that LIP5 interacts directly and specifically with the AQP2 C-tail only, not 
with the C-tails of AQP3 or AQP4 (Figure 1, A through C). Further analysis of the 
AQP2 C-tail revealed that LIP5 binds region L230 to D243 of AQP2 (Figure 1A). 
Consistent with binding to this region of AQP2, the interaction of LIP5 to AQP2 is 
independent of AQP2 phosphorylation (at Ser256) and mono-ubiquitination (at K270) 
and is also not affected by an AQP2 mutation causing NDI, because the sites of these 
modifications are outside the LIP5 binding region (Figure 3). The precise mode of 
interaction and amino acids involved remains to be established.
LIP5 Interacts with Cargo Proteins
The MVB machinery is composed of three complexes, ESCRT-I, -II, and -III, which 
are sequentially recruited to sites of MVB sorting and vesicle formation. Subsequent 
release of ESCRT-III from the membrane requires Vps4 ATPase activity and allows 
the ESCRT machinery to recycle through multiple rounds of luminal vesicle formation. 
So far, LIP5 has been shown to interact with Vps4 and several ESCRT-III components,
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including CHMP5, CHMP1B, CHMP2A, and CHMP3 (24; 45-49). Our data reveal for 
the first time that LIP5 also interacts with cargo proteins, because AQP2as well as the 
EGFR specifically co-precipitated with LIP5 (Figure 1). It will be interesting to unravel 
to which LIP5 segment these two proteins bind and whether these two proteins 
compete with CHMPs for binding to Vps4.
LIP5 Is Involved in the Lysosomal Degradation Pathway of AQP2 
Membrane proteins targeted for lysosomal degradation are sorted into vesicles that bud 
into MVBs. These MVBs can serve as long-term storage compartments, fuse with 
lysosomes to deliver the internal vesicles and their contents for degradation, or fuse 
with the plasma membrane to release the vesicles as extracellular exosomes. MVB 
vesicle formation and protein sorting require a set of class-E vacuolar protein sorting 
(VPS) proteins (50-52). Most class-E proteins function as components of one of the 
three ESCRT complexes, which are sequentially recruited to sites of MVB sorting and 
vesicle formation. The ESCRT-III proteins are the last to assemble, forming a 
membrane-associated lattice that functions in the final stages of this process. Via direct 
protein-protein interactions, Vps4 is recruited to MVBs, which induces the release of 
the ESCRT-III complex from the membrane (50; 52).
Emerging evidence points toward a role for LIP5 dimers in the disassembly of the 
ESCRT-III complex by stimulating Vps4 ATPase activity, which occurs directly 
through interaction between the conserved C-terminal VSL domain of LIP5 and Vps4 
(47-49). Consistently, deletion of Vta1 (the yeast LIP5 orthologue) in yeast results in 
altered vacuolar morphology (45), and knockdown of LIP5 in mammalian cells 
facilitates downregulation of EGFR (24).
Supplemental Figure 3. LIP5 overexpression does not affect AQP2 abundance. To examine the 
role of LIP5 on AQP2 abundance, WT10 cells (MDCK cells stably expressing AQP2) were stably 
transfected with pNRTIS21-LIP5, a tetracycline (TET) inducible vector that represses LIP5 expression 
upon tetracycline incubation. Two different clones showed a clear increase in LIP5 abundance upon 
tetracycline removal, but no difference in AQP2 abundance.
Several data suggest a similar role for LIP5 in AQP2 regulation in principal cells: First, 
LIP5 is coexpressed with AQP2 in renal principal cells (Figure 2) and LIP5 has been 
identified in AQP2-containing exosomes isolated from urine (My012 protein) (53). 
Second, renal LIP5 interacts specifically with the Cterminal tail of AQP2 (Figure 1). 
Third, LIP5 facilitates the lysosomal degradation of AQP2: Whereas induced LIP5
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overexpression in MDCK-AQP2 cells did not affect AQP2 abundance (Supplemental 
Figure 3) or translocation to the apical membrane, knockdown of LIP5 abundance 
resulted in a 1.5- to 2.5-fold increase in the AQP2 half-life after TPA treatment (Figure 
5, B and C), a condition known to induce AQP2 internalization and degradation (8 ) 
(Figure 4). Considering our finding that AQP2 levels seemed somewhat increased in 
LIP5 shRNA versus mock cells without TPA treatment (Figure 5, B and C), the half­
life of AQP2 in LIP5 knockdown cells without TPA treatment may be higher than that 
of AQP2 in dDAVP-stimulated mpkCCD cells (Figure 4C); therefore, the estimated 
increase in AQP2 half-life with LIP5 knockdown after TPA treatment should be taken 
as a rough estimate.
Under the tested conditions, the effect of LIP5 knockdown is clear upon treatment with 
TPA but not without TPA treatment, which can be explained as follows: At any 
moment in time, AQP2 resides at several locations in the cell (endoplasmic reticulum, 
Golgi, storage vesicles, plasma membrane, recycling vesicles, MVBs, and lysosomes), 
and the steady-state localization of AQP2 is a balance regulated by extracellular and 
intracellular signals, such as the presence of AVP, and cAMP-dependent 
phosphorylation or activation of the PKC pathway. TPA-induced degradation of AQP2 
in mpkCCD cells mainly occurs via lysosomes (Figure 4B) and, as illustrated by the 
large half-life of AQP2 of nearly 4 h (Figure 4C), only a small fraction of AQP2 is 
targeted for lysosomal degradation in the tested 2-h period under non-TPA conditions. 
With the TPA-induced internalization and lysosomal degradation of AQP2 (20) (Figure 
4), which decreases the AQP2 half-life to approximately 70 min, more AQP2 will thus 
pass LIP5 on its way to MVBs/lysosomes for the 2 h measured, and, therefore, the 
effect of (the absence of) LIP5 on AQP2 is larger and better detectable under these 
conditions. The partial inhibition of AQP2 degradation in our LIP5 shRNA 
experiments may suggest that, like its yeast orthologue Vta1 (49), LIP5 has only a 
modulatory role in the lysosomal degradation of AQP2; however, this cannot be 
deduced from our experiments, because as a result of incomplete infection and/or 
shRNA knockdown, our shRNA-expressing cells were not devoid of LIP5 (Figure 5B). 
On the basis of these data, we propose the following model for the role for LIP5 in the 
regulation of AQP2 in principal cells: After stimulation with AVP and translocation of 
AQP2 to the apical membrane, renal water reabsorption will occur, which may be 
increased by an extended presence of AQP2 in the plasma membrane through an 
interaction with MAL (22). With removal of AVP or activation of the PKC pathway, 
which is thought to follow binding of hormones such as endothelin, PGE2, and ATP, 
AQP2 is ubiquitinated at Lys270, which signals its endocytosis (20). After recruitment 
to clathrin-coated vesicles, AQP2 is then endocytosed from the apical membrane 
involving direct interaction with heatshock protein 70 (23). Via early endosomes, 
AQP2 is then sorted via ESCRT proteins and interaction with LIP5 to inner vesicles of 
MVBs,from where it can be targeted to lysosomes for degradation or released as 
exosomes from the cells into urine (Figure 6 ) (53). Unfortunately, we were not able to
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co-immunoprecipitate AQP2 with LIP5 from mouse kidney homogenates, which may 
be due to a reduced abundance of LIP5 or low level of AQP2-LIP5 interaction in the 
kidney.
Figure 6. Model for LIP5 
function in the regulation of 
AQP2. On the basis of our 
findings, we propose the 
following model for LIP5 
function in AQP2 regulation: 
After AVP-induced translocation 
of AQP2 to the apical membrane, 
water will be reabsorbed from the 
pro-urine. Interaction with MAL 
may increase water reabsorption 
further by extending the presence 
of AQP2 in the plasma 
membrane. Upon removal of AVP 
or activation of the PKC pathway, 
AQP2 is mono-ubiquitinated by a 
presently unknown ubiquitin E3 ligase, and, subsequently, endocytosis will occur. AQP2 is recruited to 
clathrin-coated vesicles and endocytosed from the apical membrane involving direct interaction with 
heat-shock protein 70 (HSP70). Via early endosomes (EE), AQP2 is then sorted via ESCRT-I, -II and, 
-III protein complexes to the limiting membrane of MVBs. There, interaction with LIP5 and LIP5- 
facilitated activity of VPS4 AATPase mediates translocation of AQP2 from the limiting membrane to 
inner vesicles of MVBs, from where it can be targeted to lysosomes for degradation or released as 
exosomes from the cells into urine.
The binding of LIP5 to the proximal region of the AQP2  C-tail and its independence of 
the ubiquitination and phosphorylation status of AQP2 (Figure 3) is in line with the 
finding that TPA-induced internalization of AQP2 constitutively phosphorylated at 
S256 still leads to its degradation (8 ; 54) and that AQP2 degradation is well detectable 
only at 2 h after TPA treatment, at which point AQP2 is not detectably ubiquitinated 
anymore (20). Recently, AQP2 was found to be phosphorylated at other sites in its C- 
terminus (55). It remains to be established whether phosphorylation of these sites 
influences LIP5 binding to AQP2.
Interestingly, LIP5 has also been reported to interact with the lysosomal trafficking 
regulator LYST (56), which is a cytosolic protein of 425 kD with a putative function in 
lysosome-related organelles (57). Yeast two-hybrid screens with LYST identified 
several putative partners, some of which have been shown to co-localize (HRS; 58) or 
be involved (calmodulin; 1) in the regulation of AQP2. If LYST is expressed in 
collecting duct cells, then LYST may be a scaffolding protein involved in the 
degradation of AQP2.
59
LIP5 Interacts with Aquaporin 2 and Facilitates Its Lysosomal Degradation
Moreover, calmodulin has been shown to interact with proximal C-terminal tail of 
AQP0 (59), the region bound by LIP5 in AQP2. Although these regions are similar 
between AQP0 and AQP2, we could not detect binding between heterologously 
expressed calmodulin and the AQP2 C-tail in GST pulldown experiments (data not 
shown).
In summary, we have identified that LIP5 is coexpressed with AQP2 in renal principal 
cells, interacts with the proximal C-tail of AQP2, and facilitates its lysosomal 
degradation. Our data thus indicate that LIP5 plays an important role in the 
MVB/lysosomal targeting of AQP2, as induced by AVP-counteracting hormones, after 
which it will be degraded or expelled from the cells into urine. It will be interesting to 
seehowLIP5 structurally couples to AQP2, whether the degradation of other cargo 
proteins is facilitated by direct interaction with LIP5, and whether LIP5 also affects 
AQP2 stability in vivo.
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The MIT1 domain o f LIP5 interacts with a conserved and putative amphipathic helix o f the
proximal region o f the C-terminal tail o f Aquaporin-2 water channel
Abstract
Plasma membrane proteins destined for lysosomal degradation are sorted into 
intraluminal endosomal vesicles via the multivesicular body (MVB) sorting pathway. 
The MVB sorting machinery mainly composes of three ESCRT complexes and the 
ATPase Vps4. In addition, other proteins, including LIP5, have been identified as 
positive modulators of MVB sorting. LIP5 interacts with Vps4 and members of the 
ESCRT complex, but also binds at least two different cargo proteins destined for 
degradation, EGFR and the Aquaporin-2 (AQP2) water channel. LIP5 encompasses 
three domains, involved in protein-protein interactions, a C-terminal VSL domain and 
two N-terminal MIT domains (MIT1 and MIT2). Binding of Vps4 involves the VSL 
domain, whereas binding of ESCRT complex proteins occurs through the MIT2 
domain. Here, we demonstrate that interaction between LIP5 and AQP2, the first cargo 
protein found to directly interact with LIP5, is mediated through the MIT1 domain We 
next wanted to identify the essential LIP5-binding part in AQP2. Bio-informatics 
analysis indicates that region L230-L237 is likely to form a helix, in which L230, 
L234, L237 and L240 could form a hydrophobic patch, flanked on the other site by 
E232 and V236. Exchanging L230, L234 or L237, but not L240, E232 or V236, for 
alanine in the AQP2 tail disturbed binding to LIP5, suggesting that the hydrophobic 
patch in the amphipathic helix of AQP2 were important for LIP5 binding. Indeed, 
while the proximal C-terminal tail of AQP0, 1, and AQP4-6 are also likely to form a- 
helici , GST pull down experiments demonstrated that only AQP6 , which is the only 
one that also has three leucines at the corresponding positions, also binds LIP5. In 
addition, exchanging L230 or L237 in AQP2 for the corresponding amino acids of 
AQP0 and AQP5, which most closely resemble AQP2, also led to a loss of LIP5 
binding. In conclusion, our results show that LIP5 binds its cargo protein AQP2 via its 
MIT1 domain and that its binding to AQP2 depends on the hydrophobic patch of L230, 




In the renal collecting duct, osmotic water permeability is controlled by the anti­
diuretic hormone arginine vasopressin (AVP), which regulates the translocation of the 
Aquaporin-2 (AQP2) water channel from intracellular vesicles towards the apical 
membrane. Upon hypernatremia or hypovolemia, pituitary-derived AVP binds to its 
vasopressin type 2 receptor (V2R), and, through stimulation of adenylyl cyclase, 
increases the intracellular calcium and cAMP concentration in the collecting duct 
principal cells. Augmented cAMP levels activate protein kinase A (PKA), which 
subsequently phophorylates AQP2 and other proteins (1-3), resulting in the 
translocation of AQP2 from intracellular vesicles towards the apical membrane and 
facilitated water reabsorption. When water homeostasis is restored, AVP release and 
binding decreases, which leads to the internalization of AQP2 and targeting to storage 
vesicles or its degradation, leaving the apical membrane watertight again.
Inadequate AQP2 plasma membrane expression results in nephrogenic diabetes 
insipidus (NDI), which is characterized by polyuria, and, consequently, polydipsia (4). 
Conversely, excessive water retention and hyponatremia in congestive heart failure, 
liver cirrhosis, and pre-ecclampsia is associated with increased cell-surface expression 
of AQP2 (5).
Several proteins affect the trafficking of AQP2 by directly interacting with the AQP2 
C-tail. These proteins include the Rap1 GTPase-activating protein Spa1, the 
cytoskeletal protein actin, heat shock protein 70, heat shock cognate protein 70, MAL, 
annexin II, dynamin, and clathrin heavy chain (6-11). Recently, we discovered LYST 
interacting protein 5 (LIP5), also named DRG-1, Vta1p or SBP1 (Swiss-Prot entry 
Q9CR26), to bind specifically the AQP2 C-tail (12). LIP5 is a modulating factor of the 
so-called Endosomal Sorting Complex Required for Transport (ESCRT)-III complex 
and is involved in the sorting of internalized membrane proteins to the limiting 
membrane of multivesicular bodies (MVB), which can serve as storage compartments, 
fuse with the plasma membrane to release the vesicles as exosomes, or fuse with 
lysosomes to deliver their content for degradation (13-15). Indeed, LIP5 interacts with 
AQP2 and the EGFR and facilitates their lysosomal degradation (12;13).
LIP5 has three protein binding domains, being its C-terminal VSL (Vta1/SBP/LIP5) 
domain and two N-terminal microtubule interacting and transport (MIT) domains, 
MIT1 and MIT2. Here, we investigated how LIP5 structurally couples to AQP2, the 
first cargo protein found to directly interact with LIP5, and elucidated the exact amino 
acids within AQP2 involved in LIP5 binding.
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Materials and Methods
Constructs
Expression in eukaryotic cells: For LIP5 expression, an EcoRI-XhoI fragment encoding 
full length mLIP5 was isolated from the pACT2 clone 14b (12) and ligated into the 
corresponding sites of pCDNA3. pCB6-AQP2 was as described (16). pCB6  expression 
construct encoding AQP2 with the amino acid changes L230A, E232K, L234A, 
L237A, or L240A were generated by three point PCR reactions. For this, a pT7Ts 
reverse primer (5’-GCTTAGAGACTCCATTCGGG-3’) or T7 RNA polymerase 
primer were used in combination with forward mutagenesis primers (5’- 
CCAGCCAAGAGCGCGTCGGAGCG-3’ for L230A; 5 ’ -GAGCCTGTCGAA- 
GCGCCTGGCAG-3’ for E232K; 5 ’ -TCGGAGCGCGCGGCAGTGCTG-3 ’ for 
L234A; 5 ’-CCTGGCAGTGGCGAAGG-GCCTG-3 ’ for L237A and 5’- 
GCTGAAGGGCGCGGAGCCGGAC-3 ’ for L240A) or their reverse counterparts on a 
pT7Ts-AQP2 template (17). Following digestion with BgHI and SpeI, the entire AQP2 
cDNAs including the desired mutations were isolated and ligated into a BglII and XbaI 
sites of the expression vector pCB6 . The pCB6 delBHI constructs encoding hAQP2- 
L230I, hAQP2-L230V, hAQP2-L234V-L237V, and hAQP2-L234I-L237V were 
obtained by site-directed mutagenesis using the forward primers 5’-
CTGTCGGAGCGCGTGGCAGTAATCAAGGGCCTGGAG-3’, respectively and 
their reverse counterparts, on a pCB6delBHI-hAQP2 template.
To identify the AQP2 binding site in LIP5, three partial constructs of LIP5 were 
generated by PCR. A N-terminal fragment, encoding amino acids 1-80 was constructed 
using forward primer 5’-GGAATTCAGATGGCCGCGC-3’ and reverse primer 5’- 
GCTCTAGATCAAACAGCTTCATTATCCC-3’, a central fragment (amino acids 79­
207) using forward primer 5 ’ -GGAATTCAAGCTGTTACTCAAGAAATAGTTG-3 ’ 
and reverse primer 5’-GCTCTAGATCAGCCTGGTGCCAAG-3’ and a C-terminal 
construct (amino acids 200-309) using forward primer 5’- 
GAATTCGACCCAAGCAACTTGGCACCAGGC-3’ and reverse primer 5’- 
GAATTCTCACTCCCTGCCTGTGGTCAGCAGCC-3 ’. Using the primers described 
above, also fragments containing the N-terminal and central part (1-207) or the central 
and C-terminal part (101-309) were generated. Following digestion with £coRI and 










GST fusion proteins: For the expression of the hAQP2 C-tail as a gluthation S- 
transferase (GST) fusion protein, a standard PCR was done using the forward primer 
AQP2-CtermFWD (5 ’ -GGAATTCCCAGCCAAGAGCCTGTCG-3 ’) and the reverse 
primer AQP2-C-XhoI on a pBS-hAQP2 (4) template. The PCR fragment was ligated 
into a SmaI-digested pGEX2-T vector (Amersham Biosciences, Freiburg, Germany). 
GST-hAQP4 was obtained using pGEX1-hAQP4 (18). Constructs encoding human 
AQP0, AQP1, AQP5 and AQP6  (19-23) were kindly provided by Dr P. Agre, 
Baltimore, USA, while a construct encoding human AQP3 (19-23) was given by Dr K. 
Ishibashi, Chiba, Japan. The C-tails of human AQP0,1,3,5 and 6  were obtained by PCR 
and cloned into pGEX 4T1. Proper clones were confirmed by sequence analysis. The 
encoded GST proteins were fused to the following hAQP tails: AQP0: P225-L263; 
AQP1: F219-K258; AQP2: P225-A271; AQP3: [C267-I292]; AQP4: C231-V301; 
AQP5: P226-R274; AQP6 : F231-V277.
Expression in yeast: cDNAs encoding wild-type and mutant AQP2 C-termini were 
generated by standard PCR reactions using AQP2-C-EcoRI (5’- 
GATCG GAA TTCCCGCCAGCCAAGAGCCT-3’) as a forward primer and AQP2-C- 
XhoI as a reverse primer. As template, pCB6-hAQP2 (24) or the plasmids described 
above were used. For all constructs, introduction of only the desired mutation was 
confirmed by DNA sequence analysis. Yeast two hybrid analysis was done as reported 
(1 2 ).
Cell culture, transfection and membrane stripping
HEK 293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, 
Biowittaker, Verviers, Belgium) supplemented with 10% foetal calf serum. For 
transient transfections, HEK293 cells were seeded at 1.2 x 105 cells per cm2 in 6  well 
plates. Four hours after seeding, cells were transfected using polyethylenimine 
(Polysciences, Eppelheim, Germany). 3.5 ^g of circular DNA and 14 ^l 
polyethylenimine (1 ^g/^l) was added to 80 ^l OptiMEM medium (Gibco Europe, 
Breda, The Netherlands), vortexed and incubated at room temperature for 20 min. 
Subsequently, the mixture was added to the cells and incubated overnight. Three days 
after transfection, cells were lysed.
Mouse renal collecting duct mpkCCD cells (clone 14; (25)) were stably transfected 
with 30 ^g pCB6-AQP2, pCB6-AQP2-L234A, pCB6-AQP2-L237A, pCB6-AQP2- 
L230I and pCB6-AQP2-L230V using the calcium-phospate precipitation technique and 
G418-resistant colonies were selected as described (26). Cells were grown in modified 
defined medium (DMEM:Ham’s F12 1:1 vol/vol; 60 nM sodium selenate, 5 mg/ml 
transferrin, 2 mM glutamine, 50 nM dexamethasone, 1 nM triiodothyronine, 10 ng/ml
69
The MIT1 domain o f LIP5 interacts with a conserved and putative amphipathic helix o f the
proximal region o f the C-terminal tail o f Aquaporin-2 water channel
epidermal growth factor, 5 mg/ml insulin, 20 mM D-glucose, 2% foetal calf serum, and 
20 mM HEPES (pH 7.4)) at 37oC in an air atmosphere of 5% CO2. Exponentially 
growing cells were trypsinised, seeded at a density of 1.5x105 cells/cm2 on semi­
permeable filters of 1.13 cm2 (Transwell®, 0.4 mm pore size, Corning Costar, 
Cambridge, MA), and grown for 3 days before being analyzed. Forskolin (50 mM) was 
administered to both the apical and basolateral compartments for 45 min.
To analyze whether LIP5 is attached or embedded in the cellular membrane, proteins 
were stripped from cellular membranes. For this, confluent monolayers of mpkCCD 
cells grown on filter and treated with dDAVP for 4 days to induce endogenous AQP2 
expression. Then, the cells were scraped, and homogenized in Krebs-Ringer HEPES 
buffer (KRH; 130 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM CaCl2, 20 mM 
HEPES, 1.2 mM Na2HPO4, 10 mM glucose) in the absence or presence of 4M urea. 
Membranes were isolated by ultracentrifugation at 200,000g for 30 minutes and 
dissolved in KRH. Samples from the supernatant and pellets were dissolved in Laemlli 
buffer.
Immunocytochemistry
Immunocytochemistry was done as described for MDCK cells (27). As primary 
antibodies, affinity-purified guinea pig anti-AQP2 were used. As secondary antibodies, 
goat anti guinea pig antibodies coupled to Alexa 488 (Molecular Probes, Eugene, OR; 
1 : 1 0 0 ) were used.
Immunoblotting.
All samples analyze by immunoblotting were incubated for 30 min. at 37oC to denature 
the proteins and separated on a 12% PAAG. Western blotting was done as described 
(17). As antibodies, 1:3000 diluted affinity-purified rabbit 7 anti-AQP2 (28), 1:1000 
diluted rabbit (r84) anti-LIP5 (12), or 1:4000 diluted guinea pig 9 anti-AQP2 (1:4000; 
(28) antibodies were used. As secondary antibodies, goat anti-rabbit or goat anti guinea 
pig antibodies coupled to horseradish peroxidase (HRP; Sigma, St. Louis, MO, U.S.A.; 
1:5000) were employed.
GST pull down
The GST-AQPs were produced in BL21-DE3 bacteria, induced by IPTG, and isolated 
with pre-washed Glutathione-sepharose 4B beads. LIP5 used in the pull downs came 
from lysates of MDCK cells, which endogenously express LIP5, or LIP5 fragments 
were produced by in vitro transcription/translation using the Riboprobe-T7 system
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(Promega, Leiden, the Netherlands) in the presence of 35S-methionine/cysteine 
(Redivue promix, Amersham Biosciences, Sweden). Both were incubated with the GST 
fusion protein coupled to sepharose beads and rotated overnight at 4°C. Bound LIP5 
was eluted by boiling the samples in Laemmli sample buffer and analyzed by SDS- 
PAGE. Pulled-down LIP5 was visualized using a STORM phosphor imager 
(Amersham Biosciences, Sweden) or immunoblotting.
Co-immunoprecipitation
HEK 293 cells were lysed in IP lysis buffer (1% Triton X-100/150 mM NaCl/25 mM 
Hepes (pH 7.4)) and incubated with rabbit anti-LIP5 antibodies immobilized on protein 
A-agarose beads (Kem-En-Tec A/S, Copenhagen, Denmark) over-night at 4°C. 
Immunoprecipitated proteins were analyzed by immunoblotting (12).
Modeling
The primary sequence of human AQP2 is 67% identical to that of human AQP5 (29). 
Based on the AQP5 structure (Protein Data Bank (PDB) file 3d9s), a homology model 
of human AQP2 was built, using the automatic homology modelling module of the 
WHAT IF & Yasara Twinset (30). In this model the proximal helix was optimized by 
hand for interaction with LIP5. To obtain the AQP2 tetramer, the developed AQP2 
monomeric model was superposed on each monomer in the template file 3d9s. The 
structures of both the AQP2 monomer and tetramer are available 
(http://www.cmbi.ru.nl/~hvensela/aquaporin/).
The atomic structure of the N-terminal and C-terminal halves of LIP5 have been 
reported (31). The structure of the N-terminal domain of LIP5 containing the MIT1 
domain (PDB file 2rkk), which was found to interact with AQP2, was used to model 
the interaction of LIP5 with AQP2 in Yasara (30). During this process, we optimized 
the hydrophobic interactions between the leucines in the AQP2 C-terminus and the 
hydrophobic residues of the MIT1 domain, while minimizing the amount of energetic 
unfavourable interactions like clashing side chains or the introduction of hydrophilic 
residues into a hydrophobic environment.
ClustalW (http://mrs.cmbi.ru.nl/mrs-web/clustal.do) was used to align the twelve 
human AQPs. We used the PSIPRED-server (http://bioinf.cs.ucl.ac.uk/psipred/) to 
predict the secondary structure for AQP0-12. Furthermore, we used a helical wheel 
predictor (http://cti.itc.virginia.edu/~cmg/Demo/wheel/wheelApp.html) to predict the 
position of the side chains of the residues in the putative C-terminal helix of AQP0-12. 
The residues of AQP0-6 were modelled as an a-helix using Yasara.
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The AQP2 interaction site in LIP5
LIP5 comprises three highly conserved domains, involved in protein-protein 
interactions (Fig. 1A), being two N-terminal MIT domains (referred to as MIT1 and 
MIT2) and the C-terminal VSL (Vta1/SBP1/LIP5) domain (15). To determine which 
segment in LIP5 interacts with AQP2, cDNA constructs were made encoding the N- 
terminal MIT1 domain (aa 1-80), the central MIT2 domain (aa 79-207), or the C- 
terminal VSL domain (200-309). In addition, LIP5 constructs encoding LIP5 lacking 
MIT1 (aa 79-309) or VSL (1-207) were made.
Following in vitro transcription/translation in the presence of 35S-labeled Methionine, 
these partial LIP5 proteins were subjected to pull-down assays with GST-AQP2, 
separated by SDS-PAGE, and visualized by autoradiography (Fig. 1B). Besides full- 
length LIP5 (indicated FL), the segments containing the MIT1 domain (aa 1-80, aa 1­
207; lanes 1, 4), but not those lacking it (aa 79-207, aa 200-309, aa 79-309, lanes 2,3 
and 5), interacted with the C-tail of AQP2, indicating that AQP2 interacts with the 
MIT1 domain of LIP5.
Figure 1. Interaction of AQP2 
with LIP5 domains. Partial 
fragments of LIP5 were generated, 
produced by in vitro transcription- 
translation and used in GST pull­
down assays. (A) Schematic 
representation of full-length (FL) 
LIP5 and of its different fragments 
(indicated by the corresponding 
amino acids) used in these pull 
down assays. The MIT domains and 
VSL domain are indicated. (B) 
Results of the pull down 
experiments. Only full length LIP5, 
the fragment lacking the C-terminal 
VSL domain and the N-terminal part 
of LIP5 were able to interact with 
the AQP2 C-tail. In all pull-down 
assays equal amounts of LIP5 
proteins were used, as verified by 
coomassie brilliant blue staining 
(not shown).
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The LIP5-binding region in AQP2 and the corresponding region in other AQPs likely 
forms an a-helix
For AQP2, we showed that the proximal C-terminal tail (aa 230-243) is essential for 
LIP5 binding (12). Interestingly, bio-informatics analysis of the AQP2 C-tail amino 
acid sequence revealed that this region may form an a-helix. If such a secondary 
structure would be of importance for the function of AQPs in general, we anticipated 
that this region of some other AQPs would also have the propensity to form a helix. To 
determine this, human AQP0-12 were aligned using ClustalW. The transmembrane 
domain (TMD6 ) is highly conserved in its location and can be used as a reference 
point. The following C-termini of the different AQPs are highly diverse in both length 
and sequence (Fig. 2A). Analysis of the proximal C-terminal tail of these AQPs for 
secondary structures using the PSIPRED server revealed that AQP0-2, 4-6 and AQP12 
are likely to form an a-helix (Fig. 2B). Modeling of the Pro225-Leu240 region of the 
AQP2 C-tail illustrates that this region indeed is likely to form an amphipatic structure, 
in which three Leu residues (L230, L234, and L237) form a hydrophobic patch (shown 
in yellow; Fig. 2D) and E232 and K228 form the charged side. In all AQPs, except for 
AQP12, this helix is preceded by a linker domain (Fig. 2A,C; Supplement Fig. 1). In 
AQP12, the linker domain is absent or very short. The proximal C-terminal regions of 
the other AQPs (AQP3, 7-11) are not likely to form a helix, of which it needs to be 
mentioned that the tails of AQP8  and AQP11 are too short to be considered (Fig 2A 
and Supplement Fig. 1).
If these helices are of importance for AQP function, it is also likely that they are 
conserved among species. Comparison of the putative helical sequences of AQP0-2, 4­
6  revealed some alternative amino acids at some places, but these were all conserved 
amino acid changes (Fig. 2C). Moreover, helical wheel analysis revealed that the 
propensity for helix formation is conserved for all these AQPs (not shown).
A __________ 230 234 237
TMD6 1 I i
AQP2 209-LVGAILGSLLYNYVL PPAKSLSERLAyLKGLEPDTDWEEREVRRRQSVELHSPQSLPRGTKA 
AQP0 2 0 9-IIGGGLGSLLYDFLL PRLKSISERLSVLKGAKPDVSNGQPEVTGEPVELNTQAL 
AQP1 2 0 7 -FIGGALAVLIYDF P R S S D ^T D R V K V W T S G Q V EEYDLDADINSRVEMKPK 
AQP3 2 51 -LLGSIAGVFVYQLMI C H LE QPPPSNEEENVKLAHVKHKEQI
AQP4 216-IIGAVLAGGLYEYVF PDVEFKRRFKEAFSKAAQQTKGSYMEVEDNRSQVETDDLILKPGVVHVIDVDRGEEKKGKDQSGEVLSSV
AQP5 210-IVGAVLAAILYFYLL PNSLSLSERVAIIKGTYEPDEDWEEQREERKKTMELTTR
AQP6 217- LMGALLASLIYNFVL PDIKTLAQRLAILrGrVEVGTGARAGAEPLKKESQPGSGAVEMESV
AQP7 2 6 2 -LLGAYLGGIIYLVFI STIPREPLKLEDSVAYEDHGITVLPKMGSHEPTISPLTPVSVSPANRSSVHPAPPLHESMALEHF 
AQP8 2 3 5-LLAGLLVGLLIRCFI D G K T R L IL K A R
AQP9 2 5 2 - LVGAVIGGLIYVLVI IH H P E P D S V F K A E Q S E D K P E K Y E L S V IM  
AQP10 250-LVGATVGTATYQLLVALHHPEGPEPAQDLVSAQHKASELETPASAQMLECKL 
AQP11 24 3 -PSLGILLMILMFSFF PW LHN N H T IN K K E
AQP12 2 2 8 - LTGMVLAVLLHQGRL HLFQRNLFYGQKNKYRAPRGKPAPASGDTQTPAKGSSVREPGRSGVEGPHSS
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Figure 2. LIP5 binding to various AQP C-tails. (A) Schematic representation of the proximal 
regions of the C-terminal tails of different human AQPs. The last transmembrane helix (shown in grey) 
was used as anchoring point. The region used for helical wheel analysis is indicated in italics. The 
predicted helices are underlined. (B) Helical wheel projection of the proximal part of the C-tail region 
of AQP0, -1, -2, -4, -5, and -6. AQP3 is not shown because it was not predicted to be able to form a 
helix. The colored circles indicate residue types: yellow=hydrophobic, green=polar, charged, 
pink=acidic and blue=basic. Hydrophobic patches on the helices are indicated by red bows. Only for 
AQP2 and AQP6 the hydrophobic side can be contributed to the presence of three leucines. The 
secondary structure prediction for each C-terminal region AQP is also shown. AA=the amino acid in 
one-letter code, Pred=the predicted secondary structure (Helix or Coil) and Conf=the confidence of the 
prediction (9=high, 1=low). (C) Multiple sequence alignment of different species and (D) modeling of 
the Pro225-Leu240 region of the AQP2 C-tail, illustrating that this region putatively forms an 
amphipatic structure, in which the LIP5-interacting Leu residues form a hydrophobic patch. (E) 
Overview of the known AQP structures that contain a helix in the C-terminal region. Shown are bovine 
AQP0 (2b6p), bovine AQP1 (1j4n), the modeled AQP2 and human AQP5 (3d9s). Numbers indicate 
the first and last residue of the helix (for AQP0 and AQP1 these numbers correspond to the human 
sequence). (F) Overview of the AQP2 tetramer. One of the monomers is shown in green, others are 
blue. The proximal C-terminal helix is shown in yellow.
Interestingly, the atomic structures of AQP0, AQP1, AQP4, and recently AQP5 have 
been reported. As demonstrated by Horsefield et al., AQP5 contains a helical structure 
in the proximal C-terminal region, which also appears to be present in AQP0 and 
AQP1 (29). Indeed, when we analyzed the C-termini of these structures for the 
presence of helici using Yasara., within the structures of bovine AQP0 (PDB code 
2b6p), bovine AQP1 (PDB code 1j4n) and human AQP5 (PDB code 3d9s), a helix is 
found in the same proximal C-terminal region as described above (Fig. 2E; note that 
the structure of AQP2 is included for comparison, but is based on the AQP5 structure). 
The other available AQP structures (bovine AQP0; PDB code 1ymg and 2c32, sheep 
AQP0; PDB code 2b6q, human AQP1; PDB code 1fqy, 1h6i and 1ih5, rat AQP4; PDB 
code 2d57) lack information on this region.
To determine the position of this helix within the AQP tetramer, the helix was 
visualized in the AQP5 structure and, for AQP2, the AQP2 monomer model was 
superimposed on the four monomers of the AQP5 tetramer (pdb file 3d96) using 
Yasara. As is clear from figure 2F, the helices in the proximal C-termini are located on 
the outside of the tetramer. A similar position for the helix is found for AQP0 and 
AQP1 (not shown).
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Supplementary Fig. 1. Helical wheel projection of the proximal part of the C-tail region of AQP3, 7­
12. The colored circles indicate residue types: yellow=hydrophobic, green=polar, charged, pink=acidic 
and blue=basic. The secondary structure prediction for each C-terminal region AQP is also shown. 
AA=the amino acid in one-letter code, Pred=the predicted secondary structure (Helix or Coil) and 
Conf=the confidence of the prediction (9=high, 1=low).
Details o f the LIP5 interaction site
As noted above, region 230-243 of the AQP2 C-tail may adopt an amphipathic helical 
turn (Fig. 2B,D), in which L230, L234, and L237 form the hydrophobic side, while the 
charged side is mainly formed by E232 and K228. To further specify the LIP5-binding 
region in AQP2, amino acids L230, E232, L234, V236, L237 and L240 were changed 
into alanines in the lexA-AQP2 construct and the negatively-charged E232 was 
changed into the positively charged lysine (E232K). Yeast-two-hybrid assays wit LIP5 
and subsequent X-gal staining of transformed yeast colonies revealed that the AQP2 C- 
tail with L230A, L234A and L237A mutations do not interact with LIP5, while the 
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Figure 3. LIP5 binding to subtly 
mutated AQP2. (A) Yeast cells 
expressing LexA fused to the C-tail of 
alanine mutants of the AQP2 C-tail and 
GAL4-LIP5 proteins were analyzed for 
interaction using the p-galactosidase 
activity assays. The hydrophobic amino 
acids Leu230, Leu234 and Leu237, but 
not Glu232, Val236 and Leu240 are 
essential for LIP5 binding. (B) HEK293 
cells were transiently transfected with 
LIP5 DNA (1 |ig) and three different 
amounts of DNA encoding wild-type 
AQP2, L230A, L234A, L237A, or 
L240A (0.5, 1, and 2 |ig). Cells were 
lysed and subjected to LIP5 
immunoprecipitation. Subsequent
immunoblotting demonstrated that wild­
type AQP2 and L240A co-precipitated 
with LIP5, but L230A, L234A, and 
L237A showed no interaction (upper 
panel). Immunoblotting of the lysates 
revealed the expression levels for AQP2 (middle panel) and LIP5 (lower panel). (C) GST, or GST 
fused to the C-tails of AQP0 (GST-AQP0), -1 (GST-AQP1), -2 (GST-AQP2), -3 (GST-AQP3), -4 
(GST-AQP4), -5 (GST-AQP5), or -6 (GST-AQP6) were incubated with lysate expressing LIP5, pulled 
down and immunoblotted for LIP5. LIP5 was only isolated with GST-AQP2 and GST-AQP6, and not 
with GST, GST-AQP0, GST-AQP1, GST-AQP3, GST-AQP4 or GST-AQP5 (D) LIP5 (1 ^g) was 
expressed together with AQP2, L230I, L234V, L234V/L237V, or L234I/L237V (2 ^g) in HEK293 
cells. Cells were lysed and subjected to LIP5 immunoprecipitation. Subsequent immunoblotting 
demonstrated that wild-type AQP2 co-precipitated with LIP5, but none of the mutants did (upper 
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To determine whether this interaction also holds for full-length AQP2 proteins, wild­
type AQP2, and its L230A, L234A, L237A, and L240A mutants were expressed in 
HEK293 cells, which endogenously express LIP5 (12), and subjected to LIP5 co- 
immunoprecipitation assays. In line with the yeast-two-hybrid assays, subsequent 
immunoblotting revealed that AQP2 and AQP2-L240A bind LIP5, whereas interaction 
between LIP5 and L230A, L234A, and L237A was not observed (Fig. 3B). These data 
indicated that the hydrophobic patch in the proximal C-tail of AQP2, formed by L230, 
L234 and L237, is essential for interaction with LIP5.
The helices of AQP0, AQP1 , and AQP4-6 also have the propensity to form 
amphipathic helices, although this is somewhat less clear for AQP5 and AQP6  (Fig. 
2B, arrows). Interestingly, the three leucines that, on basis of the yeast-two-hybrid 
analysis, seemed to be needed for the LIP5-AQP2 interaction are only found in AQP6  
(Fig. 2B, D). AQP0 and AQP5, which are evolutionary closest to AQP2, have an 
isoleucine or valine (AQP0) at the position that corresponds to L230 in AQP2  or 
valine/isoleucine or valine/valine (AQP5) on the position that corresponds to 
L234/L237 in AQP2 (Fig. 2C). Therefore, to determine whether leucines are relevant 
for binding to LIP5, GST fusion proteins of the tails of hAQP0-AQP6 were expressed 
in bacteria, coupled to Glutathione-sepharose 4B beads, incubated with MDCK lysates, 
which endogenously express LIP5, and tested for interaction with LIP5 in GST pull 
down experiments. Indeed, GST alone and GST-hAQP0, -1, -3, -4, and -5 did not 
interact with LIP5, whereas GST coupled to AQP2 or AQP6  revealed binding to LIP5 
(Fig. 3C).
Next, to exclude the possibility that the amino acid differences at other locations within 
this helix caused the lack of binding of AQP0 and AQP5, the isoleucines and valines as 
found in AQP0 and AQP5 were exchanged for the corresponding leucines in AQP2 , 
giving rise to AQP2-L230I and AQP2-L230V (as in AQP0), and AQP2-L234V-L237V 
and AQP2-L234V-L237I (as in AQP5). LIP5, wild-type AQP2, and these different 
AQP2  proteins were expressed in HEK293 cells and subjected to LIP5 
immunoprecipitation. Subsequent immunoblotting demonstrated that wt-AQP2 co­
precipitated with LIP5, which did not occur for AQP2 with the L230I, L230V, 
L234V/L237V, or L234V/L237I mutations (Fig. 3D). As all AQP2 proteins and LIP5 
were well expressed (Fig. 3D), these combined data provided conclusive evidence that 
L230, L234 and L237 in AQP2 are crucial for interaction with LIP5.
Effect o f AQP2 tail mutations on AQP2 folding and trafficking
In the pull-down experiments above, the lack of binding between LIP5 and GST fusion
proteins of the AQP2  tail with the L230I, L230V, L234V/L237V, or L234V/L237I
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indicated that even subtle changes of L230, L234 or L237 interfere binding to LIP5. To 
ensure that the lack of binding to LIP5 is not a result of misfolding of the AQP2 
mutants, mpkCCD cells were stably-transfected with L230I, L230V, L234V/L237V, or 
L234I/L237V AQP2 mutant, incubated with forskolin for 45 min, and subjected to 
immunocytochemistry. Indeed, similar to wt-AQP2 (24), mpkCCD cells stably- 
expressing AQP2-L230I or AQP2-L230V showed a plasma membrane expression of 
AQP2 upon stimulation with forskolin (Fig. 4). Unfortunately, upon transfection of two 
double mutants, AQP2-L234V/L237V and AQP2-L234I/L237V, no expression could 
be detected (not shown). The proper location of L230I and L230V mutants in the 
apical membrane reveals that they, and thus also the LIP5-binding region, are properly 
folded.
Figure 4. Localization of 
subtly mutated AQP2.
mpkCCD cells were stably 
transfected with L230I or 
L230V AQP2 mutant. Cells 
were incubated with 
forskolin for 45 minutes, 
fixed and subjected to 
immunocytochemistry for 
AQP2.
Model o f LIP5 binding to AQP2
Our data above revealed that three leucines, L230, L234, and L237, in the C-terminal 
helix of AQP2 are essential to interact with the N-terminal segment of LIP5, containing 
MIT1 (Fig. 1, 3). Using the resolved structure of the N-terminal domain of LIP5 (31) 
and the modelled structure of AQP2 (Fig. 2A, E), the interaction of AQP2 with LIP5 
was modelled using Yasara (Fig. 5A). Herein, we energetically optimized the 
conformation by maximizing the hydrophobic interactions between the leucines in the 
AQP2 C-terminus and the hydrophobic residues of the N-terminal LIP5 segment, while 
minimizing the amount of steric clashes between side chains and minimizing the 
introduction hydrophilic residues into a hydrophobic environment.
Based on these criteria, we built a model in which the MIT1 domain interacts with the 
C-terminal helix of AQP2 (Fig. 5A, B). In this model, the hydrophobic residues (L29, 
V32, L36, L53, I56) in the MIT1 domain of LIP5 (Fig. 5A; shown in orange) and the 
leucines in the C-terminus of AQP2 (Fig. 4A; shown in yellow) are all located in 
helices and form a three-helix bundle, a conformation more often seen in nature 
(32;33).
AQP2 AQP2- L230I AQP2- L230V
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Figure 5. Model for AQP2 interaction with LIP5. (A) Putative complex of the AQP2-model (green) 
with LIP5 (blue). The leucines in the C-tail of AQP2 involved in the interaction with LIP5 are shown 
in yellow, while the hydrophobic residues in the MIT1 domain of LIP5 are shown in orange. 
Experiments demonstrated that these yellow/orange residues are important for interaction. Therefore 
both hydrophobic areas are docked onto each other, thereby minimizing the hydrophobic area exposed 
to the solvent. (B) Overview of the tetrameric conformation of AQP2 (blue/green) in interaction with 
LIP5 (purple/yellow).
Membrane association o f LIP5
Based on the modelling, LIP5 may associate with the membrane, which may be 
strengthened by the presence of AQP2, which is an integral membrane protein that 
interacts with LIP5. Mouse collecting duct (mpkCCD) cells endogenously express 
LIP5 and AQP2 expression can be induced with the hormone dDAVP (12) Therefore, 
to test membrane association of LIP5, confluent mpkCCD monolayers were left 
untreated of incubated with dDAVP to induce AQP2 expression. Following 
homogenization, urea was added to half of the mixture to dissociate proteins from the 
membranes or was not added, after which membranes were isolated by 
ultracentrifugation. Subsequent immunoblotting revealed LIP5 in the supernatant under 
all conditions (Fig. 6 ). AQP2 immunoblotting revealed that membrane isolation 
occurred properly, indicating that gross LIP5 association to membranes is weak if at 
all, even in the presence of interacting cargo.
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Figure 6. Analysis of LIP5 association with the
membrane. Confluent mpkCCD cells were treated 
with dDAVP for 4 days, scraped and homogenized 
in the absence (left panel) or presence (right panel) 
of 4M urea. Membranes were separated from 
soluble proteins (supernatant) by
ultracentrifugation. Homogenate equivalents of the 
homogenate (H), membranes (M) and supernatant 
(S) were immunoblotted for LIP5 (upper panel) or 
AQP2 (lower panel). The mass of protein markers 
(in kDa) is indicated on the left.
Discussion
The conserved N-terminal MIT1 domain o f LIP5 is involved in A QP2 binding 
When membrane proteins are internalized, they are sorted via the early endosomes into 
the inner vesicles of MVBs. This sorting process requires the presence of three 
complexes, ESCRT-I, -II, and -III. After completing their task, these complexes are 
released from the membrane by the VPS4 ATPase and ready for another round of 
protein sorting. Recent studies indicate that LIP5 is involved in the recycling of these 
ESCRT proteins by stimulating VPS4 ATPase activity (15;31;34). This occurs directly 
by interaction of the C-terminal VSL domain of LIP5 with VPS4 or indirectly by 
binding of the MIT-II domain of LIP5 to several ESCRT-III family members, including 
CHMP1B, CHMP2A, CHMP3, and CHMP5 (13;15;31;34;34-36). Recently, we 
demonstrated that LIP5 is also capable of binding cargo, as was demonstrated for 
AQP2 and EGFR, and facilitates the degradation of these proteins, although the 
binding site within LIP5 remained elusive (12;13).
Two known hydrophobic areas within LIP5 could potentially interact with the AQP2 
helix. For the linker between the N- and C-terminus of LIP5, the structure has not been 
resolved. However, secondary structure programs, such as PsiPred, do not predict any 
other helix within LIP5 that contains hydrophobic residues. The GST pull down assays 
confirmed that the linker between the N- and C-terminus is not responsible for 
interaction with AQP2 as well (Fig. 1B, lane 2). One known hydrophobic area is 
located in the C-terminus of LIP5 between the two helices (K281-Y310 and D312- 
I330), and could thus potentially interact with the AQP2 helix. However, mutational 
analysis of this part of LIP5 has demonstrated that this region is involved in the 
dimerization of LIP5 (31), which makes it unlikely that the C-terminus is also involved 
in binding cargo proteins, such as AQP2. Indeed, our GST pull-down assays
H S M H S M
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demonstrated that the C-terminal part of LIP5 is not involved in the interaction with 
AQP2 (Fig. 1B, lane 3). Instead, our experimental data revealed the other hydrophobic 
area within LIP5, the highly conserved N-terminal MIT1 domain (1-80) is essential for 
binding to AQP2 (Fig. 1B, lane 1). As such, our study provides the first evidence for a 
role of the MIT1 domain of LIP5 in protein-protein interaction and illustrates that this 
segment is (at least) involved in cargo binding.
LIP5 interaction with the proximal region o f the AQP2 C-terminal tail involves L230, 
L234, and L237in AQP2
Analysis of the AQP2 C-tail revealed that within the proximal region of the C-tail, the 
leucine residues 230, 234 and 237, in contrast to E232, V236 and L240, were essential 
for binding to LIP5 (Fig. 3A). Secondary structure prediction indicates that the region 
L230-L237 is likely to form an amphipatic helix, in which Leu 230, 234 and 237 form 
the hydrophobic patch of the helix (Fig. 2B, D). Interestingly, although the primary 
structure of the C-tails of AQPs is quite different, helical wheel analysis of this region 
in some other AQPs (AQP0-, -1, -4, -5, and -6 ) suggested similar amphipatic helici 
(Fig. 2B). Although putatively forming amphipatic helici, the C-tails of none of these 
AQPs appeared to interact with LIP5, except for the C-tail of AQP6  (Fig. 3C). These 
data are fully consistent with an important role of the three Leucine residues in LIP5 
interaction, because in none of these AQPs the hydrophobic patch is formed by three 
leucines, except for AQP6 . Co-immunoprecipitation experiments of LIP5 and AQP2, in 
which the leucines were replaced by other hydrophobic amino acids (isoleucines and/or 
valines), thereby resembling the hydrophobic patch of AQP5, further support this (Fig. 
3D). Both LIP5 (12) and AQP6  (37) are expressed in vesicles of intercalating cells of 
the renal collecting ducts. If they co-localize, LIP5 might also facilitate the degradation 
of AQP6 .
Modeling o f LIP interaction with AQP2
In our model, Leu 230, 234 and 237 were docked onto the hydrophobic residues in the 
MIT1 domain of LIP5 (L29, V32, L36, L53, I56), thereby minimizing the hydrophobic 
area exposed to the solvent. Modeling the LIP5-AQP2 complex revealed that the 
interaction as shown above (Fig. 5) is the most optimal interaction. When modelling 
the MIT1 domain of LIP5 on the AQP2 C-tail in different directions, the interactions 
with the membrane were disturbed (not shown). Comparison of our AQP2 - LIP5 
model with the recently resolved structure of the MIT domain of Vps4 that binds to the 
MIT interacting motifs (MIM) of CHMP1A and CHMP2B revealed several strong 
similarities. The structures of the Vps4A - CHMP1A complex and Vps4B - CHMP2B
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complex revealed that the MIT domain of Vps4 is structurally similar to the first three 
helices in a tetratricopeptide repeat (TPR) motif and the MIM of CHMP supplies the 
final helix to complete the TPR motif (33;38). Similar as for the MIT1 domain of LIP5 
that binds to Leu 230, 234 and 237 of AQP2, the Vps4 MIT domain binds three 
conserved leucine residues of the CHMP motif. This similarity suggests that the AQP2 
C-tail may form a MIM for the MIT1 domain of LIP5.
Potential effects on trafficking
Although still far from complete understanding, recent progress has been made in 
elucidating parts of the ESCRT machinery, which directs membrane budding away 
from the cytosol and is needed to generate MVBs. The upstream complexes (ESCRT-I 
and II) recruit subunits of the ESCRT-III complex to mediate membrane scission. The 
ECRT-III core element proteins are CHMP2, CHMP3, CHMP4 and CHMP6 , while 
CHMP1 and CHMP5 are accessory proteins. The AAA-ATPase VPS4 forms a double 
hexameric ring and disassembles the complex while hydrolyzing ATP. LIP5 was 
demonstrated to stabilize the Vps4 dodecamer, thereby increasing the processivity of 
the Vps4 - Vta1 complex on the ESCRT-III lattice and enhances its specificity for a 
CHMP containing lattice (15;34;36;39). LIP5 clearly acts as a positive modulator of the 
MVB sorting pathway. Previously, we have demonstrated that LIP5 is involved in the 
degradation of AQP2 (12). Here, our results demonstrated that if the LIP5 interacting 
motif of AQP2 is slightly mutated (L230I, L230V, L234V/L237V, or L234I/L237V), 
AQP2 no longer binds LIP5. Together, these results suggest that degradation of these 
mutants might be disturbed. Currently, this is strictly hypothetical. It will be interesting 
to test whether a loss of LIP5 binding sites in AQP2, indeed affects its degradation rate.
In conclusion, we identified AQP2 as the first protein that binds the MIT1 domain of 
LIP5. This interaction involves L230, L234, and L237 in the AQP2 C-terminal tail, 
which is likely to form an amphipatic helix, in which the three leucines form its 
hydrophobic side. Furthermore, the C-tail of AQP1, -2, -4, -5, and -6 , but not AQP3, 
might also form amphipatic helices, but only for AQP6  the hydrophobic side consists 
of three leucines. Interestingly, AQP6  is the only AQP, besides AQP2, that binds LIP5. 
These data confirm the necessity of the three leucines in the AQP C-tail for interaction 
with LIP5.
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The Lysosomal Trafficking Regulator Interacting Protein-5 Localizes Mainly in Epithelial Cells
Abstract
Endocytosis, subsequent protein sorting into multivesicular bodies (MVBs), and 
eventual degradation in lysosomes compose an important mechanism for controlling 
protein expression on the plasma membrane. The lysosomal trafficking regulator 
interacting protein-5 (LIP5) is part of the complex protein machinery involved in MVB 
biosynthesis. LIP5 interacts with other players of the ESCRT machinery as well as with 
two known cargo proteins, AQP2 and EGFR, whose degradation is affected upon 
reduction of LIP5 expression. To investigate the expression and localization pattern of 
LIP5, we studied LIP5 protein expression in a mouse tissue panel and subjected various 
rodent and human tissues to immunohistochemistry. Immunoblotting revealed that, 
except for jejunum, LIP5 is expressed as a 42 kDa protein in all mouse tissues tested. 
Alternatively-spliced gene products could not be detected. Immunohistochemical 
studies revealed that in tissues positive for LIP5, LIP5 is detected in virtually all 
epithelial cells of the examined rodent and human tissues. The observed LIP5 
expression in epithelial tissues suggests that LIP5 is of particular importance in the 
MVB sorting and degradation of proteins expressed in polarized cells.
Introduction
Plasma membrane proteins destined for degradation are transported to the proteasome 
or the lysosome. In case of lysosomal degradation, these proteins are sorted into the 
lumen of late endosomal multivesicular bodies (MVBs) (1). As the name implies, 
MVBs contain many intraluminal vesicles that are formed by invagination of the 
limiting membrane and budding into the lumen (2). Membrane proteins that are sorted 
into these vesicles are degraded upon fusion of MVB with lysosomes (3). The 
formation of the luminal vesicles occurs through invagination and requires a diverse set 
of proteins (4), including three ESCRT (Endosomal Sorting Complex Required for 
Transport) complexes (ESCRT-I, -II, -III), which are recruited to the endosomal 
membrane, where they assist in the sorting process. Another important player in this 
process is the AAA- (ATPases associated with diverse cellular activities) ATPase 
Vps4, which is recruited to the membrane by ESCRT-III complex proteins to facilitate 
endosome invagination and MVB formation, and to disassemble and recycle the 
ESCRT-III complex proteins (5). Vps4 is mainly present as a monomer or dimer in the 
cytoplasm, but will form an oligomeric ring upon interaction with Lyst-interacting 
protein 5 (LIP5) (Swiss-Prot entry Q9CR26; corresponding gene name DRG-1)), also 
named Vta1p or SBP1. This interaction facilitates Vps4 to exert its action in MVB 
formation (6-10). Recently, we discovered that LIP5 also binds cargo proteins, as it 
specifically binds the C-terminal tail of the aquaporin-2 (AQP2) water channel and
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facilitates its degradation (11). The epidermal growth factor receptor (EGFR), whose 
degradation is also affected by LIP5, was also shown to be bound to LIP5, which 
suggests that LIP5 binds both members of the ESCRT machinery and cargo proteins 
(1 1 ; 1 2 ).
The lysosomal degradation pathway is present in every cell type. However, decreased 
expression or even a complete lack of LIP5 does not severely affect the vitality of the 
cell (13). Combined with the cargobinding feature of LIP5, this may indicate that LIP5 
facilitates the degradation of only specific protein cargo and may thus be expressed in a 
subset of cells and tissues. To examine this hypothesis, we studied the expression and 
localization of LIP5 in rodent tissues, and, by using Tissue MicroArray (TMA) 
technology, determined the distribution of LIP5 in normal human tissues.
Materials and methods
Immunoblotting
For immunoblotting, mice were sacrificed and the organs were removed rapidly. The 
tissue was homogenized in 1 ml of ice-cold sucrose dissecting buffer (300 mM sucrose, 
25 mM imidazole, 1 mM EDTA, and protease inhibitors) and cleared from nuclei and 
unbroken cells by centrifugation at 4,000 x g for 15 min and diluted to 0.5-1 jxg/^l in 
Laemmli buffer. Immunoblotting was carried out as previously described (14). To 
detect LIP5, affinity-purified rabbit anti-LIP5 antibodies [1:1500; (11)] were used. 
Goat anti-rabbit antibodies coupled to horseradish peroxidase (HRP; Sigma, St. Louis, 
MO, USA; 1:5000) were used as secondary antibodies.
RT-PCR
Total RNA was extracted from mouse kidney, spleen, liver, brain, testis, and thymus 
using TriZol Total RNA Isolation Reagent (Gibco BRL, Breda, The Netherlands). The 
obtained RNA was subjected to DNase treatment to prevent genomic DNA 
contamination. Subsequently, RNA was reverse transcribed using Moloney-murine 
leukaemia virus-reverse transcriptase (Life Technologies BRL, Breda, The 
Netherlands) at 37°C for 1 h, followed by an increase to 90°C for 2 min.
The amplification reaction contained 100 ng cDNA, 1x Cetus PCR buffer (50 mM KCl, 
10 mM Tris-HCl (pH 8.3), and 0.01 mg/ml gelatin), 1.5 mM MgCl2, 10 pmol sense 
and antisense primer (Table 1), 10 pmol dNTPs, and 1.25 U Taq polymerase. The PCR 
was based on 39 cycles of 1 min at 94°C, 1 min at 60°C, and 1.5 min at 72°C, with an 
elongation time of 10 min being used after the last cycle. The samples were 
subsequently resolved by horizontal agarose gel electrophoresis on a 2 % gel containing
2.5 ^g/ml ethidium bromide, and bands were visualized using ultraviolet illumination.
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Table 1. Primer sequences used and the expected sizes of the PCR products.
Immunohistochemistry - mouse tissues
Mice were perfused with 1% (wt/vol) paraformaldehydelysine-periodate (PLP). The 
organs or tissues were removed, cut into 2-3 mm sections, and incubated in PLP for 2 
h. After fixation, the organs were dehydrated and embedded in paraffin. Five 
micrometer sections were cut, stretched in a water bath at 37°C, and dried onto gelatin- 
coated object glass (Menzel Gläser, Braunschweig, Germany) for at least 1 h at 37°C. 
The sections were subsequently deparaffinized in xylol, rehydrated in a descending 
series of ethanol baths (100, 96, 90, 80, 70, and 50%) and mounted in mowiol. To 
detect LIP5, AQP0, and AQP4, the sections were incubated with affinity-purified 
rabbit anti-LIP5 antibodies (1:25), goat anti rabbit antibodies coupled to Alexa 594 
(Molecular Probes, Eugene, OR; 1:100), and, subsequently, with affinity- purified 
guinea pig anti-AQP0 or anti-AQP4, or anti- AQP5, and goat anti guinea pig antibodies 
coupled to Alexa 488 (Molecular Probes, Eugene, OR; 1:100). To detect LIP5 and 
AQP5 in a single tissue section (salivary gland), sections were subsequently incubated 
with rabbit anti AQP5 antibodies and goat-anti-rabbit antibodies coupled to Alexa 594 
(Molecular Probes, Eugene, OR; 1:100) followed by a blocking step using rabbit serum 
instead of goat serum. Then, LIP5 was visualized using Alexa-488 (directly-)labelled 
rabbit anti LIP5 antibodies. The specificity of our LIP5 antibodies used for 
immunohistochemical staining has been reported (11). To demonstrate the specificity 
of our primary antibodies to LIP5, AQP0, AQP4 and AQP5 in these studies, 
incubations with similar dilutions of pre-immune sera or peptide-blocking experiments 
were carried out in parallel. These controls did not reveal staining (not shown). Nuclear 
staining was performed by propidium iodide staining. For this, sections were incubated 
in PBS containing 1 mg/ml RNAse A at room temperature for 30 min, washed with 
PBS and incubated in 2 ^g/ml prodidium iodide in PBS for 30 min. After this, sections 
were washed twice with PBS and mounted for microscopic analysis.
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Immunohistochemistry - rat tissues
Kidney sections were prepared and immuno-labeling was performed as previously 
described (15). For immunoperoxidase labeling, staining was detected using a 
horseradish peroxidase-conjugated secondary antibody (Dako P448, donkey anti-rabbit 
IgG) and visualized with 0.05% 3,3’-diaminobenzidine tetrachloride (DAB, Kemen 
Tek, Copenhagen, Denmark). Light microscopy was carried out with a Leica DMRE 
(Leica Microsystems). For confocal laser scanning microscopy studies, the following 
secondary fluorescent antibodies were used at a 1:1,000 dilution: goat anti-rabbit IgG, 
Alexa Fluor 488; goat antichicken IgG, Alexa Fluor 546 (Molecular Probes, 
Invitrogen). Laser confocal microscopy was carried out with a Leica TCS-SP2 laser 
confocal microscope. Antibodies used were rabbit anti-LIP5 (1:500 dilution) and a 
chicken anti-AQP2 antibody (1:5000).
Human tissue microarrays
Normal human Tissue MicroArrays (TMAs) were obtained from the Cooperative 
Human TissueNetwork (CHTN) of The National Cancer Institute (NCI), the National 
Institutes of Health, Bethesda, MD, USA (http://www.chtn.nci.nih.gov/). The “body on 
a slide” CHTN2002N1 TMA contained formalin fixed paraffin embedded samples of 
6 6  non-neoplastic adult tissues obtained from surgical resection specimens, obtained 
within 1 h of surgical removal from anonymous donors. All the tissues represented on 
the CHTN2002N1 TMA were normal with the exception of parathyroid gland that was 
from a benign parathyroid adenoma and lymphatic tissue, which was from a benign 
lymphangioma. The central nervous system tissues on the CHTN2002N1 TMA were 
obtained from autopsy specimens within 36 h of death. Further information on tissue 
collection, processing and storage may be found on the CHTN website 
(http://www.chtn.nci.nih.gov/tissue.html). The organization and design of this TMA 
grouped these tissues into various ‘body systems’ including cardiovascular, respiratory, 
gastrointestinal, hepatic and pancreatobiliary, oral, salivary and nasal, mammary, 
endocrine, genital tract, central and peripheral nervous systems, urinary tract, skin, 
cartilage and synovium.
Immunohistochemistry - human TMAs
Immunohistochemical staining was performed on CHTN2002N1 TMAs using a 
DakoCytomation EnVision + Dual Link System, Peroxidase (DAB+) kit essentially as 
recently described (16). This system is a two-step technique that takes advantage of the 
superior sensitivity of a horseradish peroxidase labelled polymer, which is conjugated 
with secondary antibodies. The labeled polymer does not contain avidin or biotin and, 
consequently, nonspecific immuno staining resulting from endogenous avidin-biotin 
activity in tissues such as liver and kidney is eliminated. The immunohistochemical 
protocol employed was initially optimized using “test” human tissue microarrays, 
which contained a small number samples including epithelial tissues. These control
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arrays were used to titrate immunohistochemical assay parameters and antibody 
dilutions prior to use of the more comprehensive tissue microarrays for the 
immunohistochemical analysis of LIP5. TMAs were deparaffinized in xylene for 20 
min to remove embedding media and washed in absolute ethanol for 3 min. The TMAs 
were gradually rehydrated in a series of alcohol baths (96, 85 and 50%) and placed in 
distilled water for 5 min. Endogenous peroxidase activity was blocked with 3% 
hydrogen peroxide and 0.01% sodium azide. The TMAs were then incubated for 30 
min hour at room temperature (RT) with 1% protease free bovine serum albumin 
(Sigma A-3294) in TBS containing 0.5% Tween 20 (TBS-T) to block any potential 
non-specific binding of the primary antibody. Slides were incubated overnight at 4°C 
with affinity purified polyclonal antibodies to LIP5 (diluted 1:200 in TBS-T). The 
diluted antibody was centrifuged (10,000 x g for 5 min) at 4°C to remove any insoluble 
contaminants before use. After 24 h at 4°C the slides were washed three times for 5 
min each in TBST before incubation with horseradish peroxidase (HRP) labeled 
polymer conjugated to affinity purified goat antirabbit immunoglobulins for 30 min at 
RT. The sections were washed three times for 5 min in TBS-T before applying liquid 
DAB+ Chromogen (DAKO; 3,3’-diaminobenzidine solution) for up to 10 min. The 
development of the brown-colored reaction was stopped by rinsing in distilled water. 
The stained slides were immersed for 5 min in a bath of haematoxylin (Papanicolaou’s 
solution 1 b Haematoxylin solution S) (Merck) to counterstain cell nuclei. Finally the 
slides were washed for 5 min in running water and dehydrated in a series of graded 
ethanol baths before rinsing in three xylene baths and mounting in 1,3- diethyl-8 - 
phenylxanthine (DPX) (BDH laboratories, UK). Control experiments were performed 
by incubating slides with non-immune rabbit serum, by omitting the primary antibody 
to LIP5 or by exposing TMA slides to the secondary peroxidase conjugated antibody 
only.
Data acquisition and analysis
The TMA slides immunostained with antibodies to LIP5 were examined using a Nikon 
Eclipse 80i microscope and images captured using a Nikon Digital Sight DS-5 M 
camera connected to a PC running Eclipsenet imaging software (v 1.20, Laboratory 




Figure 1. Expression of LIP5 in mouse tissues. Different mouse tissues were dissected, lysed in 
Laemmli buffer and subjected to immunoblotting using three different LIP5-specific antibodies, 
directed against full-length LIP5 (indicated as R84, R85, and R86). LIP5 protein was detected as a 42 
kDa protein in all tissues tested, except jejunum. Besides the 42 kDa band, additional bands of 27, 33 
and 38 kDa bands were detected by at least two of the antibodies in testis, spleen, thymus, liver.
Detection o f LIP5 in different tissues
According to AceView, which provides all publicly deposited cDNA clones and 
sequences, the human LIP5 gene (C6orf55) is expressed at high level, 2.4 times the 
expression of an average gene. Its sequence is defined by more than 650 sequences in 
GenBank, including sequences from brain (30 accessions), testis (10), hippocampus 
(9), skin (9), amygdala (8), lung (8), kidney (7), and 95 other tissues. Likewise, the 
mouse homologue, the Vtal gene, is expressed 2.8 times the expression of an average 
gene in the latest release of the mouse genome (June 2007). The Vtal gene is defined 
by 297 GenBank accessions from 285 cDNA clones from thymus (seen 17 times), 
visual cortex (16), mammary (15), mammary gland (12), adult brain (11), lateral wall 
of lateral ventricle (11), bone marrow (10) and 61 other tissues. To determine whether 
the LIP5 protein is also ubiquitously expressed, we tested a mouse tissue panel for
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LIP5 expression. Immunoblotting and subsequent detection with three different 
antibodies (R84, R85, and R86) raised against full-length LIP5 (11) demonstrated a 
LIP5 band of 42 kDa protein in most tissues tested (Fig. 1). Although this mass differs 
from that deduced from direct translation of full-length mRNA (i.e. 33.9 kDa), it 
corresponds to full-length LIP5, because an identical mass is found for LIP5 in cells 
transfected with a construct encoding the full-length protein (11). Surprisingly, only 
jejunum showed no expression of LIP5. These data demonstrate that the LIP5 protein is 
ubiquitously expressed as a 42 kDa protein.
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Fig. 2 Alternatively spliced mRNAs of the mouse Vtal gene. (A) Representation of five mRNA 
splice variants from Aceview that are likely to exist in vivo. (B) cDNA derived from mice kidney, 
spleen, liver, brain, testis, and thymus was amplified by PCR, using different primer sets specific for 
the putative splice variants. Subsequent gelelectrophoresis and ultraviolet illumination demonstrated a 
band of approximately 512 bp in liver, brain, and testis, when using the primer set specific for splice 
variant D (Dvar-E8). No bands were detected in kidney, spleen, and thymus. Using a primerset specific 
for splice variant E (E1-Evar) resulted in a band of approximately 258 bp in all cDNAs. MQ (-) was 
used as a negative control in all experiments.
Identity o f the LIP5 signals: splice variants or other?
Besides the 42 kDa band, additional signals were detected in various tissues, including 
skeletal muscle, brain, eye, testis, spleen, thymus, stomach, duodenum, liver, kidney, 
and skin (Fig. 1). Most additional bands, however, were detected by only one of the 
three antibodies and were therefore considered non-specific. In testis, spleen, thymus 
and liver, however, particular additional bands (testis: 38 kDa; spleen/thymus: 38, 33, 
27 kDa; liver: 38, 33 kDa) were consistently detected with more than one antibody 
(Fig. 1). These additional bands could be LIP5 degradation products or LIP5 proteins 
derived from alternatively spliced RNAs. Regarding the mouse Vtal gene, AceView 
supports at least seven spliced variants, likely encoding proper proteins. The complete 
mRNA, which comprises eight exons (Fig. 2A), is reconstructed from 255 cDNA 
clones and will result in a protein of 309 amino acids (33.9 kDa), that has been 
described previously by Fujita et al. (17). Splice variants, depicted as B, C, D, and E in
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Fig. 2, are represented by 3, 7, 3, and 1 cDNA clones, respectively. Variant B lacks 
exon 7 and contains an alternative 3’ end, thereby encoding a predicted protein of 308 
amino acids (34.2 kDa). Splice variant C is as A, but lacks exon 2, and encodes a 
putative protein of 251 amino acids (27.2 kDa). Variant D starts with exon 6  of the 
fulllength transcript (A) and further contains exon 7 and 8 , resulting in a predicted 
protein of 106 amino acids (11.1 kDa). Finally, variant E exists of exon 1 and 2 and an 
alternative 3’ end, and encodes a putative protein of 79 amino acids (9.0 kDa).
As the mass of LIP5 as detected with immunoblotting (42 kDa; Fig. 1) is larger than 
the calculated mass (33.9 kDa), the LIP5 splice variants described above may encode 
the LIP5 proteins with predicted molecular masses of 34.2, 27.2, 11.1, and/or 9.0 kDa. 
To test whether the additional bands could be LIP5 proteins derived from alternatively 
spliced mRNAs proteins, cDNA derived from mice kidney, spleen, liver, brain, testis, 
and thymus was subjected to PCR, using different primer sets specific for the LIP5 
splice variants described above (Table 1). Subsequently, gel electrophoresis was used 
to separate and visualize the samples by size. To be able to discriminate between splice 
variant A, B, and C, three different primer sets were used (Table 1). However, only 
bands of approximately 857, 433, and 540 bp, corresponding to full-length LIP5, were 
detected with these primer sets (data not shown). None of these combinations resulted 
in additional bands. Also, when using the primer set specific for variant B, no band of 
552 bp could be detected in any of the tissues (data not shown). Surprisingly, bands of 
approximately 512 bp were detected in liver, brain, and testis, when using the primer 
set specific for splice variant D (Fig. 2B; Dvar - E8 ). These bands were not detected in 
kidney, spleen, and thymus. A PCR with primers specific for splice variant E resulted 
in a band of approximately 258 bp in all cDNAs tested here, suggesting splice variant E 
might be expressed in these tissues (Fig. 2B; E1 - Evar). However, the masses 
corresponding with the additional protein bands detected in mice testis, spleen, thymus 
and liver lysates appear to be higher than 9.0 and 11.1 kDa, respectively. Therefore, 
they will most likely not correspond with splice variant D or E. More likely, these 
bands are proteins of unknown identity which share the epitope of LIP5 against which 
the antibodies were raised.
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Figure 3. Distribution of LIP5 in mouse tissues. Sections of mouse salivary gland (A) were 
incubated with rabbit anti AQP5 antibodies and Alexa 594-conjugated anti-rabbit antibodies. LIP5 was 
then visualized using Alexa-488 labeled rabbit anti LIP5 antibodies. Sections of eye lens (B), brain 
(C), stomach (D), ileum (E) and urinary bladder (F) were incubated with rabbit LIP5 antibodies, in 
combination with affinity-purified guinea pig anti-AQP0 (B) or AQP4 (C) antibodies, or with 
propidium iodide staining to visualize the nucleus (D-F). Alexa 488-conjugated anti-rabbit and Alexa 
568-conjugated anti-guinea pig IgGs were used as secondary antibodies. LIP5 and AQPs/nuclei are 
given in the middle and left panel, respectively, while overlap appears in the right panel. Indications 
are as follows: a regions of LIP5 and AQP5 co-localization in the upper panel (arrows), which is 
magnified in the middle panel; d parietal cells (arrows); e lumen (l), enterocyte (e), connective tissue 
(c); f  lumen (l), transitional epithelium (t), connective tissue (c). Bars in (A), upper panel represents 
267 ^m, and in middle and lower panel 40 ^m. Bar in (B) is 10 ^m, and bar in (C) is in upper panel 50 
^m and in lower panel 200 ^m. Bar in (D) represents 63 ^m, and bar in (E) is in upper panel 340 ^m 
and in lower panel 34 |im. Bar in (F) represents 37^m.
LIP5 localization in rodents
To determine the tissue distribution of LIP5 in tissues positive for LIP5 in 
immunoblotting, various mouse tissues were subjected to LIP5 immunohistochemistry, 
in which the respective tissue was co-stained for different AQPs or counterstained for 
the nucleus to visualize the gross structure (Fig. 3). Previously, we demonstrated that
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LIP5 co-localizes with AQP2  on the apical side of the renal principal cells. In AQP2 - 
negative tubules and intercalating cells, LIP5 showed a punctuate staining (11). In the 
salivary gland, there are epithelial cells observed which are LIP5-positive only, AQP5- 
positive only and cells which express both proteins (Fig 3A, upper panel; magnification 
in middle panel). In cells lacking AQP5, LIP5 expression is dispersed through the cell. 
In serous acini, which produce salivary and which are characterized by central and 
round nuclei, LIP5 and AQP5 co-localize on the apical side of the cells (Fig. 3A, lower 
panel). In the eye lens, LIP5 completely co-localizes with AQP0, which is a marker for 
the plasma membrane of the lens epithelial fiber cell (Fig. 3B). In brain, AQP4 is 
expressed in the endfeet of astroglial cells surrounding brain capillaries [(18); Fig. 3C], 
but these cells are negative for LIP5. Based on the dispersed overall staining for LIP5, 
neurons are likely LIP5-positive. However, other glial cells, like oligodendrocytes and 
microglia cells cannot be excluded to express LIP5. Main cells of the stomach glands, 
which produce pepsinogen, are LIP5-positive, and the acid-producing parietal cells 
show strong LIP5 staining (Fig. 3D). In contrast, the connective tissue surrounding the 
stomach glands are void of LIP5. In ileum, LIP5 is found in all epithelial (enterocytes 
and goblet) cells and is evenly distributed over the cell (Fig. 3E). Occasionally, a 
strongly LIP5-stained cell was observed, of which the identity is unknown. In the 
lamina propria connective tissue, most, but not all, cells are LIP5 negative. All cells of 
the transitional epithelium of the bladder express LIP5, whereas the connective tissue is 
mostly negative (Fig. 3F). Tissues treated with pre-immune serum were negative for 
LIP5 staining (not shown).
In the rat kidney (Fig. 4A, B, C, D), LIP5 is abundantly expressed in the collecting duct 
and inner medullary collecting ducts (IMCD). LIP5 was predominantly localized 
intracellularly, with some labeling associated with the apical plasma membrane 
domains (Fig. 4A + inset). In rat kidney cortex (Fig. 4B), in addition to collecting 
ducts, LIP5 was detected in the distal convoluted tubule (DCT), where it localizes to 
the apical plasma membrane (inset, arrows). LIP5 could also be detected in proximal 
tubule (PT) and glomeruli, but in low abundance. In the rat IMCD (Fig. 4C, D), LIP5 
partially co-localizes with Aquaporin-2 both intracellularly and at the apical plasma 
membrane. In the mouse kidney (Fig. 4E, F), a similar pattern of labelling is observed, 
with LIP5 localized predominantly in the IMCD, both intracellularly and at the apical 
plasma membrane (inset, arrows), where it partially co-localizes with Aquaporin-2.
In summary, in mice, LIP5 is expressed in epithelia of many different tissues and 
organs.
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Figure 4. Localization of LIP5 in mouse and 
ra t kidney. Rat kidney sections were 
immunoperoxidase labeled, using a horseradish 
peroxidase-conjugated secondary antibody 
(Dako P448, donkey anti-rabbit IgG), followed 
by 0.05% 3,3’-diaminobenzidine tetrachloride 
for detection. (A) Light microscopy showed 
abundant LIP5 expression in the collecting duct 
and inner medullary collecting ducts (IMCD). 
LIP5 was predominantly localized 
intracellularly, with some labelling associated 
with the apical plasma membrane domains 
(inset). (B) In addition to collecting duct, LIP5 
was detected in the distal convoluted tubule 
(DCT), where it localizes to the apical plasma 
membrane (inset, arrows). (C) Rat kidney 
slides were incubated with rabbit anti-LIP5 and 
a chicken anti-AQP2 antibody, followed by 
incubation with Alexa 488-conjugated anti­
rabbit and Alexa 546-conjugated anti-chicken 
antibodies. Subsequent laser confocal 
microscopy revealed that LIP5 partially co- 
localizes with Aquaporin-2 intracellularly in IMCD. (D) In addition to intracellular co-localization, 
LIP5 and AQP2 also co-localize at the apical plasma membrane in rat IMCD. (E) Light microscopy on 
mouse kidney slides, which were treated as described for the rat slides, displayed a similar pattern of 
labeling, with LIP5 localized predominantly in the IMCD, both intracellularly and at the apical plasma 
membrane (inset, arrows). (F) In addition, laser confocal microscopy demonstrated that these slides 
showed partial co-localization of LIP5 with AQP2. Bar in all panels is 30 ^m.
LIP5 localization in humans
Next, we wanted to determine the LIP5 localization in human tissues. Based on the 
high homology between mouse and human LIP5, we anticipated that the antibodies 
raised against mouse LIP5 also recognize human LIP5 proteins. Indeed, our antibodies 
recognized human LIP5 as well (Fig. 5). In the salivary gland (Fig. 5A), LIP5 is 
expressed in acini and ductal epithelial cells. In the adrenal gland (Fig. 5B), clear LIP5 
staining is observed in the (nor)adrenaline-producing medullary cells. In the zona 
reticularis of the adrenal cortex, LIP5 is weakly expressed. In skin (Fig. 5C), the 
keratinized stratified epithelium, and especially the stratum granulosum, shows strong 
LIP5 staining. Moreover, the epithelium of the hair shaft is positive for LIP5 as well. In 
contrast, dermal connective tissue does not express LIP5. For the prostate gland (Fig. 
5D) and seminal vesicles (Fig. 5E), the epithelial cells are clearly LIP5 positive. In the 
lung, the bronchial pseudostratified ciliated epithelium is strongly positive for LIP5 
(Fig. 5F), with emphasis on the apical cell region. Moreover, the perichondrial layer 
surrounding the bronchial cartilage weakly stains for LIP5, whereas the cartilage is
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LIP5-negative. In the ectocervix (Fig. 5G), the non-keratinized stratified epithelium 
expresses LIP5. In ileum (Fig. 5H), the enterocytes of crypt and villi epithelium are 
strongly positive for LIP5. For colon (Fig. 5I), all epithelial cells of crypts are LIP5- 
positive. The endometrium shows LIP5 expression in endometrial glands (Fig. 5J). For 
the oviduct, LIP5 staining was found in the ciliated epithelium (Fig. 5K). Finally, in the 
testis, the testosterone-producing Leydig cells and epithelium of the seminiferous 
tubules, which consist of cells at different stages of spermatogenesis, express LIP5 
(Fig. 5L).
Figure 5. Distribution of LIP5 in hum an tissues. Sections of normal human tissues were incubated 
with rabbit LIP5 antibodies, HRP-coupled goat anti rabbit IgG and colored brown using DAB. Nuclei 
were counterstained using haematoxylin. Tissues shown are (A) salivary gland, (B) adrenal gland, (C) 
skin, (D) prostate, (E) seminal vesicles, (F) lung bronchial epithelium and cartilage, (G) ectocervix, 
(H) ileum, (I) colon, (J) endometrium, (K) oviduct (fallopian tube) and (L) testis. Used indication are: 
(A) acini (a), duct (d), white adipose tissue (w); (B) cortex (c), medulla (m), blood vessel (v); (C) 
connective tissue (c), epithelium (e); (F) bronchial cartilage (bc) and epithelium (be); (G) connective 
tissue (c), epithelium (e); (H) crypt (cr), villi (v); (I) crypt (cr); (J) gland (g); (I) leydig cells (l), 
seminiferous tubule (st). Bars represent 100 and 25 ^m.
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For the cortex of the human kidney (Fig. 6 A, C), LIP5 staining was found in proximal 
tubules and distal tubule, while in glomeruli some cells stained weakly for LIP5. In the 
renal outer medulla of the human kidney (Fig. 6 B, D), all epithelial cells of the tubules 
and ducts expressed LIP5.
As omission of the primary LIP5 antibody or use of preimmune rabbit serum did not 
reveal any staining (not shown), our data reveal that LIP5 is present in virtually all 
epithelial cells of the examined human tissues.
Figure 6. Localization of LIP5 in hum an kidney. Detection of LIP5 was done as described in the 
legend of Fig. 5. LIP5 expression is shown in renal cortex (A, C) and renal outer medulla (B, D) in low 
(A, C) and high (C, D) magnification. Distal convoluted tubule (dct), glomerulus (g) and proximal 
tubule (pt) are indicated. Bars represent 100 ^m.
Discussion
During the last years, a role for LIP5 in the lysosomal degradation pathway has been 
established (11; 12). LIP5 was demonstrated to interact with several members of the 
protein machinery that forms the lysosomal degradation pathway and binds at least two 
cargo proteins, the EGFR and the AQP2 water channel. Upon a reduction in LIP5 
expression, the degradation of both proteins is decreased. Until now, detailed
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information on the mammalian tissue distribution of LIP5 was lacking. The goal of the 
present study was to identify organ tissues and cell types expressing LIP5.
Lip5 proteins are ubiquitously expressed
According to AceView, the LIP5/Vta1 gene is highly expressed in a wide variety of 
tissues. In conformity with Vtal gene expression (mouse LIP5), LIP5 proteins are 
ubiquitously expressed in most mouse organs, including heart, skeletal muscle, brain, 
eye, lung, testis, spleen, thymus, stomach, duodenum, ileum, liver, kidney, skin, 
bladder, and colon (Fig. 1). Besides the 42 kDa signal, which had been described 
previously for LIP5, additional bands are consistently detected in testis (38 kDa), 
spleen (27, 33, and 38 kDa), thymus (27, 33, and 38 kDa), and liver (33 and 38 kDa). 
Interestingly, Fujita et al. also detected an additional protein band of approximately 36 
kDa in liver, using a different antibody, which might correspond to the ~38 kDa band 
observed here (17). AceView describes several putative LIP5 splice variants 
(schematically represented in Fig. 2), which possibly encode proteins of similar size. 
However, RT-PCR on cDNAs derived from brain, testis, thymus, spleen, kidney, and 
liver only revealed transcripts that correspond with full-length LIP5 mRNA, and splice 
variants D and E (Fig. 2B). Splice variants D and E encode putative proteins of 11.1 
and 9.0 kDa, respectively. Although it can not be excluded, it is therefore unlikely that 
the additional protein bands are derived from splice variants. More likely, the 
additional bands constitute epitope related proteins of degradation products of LIP5.
LIP5 is mainly localized in epithelial tissues
Based on the immunoblotting results, we performed immunohistochemistry for LIP5 
on several rodent and human tissues. Our results demonstrate that LIP5 is abundantly 
expressed in epithelial cells of many rodent and human tissues (Figs. 3, 5). All organs 
and tissues originate from the three germ layers formed during embryogenesis, the 
ectoderm, the endoderm, and the mesoderm. Interestingly, LIP5 staining is mainly 
localized in tissues and organs derived from both ectoderm and endoderm. Among 
others, the salivary gland (Figs. 3A/5A), eye lens (Fig. 3B), stratified epithelium of the 
skin and the hair shaft epithelium (Fig. 5C) are ectoderm-derived tissues and strongly 
express LIP5. Moreover, endoderm-derived organs and tissues, such as stomach glands 
and parietal cells (Fig. 3D), ileal enterocytes (Fig. 3E), bladder epithelium (Fig. 3F), 
and the bronchial pseudo-stratified epithelium of the lung (Fig. 5F) are also LIP5- 
positive. In contrast, the connective tissue surrounding stomach glands (Fig. 3D), the 
ileal lamina propria (Fig. 3E), the connective tissue of the bladder (Fig. 3F), the dermal 
connective tissue (Fig. 5C), and the bronchial cartilage (Fig. 5F), which all derive from 
mesoderm, stain negative for LIP5.
Although the function of LIP5 in these cells and tissues remains unclear, proteins 
involved in MVB sorting are highly conserved and several data indicate that MVB 
sorting is a critical process in embryogenesis. Shim et al., for example, demonstrated
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that CHMP5 is ubiquitously expressed in embryonic mouse tissue and that it is 
essential for mouse embryogenesis (19). In addition, CHMP1A, CHMP1B, and VPS24, 
were found to be involved in the development of plant (20; 21). Considering the 
expression pattern and role of these proteins during embryogenesis, also LIP5, which 
interacts with both CHMP5 and CHMP1B, might be expressed and play an important 
role early in embryogenesis.
The pronounced LIP5 expression in epithelial cells may point to another function of 
LIP5. Epithelial layers not only line the cavities and surfaces of structures throughout 
the body, but are the gate-keeping layers for selective absorption, filtration, excretion, 
and secretion of ions, nutrients, hormones, and other molecules. To enable vectorial 
transport of these solutes, polarization of epithelial cells is crucial. All these functions 
require a complex network and polarized expression of cooperating proteins within the 
epithelial cell. Hence, epithelial cells might be defined by high protein turnover rates, 
and, coupled with this, active degradation pathways, which are facilitated by LIP5. Fast 
and efficient lysosomal degradation in epithelial cells may thus require and explain the 
high levels of LIP5 expression in epithelial cells, which remains to be established.
With respect to our data that LIP5 binds and facilitates the degradation of AQP2 (11), it 
is interesting to note that LIP5 does not co-localize with AQP4 in brain (Fig. 3C), but 
that it does co-localize with AQP5 (Fig. 3A) in salivary gland and AQP0 in eye (Fig. 
3B). As these latter two aquaporins are most homologous to AQP2, it will be 
interesting to test whether LIP5 also binds and facilitates the degradation of AQP5 and 
AQP0. In kidney and salivary gland, cells negative for AQP2 and AQP5 expression, 
respectively, LIP5 distribution is more dispersed through the cells, which might 
correspond to MVB-associated staining. Although it cannot be excluded that our 
immunohistochemical experiments also reveal some staining derived from the epitope- 
sharing, degradation or splice-variants of LIP5, the strong immunoblot signals for the 
full-length LIP5 proteins and the overlap of immunoblot and immunohistochemical 
detection of LIP5 in all mouse tissues examined suggests that most (if not all) of the 
immunohistochemical staining is derived from genuine and full-length LIP5 
expression.
In conclusion, our study establishes the expression and localization of LIP5 in both 
rodent- and human tissues and shows that LIP5 primarily localizes in the polarized 
epithelial cells.
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Abstract
Vasopressin regulates water reabsorption in the collecting duct, but extracellular 
nucleotides modulate this regulation through incompletely understood mechanisms. We 
investigated these mechanisms using immortalized mouse collecting duct (mpkCCD) 
cells. Basolateral exposure to dDAVP induced AQP2 localization to the apical 
membrane, but co-treatment with ATP internalized AQP2. Because plasma membrane- 
bound P2  receptors (P2 R) mediate the effects of extracellular nucleotides, we examined 
the abundance and localization of P2R in mpkCCD cells. In the absence of dDAVP, 
P2Y1 and P2Y4 receptors localized to the apical membrane, whereas P2X2, P2X4, P2X5, 
P2X7, P2Y2, P2Y11, and P2Y12 receptors localized to the cytoplasm. dDAVP induced 
gene expression of P2 X1, which localized to the apical domain, and led to translocation 
of P2X2 and P2Y2 to the apical and basolateral membranes, respectively. In co­
expression experiments, P2R activation decreased membrane AQP2 and AQP2- 
mediatedwater permeability in Xenopus oocytes expressing P2 X2, P2 Y2, or P2 Y4 
receptors, but not in oocytes expressing other P2 R subtypes. In summary, these data 
suggest that AQP2-mediated water transport is downregulated not only by basolateral 
nucleotides, mediated by P2 Y2 receptors, but also by luminal nucleotides, mediated by 
P2X2 and/or P2Y4 receptors.
Introduction
Urinary concentration and water homeostasis are primarily under the control of 
arginine vasopressin (AVP) acting on the renal collecting duct (CD). AVP ultimately 
exerts its effect by controlling the abundance of aquaporin 2 (AQP2) water channels in 
the apical membrane of CD principal cells (PCs): it activates V2 receptors in the 
basolateral membrane of these cells and stimulates adenylylcyclase (increasing 
intracellular cAMP levels), which in turn results in phosphorylation of AQP2  and its 
rapid (within minutes) trafficking and insertion into the apical membrane (from 
subapical storage vesicles) (1; 2) together with reduced endocytosis of AQP (2; 3) 
continued exposure to AVP over several days stimulates AQP2 gene transcription (4; 
5). Increased apical abundance of AQP2 enhances water reabsorption and produces a 
concentrated urine; in the absence of AVP, AQP2 is internalized by ubiquitin- 
dependent endocytosis (6 ), leading to reduced water reabsorption and a dilute urine. 
Therefore, any dysregulation of AQP2 synthesis or surface membrane abundance will 
affect fluid balance: lack of normal AQP2 abundance or function in cranial or 
nephrogenic diabetes insipidus causes excessive water loss and hypernatremia (7 -9 ), 
while increased apical membrane abundance of AQP2 in congestive heart failure, liver 
cirrhosis, or the syndrome of inappropriate ADH secretion causes enhanced water 
retention and hyponatremia (10; 11). Several paracrine or autocrine factors, including
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extracellular nucleotides, have been shown to inhibit AVP-stimulated and AQP2- 
mediated water transport in the CD (12-20). The effect of extracellular nucleotides is 
mediated by activation of plasmamembrane-bound P2 receptors (P2R) in CD PCs. The 
presence of almost all of the molecularly identified subtypes of ionotropic (P2X) and 
metabotropic (P2 Y) P2 R has been demonstrated in CD epithelial cells and 
immortalized distal nephron epithelial cell lines (21-24). Ionotropic P2X receptors are 
represented by homomeric assemblies (P2 X1, P2 X2, P2 X3, P2 X4, P2 X5, P2X6, and 
P2X7) and heteromeric assemblies (P2X1/2, P2X1/4, P2X1/5, P2X2/3, P2X2/6, P2X4/6, and 
P2X4/7) (25). Metabotropic P2Y receptors are represented by P2Y1, P2Y2, P2Y4, P2Y6, 
P2Y11, and P2Y12, and the recently cloned P2Y13 and P2Y14 subtypes (25). Based on 
pharmacologic profiling (although it should be noted that truly specific agonists are not 
available for P2 R), the P2 R subtype thought to inhibit AVP-stimulated water transport 
in the CD is the P2Y2 receptor present in the basolateral membrane of PCs (12; 15). 
This P2 R-mediated inhibition is PKC dependent and the result of decreased 
intracellular cAMP and increased PGE2 levels (26; 27). In support of a role for the 
P2 Y2 receptor in modulating AVP-mediated changes in CD water transport, infusion of 
AVP (for 90 min) increases P2 Y2 mRNA and protein levels in the CD of hydrated rats 
(28). Therefore, it has been proposed that activation of basolaterally located P2Y2 
receptors by extracellular nucleotides significantly affects AQP2 abundance, and 
thereby AVP-mediated water reabsorption, in the CD (29). Indeed, P2Y2 knockout 
mice exhibit higher levels of AQP2 compared with wild-type mice, despite similar 
AVP levels (30; 31). Activation of basolaterally localized P2Y2 receptors has also been 
linked to the local control of amiloride-sensitive Na+ reabsorption in CD PCs (22), an 
effect that also occurs with luminal (apical) ATP. However, we have recently shown 
that the P2 Y2 subtype is not the only P2R to mediate a luminal effect of ATP on CD 
Na+ transport (24). Combining molecular and pharmacologic approaches, we found that 
activation of P2 Y4 (which is almost identical in its pharmacologic profile to P2 Y2), 
P2X4, or P2X4/6 receptors can also affect Na+ transport. Furthermore, we showed that 
changing dietary Na+ intake alters P2R mRNA and protein levels (24). Two questions 
arise from the previously published work: [1] Can AVP alter the protein abundance and 
mRNA levels ofP2R other than the P2Y2 subtype? [2] Can P2R other than the P2Y2 
subtype affect AVP-stimulated AQP2 abundance in CD PCs? In the present study, we 
have used immortalized mouse mpkCCD (c14) cells and the Xenopus oocyte 
heterologous expression system to clarify the molecular interactions between P2R 
subtypes and AQP2 abundance, and internalization.
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Materials and Methods
Cell Culture
mpkCCD cells (clone 14) were grown in a modified cell medium (DMEM:Ham’s F12 
1:1 vol/vol; 60 nM sodium selenate, 5 ^g/ml transferrin, 2 mM glutamine, 50 nM 
dexamethasone, 1 nM triiodothyronine, 10 ng/ml EGF, 5^g/ml insulin, 20mM D- 
glucose, 2% FCS, and 20m MHEPES [pH 7.4]) (32). Cells were seeded at a density of
1.5 x 105 cells/cm2 on semi permeable filters (Transwell®, 0.4 ^m pore size, Corning 
Costar, Cambridge, USA); 1.13 cm2 filters were used for immunocytochemistry or 
immunoblotting, and 4.7 cm2 filters for biotinylation experiments. The cells remained 
in culture for 8  d before being analyzed. Where stated, cells were treated with 1 nM 
dDAVP (added to the basolateral medium) for the last 4 d to induce AQP2 expression 
maximally (75 to 85% of mpkCCD cells expressed AQP2 after dDAVP treatment) 
(33), and the nucleotide compounds ATPyS, ATP or UTP, or the PKA inhibitor H-89, 
were applied to the basal and/or apical medium for the final 2 h. In some cases, 
DPCPX (and ATPyS) was applied to the basal and apical medium for the final 8  h.
Real-Time PCR
RNA was extracted from confluent monolayers of mpkCCD cells using an adapted 
guanidium thiocyanate-phenol-chloroform method. One microgram of total RNA was 
reverse transcribed with 0.5 ^g oligo(-dt) 12 to 18 primer and a first-strand cDNA 
synthesis kit (Superscript II RNaseH- reverse transcriptase, Life Technologies BRL, 
UK). The resulting cDNA transcripts were used for PCR amplification using a Roche 
Lightcycler (Roche diagnostics, Germany) and QuantiTect SYBR®Green PCR kit 
(Qiagen, West Sussex UK). Gene-specific primers for P2R and the constitutively 
expressed gene hypoxanthine phosphoribosyl transferase (HPRT) were used as 
described previously (24). To quantify mRNA expression, standard curves were 
generated with known amounts of each PCR product. PCR products for each gene were 
separated on 2% (w/v) agarose-TAE (Tris-acetate EDTA) gel containing 0.5 ^g/ml 
ethidium bromide (Sigma-Aldrich Co., Ltd., Poole, UK). PCR bands were observed 
under ultraviolet illumination, excised from the gel and purified using a Geneclean kit 
(Qbiogene, Cambridge, UK). Purified DNA was serially diluted 10-fold, covering a 
dynamic range of 6  logarithmic orders, and 1^l of each standard was amplified by PCR 
using the relevant gene specific primers. One set of P2R standards was amplified in 
duplicate with the HPRT standards to generate two standard curves. For each sample, a 
ratio of relative abundance of each gene to the housekeeping gene HPRT was 
calculated by the Lightcycler Relative Quantification software, Version 1.0 (Roche 
Diagnostics, Germany). Melting curve analysis was carried out to determine primer 
specificity. PCR products were also analyzed by gel electrophoresis and visualized 




Immunocytochemistry and confocal laser scanning microscopy of cells grown on semi 
permeable filters were performed as described previously (34). Cells were incubated 
with affinity-purified rabbit anti-AQP2 antibodies or rabbit anti-P2R antibodies (24; 
35). Non-commercial P2X antibodies were previously demonstrated to show subunit 
specificity (36).
Patch Clamp Electrophysiology
Patch clamp electrophysiology of cells grown on glass coverslips was performed as 
described previously (24). The whole-cell configuration was used; this was achieved 
using a nystatin perforated-patch method. To establish the perforated-patch, nystatin 
(50 to 100 ^g/ml) was added to the pipette solution (50mM KCl, 90mM K-gluconate, 
3mM MgCl2, 3 mM EGTA and 10 mM Hepes [pH 7.2, KOH]). Patch pipettes were 
pulled from borosilicate glass capillaries (Harvard Apparatus Ltd, Edenbridge, UK) 
and had a resistance ranging between 4.0 and 6.0 MQ.
Cells were superfused (4 ml/min) with bathing solution (140mM NaCl, 5 mM KCl, 2 
mM CaCl2, 1 mM MgCl2 and 10 mM Hepes [pH7.4, NaOH]) by a gravity-fed, 
continuous flow system that allowed drug addition and washout. P2R agonist-activated 
membrane currents were recorded at a holding potential (Vh) of -60 mV, sufficient to 
drive P2X-mediated inward cationic currents and P2Y-mediated reporter currents. P2R 
agonists were applied for 60 s or until the current reached a peak, whichever was 
longer, then washed out for 3 min to avoid run-down.
Water Permeability (Pf) Measurements
Xenopus laevis oocytes were obtained and defolliculated as described previously (37). 
Defolliculated oocytes were injected with 50 nl of sterile water, or cRNA/cRNA 
combination (50% P2R/50% AQP2) in the case of co-expression studies (total cRNA 
quantities: human AQP2, 0.5 ng; rat P2Xb P2X3, P2X6, P2Yb P2Y2, P2Y4 and P2Y6, 
50 ng; rat P2X2 and P2X7, 20 ng). Injected oocytes were incubated for 48 h at 18°C in 
Barth’s solution (88 mM NaCl, 1 mM KCl, 0.82 mM MgSO4, 0.33 mM Ca(NO3)2, 2.4 
mM NaHCO3, 0.41 mM CaCl2, and 10 mM Hepes [pH 7.4]) and was supplemented 
with 50 ^g/L gentamicin sulfate, then kept at 4 °C until used in experiments. 
Recombinant cRNA was not available for P2Y6, P2Yn , or P2Yi2 receptors. Oocytes 
were analyzed after 48 h in a swelling assay as described previously (7). Oocyte 
swelling was performed at 22 °C after transfer from 200 to 70 mOsM/kg. Where stated, 
oocytes were preincubated with ATP (10 ^M) for 15 min before the swelling assay 
started.
Immunoblotting
Immunoblotting and biotinylation experiments were performed as described previously 
(5; 7). Affinity-purified rabbit anti-AQP2 antibodies (1:3,000) (35) or mouse anti-p-
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actin (Sigma, St. Louis, MO; 1:25,000) primary antibodies were used. As secondary 
antibodies, goat anti-rabbit or sheep anti-mouse antibodies coupled to horseradish 
peroxidase (HRP; Sigma, St. Louis, MO; 1:10,000) were used. Films were scanned 
using a GS-690 Imaging Densitometer (Bio-Rad, Hercules, CA) and analyzed using 
Bio-Rad software.
Statistical Analysis
All data are presented as mean values ± S.E.M.; significance was evaluated by t test 
(Instat v3.0: GraphPad Software, San Diego, CA), with P<0.05 considered significant. 
Each experiment was repeated at least three times.
Results
Immunocytochemical Localization of AQP2 in mpkCCD Cells
To determine whether AVP induces plasma membrane localization of AQP2 in 
mpkCCD cells, monolayers of these cells were either left untreated or were treated with 
dDAVP. In the absence of dDAVP (n = 12), no immunofluorescent staining for AQP2 
was detectable in the cells or their apical membranes (Figure 1A); however, treatment 
with dDAVP (1 nM applied to the basolateral medium for 96 h; n = 12) resulted in 
strongly positive immunofluorescence for AQP2 in the apical membrane (Figure 1B). 
Thus, as in earlier published studies (32; 33) treatment with dDAVP for 96 h is 
sufficient to induce endogenous AQP2 synthesis and apical localization.
Figure 1. dDAVP-induced localization of AQP2 in 
mpkCCD cells. Confocal microscopy was used to 
visualize the cellular distribution of AQP2 in monolayers 
of mpkCCD cells grown to confluence on transwell 
permeable supports in the absence or presence of 1 nM 
dDAVP (applied to the basolateral medium) for 96 h. 
Images shown are x-y planes (large rectangle) and x-z 
planes (shown beneath the x-y plane). Monolayers were imaged in x-z planes from apical to basal 
boundaries of the cells. The x-z image is from the site indicated by the dashed line. (A) In cells 
untreated with dDAVP, immunostaining for AQP2 was not evident. (B) Treatment of cells with 
dDAVP resulted in positive immunostaining (FITC) for AQP2 in the apical domain. Scale bar 
represents 5 ^m.
mRNA Levels o f P2R in mpkCCD Cells
To investigate the relative abundance of P2R mRNA in monolayers of cells treated or 
untreated with dDAVP, we performed real-time PCR analysis and calculated the ratio 
of expression of the P2R gene of interest to a constitutively expressed housekeeping 
gene (hypoxanthine phosphoribosyl transferase [HPRT]). In untreated cells, we could
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not detect significant levels of P2Xi, P2X3, or P2X6 subunit mRNA, or of P2Y6 
receptor mRNA (n = 6; Figure 2A and B, respectively). In contrast, significant amounts 
of mRNA were detected for P2X2 , P2X4, P2X5, and P2X7 subunits (Figure 2A), and for 
P2Yi, P2Y2, and P2Y4 receptors (Figure 2B); mRNA abundance had a rank order of 
P2Y2 > P2X2 = P2X4 = P2Yj = P2Y4 > P2X5 = P2X7.
Cells treated with dDAVP showed a significant increase in abundance of P2Y2 mRNA 
(by 7-fold; n = 6; P < 0.01), a significant decrease in abundance of P2Yi mRNA (by 
2.5-fold; n = 6; P < 0.01), but no change in P2X2, P2X4, P2X5, P2X7, orP2Y4 mRNA 
levels (Figure 2, A and B). P2X1 mRNA levels increased significantly in cells treated 
with dDAVP (Figure2A). Rank order of abundance for P2R mRNA in cells treated 
with dDAVP was P2Y2 > P2X = P2X4 > P2X2 = P2Y1 = P2Y4 > P2X5 = P2X7.
These data suggest that mpkCCD cells express a variety of P2R and that chronic 
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Figure 2. Effect of dDAVP 
on P2R mRNA levels in 
mpkCCD cells. Real-time 
PCR was used to compare 
P2X and P2Y receptor 
mRNA levels in monolayers 
of mpkCCD cells grown to 
confluence on transwell 
permeable supports
maintained in either the absence or presence of 1 nM dDAVP (applied to the basolateral medium) for 
96 h. The data are presented as a ratio of the P2R gene of interest to the constitutively expressed 
housekeeping gene HPRT. (A) Following dDAVP treatment, mRNA levels for P2X1 subunits were 
significantly increased (n = 6; P < 0.01). (B) Following dDAVP treatment, mRNA levels for P2Y 1 
receptors were significantly decreased (n = 6; P < 0.01), and mRNA levels for P2Y2 receptors were 
increased (n = 6; P < 0 .01).
Localization o f P2R in mpkCCD Cells
To investigate P2R protein localization in untreated mpkCCD cells, monolayers of 
cells (n=6) were stained for different P2Rusing specific antibodies. Positive 
immunofluorescence for P2Yi and P2Y4 receptors was seen apically, whereas P2X2, 
P2X4, P2X5, and P2X7 receptor subunits and P2Y2, P2Yn , and P2Yi2 receptors were 
located throughout the cytoplasm, toward the cell borders and in the perinuclear region 
(Figure 3A). Immunofluorescent staining for P2Xb P2X3, and P2X6 subunits and the 
P2Y6 receptor was not seen. These data broadly agree with the real-time PCR findings. 
To corroborate the apical localization of P2Yi and P2Y4 receptors in cells untreated 
with dDAVP, whole-cell perforated patch-clamp recordings were made on individual 
cells using P2R-selective agonists. Figure 3B shows ATP- and other P2R agonist-
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evoked (all at 1 0  ^M) whole-cell inward currents in voltage-clamped (holding potential 
[Vh] = -60 mV) cells in a confluent monolayer. Agonists were chosen according to 
their P2R selectivity (see Table 1) (24; 38). The amplitudes of 10 ^M agonist-evoked 
currents were 584 ± 59 pA (for ATP; n=5), 540 ± 48 pA (for UTP; n=5), 226 ± 26 pA 
(for ADP; n=5), 29 ± 11 pA (for BzATP; n=5), 343 ± 29 pA (for ATPyS; n=5), and 234 
± 40 pA (for 2meSADP; n=5); consistent with apical P2Yi and P2Y4 receptor 
localization.
Figure 3. P2R localization in mpkCCD 
cells. Confocal microscopy was used to 
determine the cellular distribution of P2R 
in monolayers of mpkCCD cells grown to 
confluence on transwell permeable 
supports (maintained for 96 h in the 
absence of dDAVP). Images shown are x-z 
planes. Monolayers were imaged in x-z 
planes from apical to basal boundaries of 
the cells. Scale bar represents 5 ^m. (A) 
Positive immunostaining (CY3) for P2Y1 
and P2Y4 receptors was seen in the apical 
region, whereas P2X2, P2X^, P2X5, and 
P2X7 receptor subunits, and P2Y2, P2Yn, 
and P2Y12 receptors, were located 
throughout the cytoplasm extending up to 
the cell border. (B) Typical trace showing 
a series of P2R agonist-evoked (10 ^M) 
inward currents from a whole-cell nystatin-permeabilized patch-clamped mpkCCD (c14) cell in a 
confluent monolayer (grown on a glass coverslip and maintained for 96 h in the absence of dDAVP). 
The cell was voltage-clamped at -60 mV, and there was 5 min interval between agonist applications. 
P2R agonists ATP, UTP, ADP, ATPyS, and 2meSADP evoked inward currents consistent with apical 
P2Yi and P2Y4 activation.
















Table 1. Pharmacologic profiles of those P2R subtypes identified in the apical mem brane of 
mpkCCD cells (in the absence of dDAVP treatm ent; see Figure 3). Information taken from King 
and Townsend-Nicholson, 2003; Wildman et al, 2008 (24; 34). i.a., inactive agonist at 10 ^M.
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To test whether dDAVP alters the abundance and/or localization of P2R, mpkCCD 
cells were treated with dDAVP and subjected to immunocytochemistry using P2R- 
specific antibodies. Treatment with dDAVP (1 nM; 96 h; basolateral medium) resulted 
in positive immunostaining for P2X1 and P2X2 receptor subunits in the apical regions, 
and basolateral staining for P2Y2 receptors (Figure 4A and B), suggesting that dDAVP 
induces the synthesis of P2X1, and targets P2X1, and P2X2 receptor subunits, as well as 
P2Y2 receptors, to the plasma membrane. Fluorescence immunostaining for all other 
P2R remained unchanged (data not shown).
To investigate whether dDAVP-dependent P2R synthesis and localization is cAMP- 
dependent, dDAVP-treated mpkCCD cells were incubated with the cell-permeable 
PKA inhibitor H-89 and subjected to immunocytochemistry using P2X1-, P2X2-, and 
P2Y2-specific antibodies. Treatment with H-89 (1 ^M; 30 min; basolateral medium) 
abolished dDAVP dependent P2X1 synthesis (and apical localization), dDAVP- 
dependent P2 X2 apical localization, and dDAVP-dependent P2 Y2 basolateral 
localization (data not shown), strongly suggesting that dDAVP-dependent P2R 
synthesis and localization in mpkCCD cells is cAMP-dependent. In the absence of 
dDAVP, H-89 failed to alter fluorescence immunostaining for any P2R.
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Figure 4. Effect of 
dDAVP on




used to determine 
the cellular
distribution of P2R
in monolayers of mpkCCD cells grown to confluence on transwell permeable supports. Images shown 
are x-z planes. Monolayers were imaged in the x-z plane from apical to basal boundaries of the cells. 
Scale bar represents 5 ^m. (A) In cells untreated with dDAVP, positive immunostaining (Cy3) for 
P2X2 receptor subunits and P2Y2 receptors was found throughout the cytoplasm up to the cell border.
(B) Treatment of cells with dDAVP (1 nM, applied to the basolateral medium for 96 h) resulted in 
positive immunostaining (Cy3) for P2X1 and P2X2 subunits in the apical domain, and for P2Y2 
receptors in the basolateral domain. Not shown, staining for P2X3 and P2X6 subunits, and P2Y6 
receptors, was still not seen in the presence of dDAVP; dDAVP treatment also did not alter the 
positive immunostaining for P2Y1 or P2Y4 receptors in the apical domain, or affect the pattern of 
immunostaining for P2X^, P2X5 or P2X7 subunits, or P2Y11 or P2Y12 receptors throughout the 
cytoplasm (as seen in Figure 3).
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Figure 5. Effect of ATP 
on localization and 
mem brane abundance of 
AQP2 in mpkCCD cells.
(A) Confocal microscopy 
was used to determine the 
cellular distribution of 
AQP2 in monolayers of 
mpkCCD cells grown to 
confluence on transwell 
permeable supports
following treatment with 1 
nM dDAVP (applied to the 
basolateral medium) alone 
for 96 h, or along with 1 
^M ATPyS (applied to 
either the apical or 
basolateral medium) for 
the final 2 h. Monolayers 
were imaged in x-z planes. 
In cells where ATPyS was 
added to the apical or 
basolateral medium,
positive immunostaining for AQP2 was no longer evident in the apical domain (see top panel), but 
instead was present weakly throughout the cytoplasm. Scale bar represents 5 ^m. (B) Confluent 
mpkCCD monolayers were stimulated with 1 nM dDAVP (96 h, basolateral medium) and 
subsequently treated with dDAVP only (dDAVP) or together with 100 ^M ATP on both the apical and 
basolateral sides (dDAVP + ATP), the apical side only (dDAVP + ATP [apical]), or the basolateral 
side only (dDAVP + ATP [basolateral]), for 2 h. Cells were then subjected to a cell surface 
biotinylation assay. Biotinylated proteins were pulled down and immunoblotted for AQP2 (Gly-AQP2 
and AQP2). Total lysates were also immunoblotted for AQP2 (Total AQP2). (C) The signals from B 
were scanned and the amount of AQP2 was semi quantified in arbitrary units (AU). Significant 
differences from untreated cells are indicated by asterisks. The inhibitory effects of apical and 
basolateral ATP on AQP2 surface abundance were additive. (D) The signals from an experiment 
similar to that described in B, except that 100 ^M ATP, 100 ^M UTP or 100 ^M 2meSADP was 
present on the apical side for 2 h, were scanned and the amount of AQP2 was semi quantified in AU. 
Significant differences from untreated cells are indicated by asterisks. Biotinylation experiments were 
performed in triplicates in two independent experiments.
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Acute Effects o f P2R Activation on AQP2 Membrane Localization in mpkCCD Cells 
To investigate the effect of ATP on AQP2 localization, dDAVP-treated mpkCCD cell 
monolayers were treated with 1 ATPyS (a stable analogue of ATP with agonist 
activity at most P2R) for 2 h, added to either the apical or basolateral medium (n = 5). 
Immunostaining revealed that whereas AQP2 was localized to the apical membrane in 
the absence of ATPyS, it was present intracellularly following exposure to ATPyS in
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either the apical or basolateral medium (Figure 5A), consistent with AQP2 
internalization.
To confirm that ATP itself causes internalization of AQP2, ATP was added to both 
apical and basolateral medium of cultured mpkCCD cells or to each medium separately 
for 2 h. Subsequent cell surface biotinylation, and semi quantification of AQP2 
abundance by immunoblotting, showed that AQP2 was internalized from the plasma 
membrane when ATP was added to either the apical or basolateral medium (Figure 5B 
and C), and that this effect was increased when ATP was added to both medium 
(Figure 5B and C). These data indicate that both apical and basolateral P2R can affect 
apical membrane abundance of AQP2, and that the effect is additive. To investigate 
which of the apically localized P2R (P2X1, P2X2, P2Y1 and/or P2Y4; see Figures 3A 
and B, and 4) causes internalization of AQP2, a selection of partially selective 
P2Ragonists was added to the apical medium of cultured mpkCCD cells for 2 h. 
Subsequent cell surface biotinylation, and semi quantification of AQP2 abundance by 
immunoblotting, showed that AQP2 was internalized from the plasma membrane when 
ATP (100 ^M; a potent agonist at P2X1, P2X2, andP2Y4 receptor subtypes) or UTP 
(100 ^M; an agonist selectively favouring the P2Y4 receptor subtype), but not 
2meSADP (100 ^M; an agonist selective for the P2Yi receptor subtype), was added 
(Figure 5D). AQP2 membrane abundance was reduced to a greater extent by ATP than 
by UTP. These data indicate that apical P2 Y4 receptors and P2 X1 and/or P2 X2 
receptors, but not P2 Y1, play an important role in altering AQP2 abundance and 
localization.
Longer-term Effects o f P2R activation on AQP2 Levels in mpkCCD Cells 
To test whether P2R activation results in AQP2 protein degradation, dDAVP-treated 
mpkCCD cells were incubated with ATP (100 ^M) added to both sides (apical and 
basolateral) for8  h. Subsequent immunoblotting for AQP2 and B-actin (to normalize for 
the amount of protein loaded) indicated that ATP treatment reduced AQP2 protein 
levels by approximately 90% (Figure 6 A and B).
To investigate whether adenosine, derived from the breakdown of ATP, could be 
responsible for the ATP-evoked reduction in AQP2 membrane abundance, dDAVP- 
treated cells were incubated with ATP (100 ^M) and DPCPX (10 ^M; a non-selective 
adenosine, P1, receptor antagonist) added to both sides for 8  h. Subsequent 
immunoblotting for AQP2 demonstrated that simultaneous treatment with ATP and 
DPCPX also markedly reduced AQP2 protein levels (Figure 6 C and D). Furthermore, 
dDAVP-treated cells were incubated with ATPyS (100 ^M; a stable analogue of ATP 
with agonist activity at most P2R) added to both sides for 8  h; subsequent 
immunoblotting for AQP2 demonstrated that ATPyS reduced AQP2.
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Figure 6. Effect of extracellular ATP on AQP2 protein levels in mpkCCD cells. (A) Confluent 
monolayers of mpkCCD cells were stimulated with 1 nM dDAVP for 4 d, subsequently treated with 
dDAVP only or together with 100 ^M ATP for 8 h, and subjected to immunoblotting for AQP2. (B) 
The signals from A were scanned and the amount of AQP2 was semi quantified in AU. A significant 
difference in relative AQP2 abundance between untreated and treated cells is indicated by an asterisk.
(C) As in A, except cells were left untreated or treated with 100 ^M ATP and 10 ^M DPCPX (an 
adenosine receptor antagonist) for 8 h. (D) The signals from C were scanned and the amount of AQP2 
was semi quantified in AU. The asterisk indicates a significant difference. Immunoblotting 
experiments were performed in duplicates in two independent experiments.
A Q P 2
B
A Q P 2
AQP2
A ] control 
| + 10 ijM ATP
Figure 7. Effect of 
P2R activation on 
AQP2-mediated 
water permeability 
in Xenopus oocytes. 
Comparison of 
osmotic water
permeability (Pf) in 
Xenopus oocytes co­
expressing AQP2 
and the P2R of
interest, in the absence or presence of 10 ^M ATP (15 min preincubation). P f  was determined from 
monitoring and measuring cell swelling (at 1.7 s intervals for 1 min) after cells were placed in a 
hypotonic solution. Significant differences from untreated cells are indicated by asterisks. (A) 
Activation of co-expressed P2X2 receptors by extracellular ATP resulted in a significant decrease in P f 
(n = 6; P  < 0.01). (B) Activation of co-expressed P2Y2 or P2Y4 receptors also resulted in significant 
decreases in P f  (n = 6; P  < 0.01). These data show that activation of P2X2, P2Y2, or P2Y4 subtypes 
inhibits AQP2 activity within 15 min.
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Effect o f P2R Activation on AQP2-Mediated Water Permeability in Xenopus Oocytes 
To help determine which of the P2R localized in mpkCCD cells could mediate the 
observed downregulation of AQP2 abundance, the P2R localized in the plasma 
membrane of mpkCCD cells with or without dDAVP (and a number of others) were 
co-expressed with AQP2 in Xenopus oocytes, and the oocytes subjected to a cell 
swelling assay with or without P2R activation with 10 ATP.
AQP2-mediated water permeability (Pf) was significantly decreased following P2R 
activation in oocytes co-expressing P2X2 (by 46±8%; n=6; P<0.01; Figure 7A), P2Y2 
(by 53±7%; n=6; P<0.01; Figure 7B) or P2Y4 receptors (by 57±3%; n = 6; P < 0.01; 
Figure 7B). Inhibition of AQP2-mediated Pf  was achieved within 15 min. All other 
P2R tested, including P2X1, did not change AQP2-mediated Pf  (n = 6; Figure 7A and 
B).
To determine if the reduction of AQP2-mediated water permeability by P2R activation 
also reduced plasma membrane AQP2 abundance, total membrane and plasma 
membrane fractions were made. Immunoblot analysis demonstrated that in Xenopus 
oocytes expressing only AQP2 (Figure 8A), or AQP2 co-expressed with P2 X1 , P2 X3 , 
or P2 X4 receptors, extracellular ATP did not alter AQP2 membrane abundance (data 
not shown). In contrast, in oocytes expressing those P2R that reduced AQP2-mediated 
water permeability on exposure to ATP (P2X2, P2Y2, and P2Y4), plasma membrane 
abundance of AQP2 was reduced. This is consistent with P2R-mediated inhibition of 
Pf  by P2X2, P2Y2, and P2Y4 receptors by removal of AQP2 protein from the plasma 
membrane (n=3; Figure 8B).
A B
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A Q P 2  + A T P
P2X2/ P2X2/ P2Y / P2Y2/ P2Y / P2Y</ 
T ri;2' AQP2 P2Y2/ AQP2 r? Y4/ AQP2
Lane 1 2 Lane 1 2
+ ATP
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29 kD a 29 kD a
4 5 63
Figure 8. Activation of P2X2, P2Y2, or P2Y4 receptors decreases plasma m em brane abundance 
of AQP2 in Xenopus oocytes. Typical Western blot analysis of AQP2 protein in oocyte plasma 
membrane homogenates. (A) Oocytes expressing AQP2 in the absence (lane 1) or presence of 10 ^M 
ATP (15 min; lane 2). The data show that extracellular ATP in the absence of P2R expression does not 
directly affect AQP2 membrane abundance. (B) Oocytes co-expressing AQP2 with P2X2 in the 
absence (lane 1) or presence of 10 ^M ATP (15 min; lane 2); co-expressing AQP2 with P2Y2 in the 
absence (lane 3) or presence of 10 ^M ATP (15 min; lane 4); and co-expressing AQP2 with P2Y4 in 
the absence (lane 5) or presence of 10 ^M ATP (15 min; lane 6). The data show that P2 receptor- 
mediated inhibition of cell swelling in Xenopus oocytes is associated with removal of AQP2 protein 
from the oocyte plasma membrane within 15 min.
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Discussion
The main findings of our in vitro study in mpkCCD cells are that AVP can alter P2R 
abundance and localization, and that activation of apically (and basolaterally) localized 
P2R can cause the internalization (and degradation) of AQP2 (Figure 9). More 
specifically, we report that: (1) P2Yi and P2Y4 receptors are localized in the apical 
membrane, independent of the presence of dDAVP; (2) AVP induces cAMP-dependent 
synthesis and apical localization of AQP2, and of the P2Xi receptor; (3) AVP induces 
cAMP-dependent translocation and subsequent localization of P2X2 and P2Y2 
receptors in the apical and basolateral membrane, respectively; (4) activation of 
basolaterally localized P2Y2 receptors, and of apically localized P2X2 and P2Y4 
receptors, stimulates AQP2 internalization in the presence of AVP. These findings 
suggest a complex regulatory relationship between apical and basolateral P2R in AVP 
stimulated, AQP2-mediated water transport in the CD.
A B C
Figure 9. Vasopressin alters P2R abundance and localization, and P2R activation results in the 
internalisation of AQP2. (A) Immunocytochemistry and patch clamp electrophysiology demonstrate 
that P2Yi and P2Y4 receptors are localized in the apical membrane of mpkCCD cells. (B) Treatment 
with dDAVP (acting via basolateral V2 receptors) results in the translocation of P2X2 to the apical 
membrane, P2Y2 to the basolateral membrane, and the synthesis and sorting (or trafficking) of P2X1 
and AQP2 to the apical membrane. (C) Addition of ATP to either the basal or apical side causes AQP2 
to be internalized in mpkCCD cells. Experiments using a Xenopus oocyte swelling assay suggest that 
the effects of ATP are mediated via P2Y2, P2Y4, and P2X2 activation.
P2R Abundance and Localization in mpkCCD Cells
As already mentioned, in cells untreated with AVP, we demonstrated localization of 
P2Y1 and P2Y4 receptors in the apical membrane (corroborated by pharmacologic 
characterization); and of P2X2, P2X4, P2X5, and P2X7 subunits and P2Y2, P2Y11, and 
P2Y12 receptors throughout the cytoplasm. In cells treated with AVP, in which AQP2 is 
localized in the apical membrane, we demonstrated apical localization of P2 X1 and 
P2 X2 subunits, and of P2 Y1 and P2 Y4 receptors, and basolateral localization of P2 Y2
118
Chapter 5
receptors; while P2X4, P2X5, and P2X7 subunits and P2Yn and P2Y12 receptors 
remained within the cytoplasm. Furthermore, using real-time PCR, we showed that 
AVP treatment increases mRNA levels of apically localized P2X1 and basolaterally 
localized P2Y2 receptors (Figure 2). Taken together, these data suggest that AVP 
induces not only AQP2 translocation and abundance, but also P2X1 subunit and P2Y2 
receptor synthesis and membrane trafficking, and P2X2 subunit membrane trafficking. 
Our immunocytochemistry findings of P2R localization in mpkCCD cells agree 
broadly with previous reports of the presence of P2X1, P2X2, P2X3, P2X4, P2X5, and 
P2X6 subunits and P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, and P2Y13 receptors in rodent CD 
PCs (12; 24; 39-43). Although others have not reported P2Y1 receptor protein 
localization in the CD or in other PC-like cells in culture, P2Y1 mRNA has been 
detected in rat CD (44). In contrast to our findings that chronic dDAVP treatment (96 
h) causes an increase in P2Y2 mRNA (Figure 2) and translocation of P2Y2 receptors 
into the basolateral membrane (Figure 4), Sun and colleagues reported that chronic 
dDAVP infusion (120 h) in rats decreases P2Y2 protein levels in the innermedullary 
CD (28). The same group also reported that chronic water loading (48 h), which should 
lower endogenous AVP levels, increases P2Y2 abundance (27). In these in vivo studies, 
as acknowledged by the authors, the changes in P2Y2 abundance could have been due 
to either a direct effect of AVP or changes in medullary tonicity. Given our findings, 
the latter seems amore likely explanation: an increase in tonicity causing suppression, 
and a decrease causing enhancement, of P2Y2 abundance. In addition to finding that 
chronic AVP treatment alters P2Y2 abundance and localization in mpkCCD cells, we 
also found changes in the synthesis and apical localization of P2X1 receptors, and the 
translocation and subsequent apical localization of P2X2 receptors. We have shown 
recently that protein localization and mRNA levels of P2R in the rat CD can be 
affected by changes in dietary Na+ intake (24). We found that P2X1, P2X4 and P2X6 
subunits, and P2Y4 receptors, were upregulated by a low Na+ diet, an effect we 
attributed to increased circulating aldosterone levels. Activation of the apically 
localized P2Y4 receptor inhibits the CD epithelial Na+ channel (ENaC), whereas the 
apical P2X4 subunit can inhibitor stimulate this channel. For the apical P2Y4 receptor at 
least, this suggests the possibility of a coupling between its inhibitory effect on Na+ and 
water transport in the CD. Interestingly, Schafer and Chen have reported that in Na+- 
depleted rats the stimulatory effect of AVP on Na+ and water transport in the CD is 
significantly reduced (45).
P2R-mediatedInternalization o f AQP2
Until recently, most attention in the CD has focused on P2Y2 receptors, reinforced by 
recent studies of a P2Y2 knockout mouse (31), and it has already been established that 
activation of basolaterally localized P2Y2 receptors by extracellular nucleotides can 
inhibit AQP2-mediated water transport in the CD (12-15). This inhibition of AVP- 
stimulated, AQP2-mediatedwater transport is PLC- and PKC-dependent, and results in
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decreased intracellular cAMP and increased PGE2 (12; 13; 15; 46), which is known to 
cause AQP2 internalization (47). The novel data provided by the present study are the 
effects of activating apically localized P2R, including P2X subtypes, on AQP2 
trafficking. Although a previous investigation has reported that stimulation of apical 
P2Y2 receptors in the terminal segment of the inner medullary CD is without 
significant effect on AQP2-mediated water reabsorption (15), an effect by other apical 
P2R subtypes was not excluded in that study. Here we report that activation of apically 
localized P2X2 andP2Y4 receptors, rather than apical P2Y2, stimulates AQP2 
internalization in a cell line derived from the cortical CD, the region of the CD in 
which most AVP-stimulated water. It is likely that the signal transduction pathway for 
P2Y4-mediated inhibition of AVP-sensitive water reabsorption is similar to that for 
P2Y2 and is Gq protein coupled. However, from our recent study of apical P2R control 
of Na+ transport, we know that P2X signal transduction involves stimulation of PI3K 
(24), which when activated has also been shown to stimulate retrieval of AQP2 from 
the apicalmembrane (48).
Physiologic Significance
Trying to establish a physiologic role for paracrine or autocrine regulators of AVP- 
sensitive water transport is not easy and risks unwarranted speculation. While there are 
obvious limitations to both in vitro and in vivo models when it comes to manipulating 
the levels and action of AVP, even knockout mice have so far served only to illustrate 
how much complex interaction and compensation can occur in the local and 
intracellular control of AVP-dependent water permeability in the CD (46) However, 
there are at least two obvious questions to ask: (1) Where does the ATP come from in 
the CD and how is it released? (2) Why should there be apical as well as basolateral 
control by P2R? Concerning the source and release of ATP, it is generally believed that 
ATP is released locally, and that the stimulus to release may be cell swelling or shear 
stress, including flow-triggered release via the PC apical membrane cilium (46; 49). 
Cell swelling under local and more generalized hypotonic conditions, for example, in 
hyponatremia, could lead to ATP release, which would then help to maximize water 
excretion by its action on basolateral P2Y2 receptors and apical P2R. Similarly, the 
water diuresis in this setting could further stimulate flow-dependent ATP release to 
increase water loss. In summary, while acknowledging that the present findings are 
from an in vitro model, we have confirmed the location and function of the basolateral 
P2Y2 receptor in mediating ATP inhibition of AVP-dependent water transport along 
the CD, but in addition, as with Na+ transport, we have defined novel P2R-mediated 
inhibition of AVP-dependent water transport through apically located P2R. This apical 
regulation involves P2X2 subunits and P2Y4 (rather than P2Y2) receptors; in addition, 
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Abstract
Water homeostasis is regulated by a wide variety of hormones. When in need for water 
conservation, vasopressin, released from the brain, binds renal principal cells and 
initiates a signalling cascade resulting in the insertion of AQP2 water channels in the 
apical membrane and water reabsorption. Conversely, hormones, including 
extracellular purines and dopamine antagonize AVP-induced water permeability, but 
their action mechanism, which is largely unknown, was investigated here.
Addition of these hormones to mpkCCD cells decreased total and plasma membrane 
abundance of AVP-induced AQP2, partly by increasing its internalization to vesicles 
and lysosomal degradation. The internalization was ubiquitin-dependent, because the 
hormones increased AQP2 ubiquitination, and the plasma membrane localization of 
AQP2-K270R, which cannot be mono-ubiquitinated, was unaffected by these 
hormones. Both hormones also increased AQP2 phosphorylation at Ser-261, which 
occurred time-wise after its ubiquitination. A similar process occurs in vivo, as 
incubation of dDAVP-treated kidney slices with both hormones also resulted in the 
internalization and Ser-261 phosphorylation of AQP2. Both hormones also reduced 
cAMP and AQP2 mRNA levels, suggesting an additional effect on AQP2 gene 
transcription. Interestingly, phorbol esters only reduced AQP2 through the first 
pathway.
Together, our results indicate that ATP and dopamine counteract AVP-induced water 
permeability by increasing AQP2 degradation in lysosomes, preceded by ubiquitin- 
dependent internalization, and by decreasing AQP2 gene transcription by reducing the 
AVP-induced cAMP levels.
Introduction
Vasopressin (AVP)-regulated maintenance of the water balance in the renal collecting 
duct occurs via alternating cell surface expression of the water channel aquaporin- 2  
(AQP2), and depends on the body’s need for water conservation. In states of 
hypernatremia and hypovolemia, AVP is released into the bloodstream, interacts with 
its renal type 2 receptors and initiates a signal transduction cascade (1). This includes 
activation of adenylate cyclase, a rise in intracellular cAMP and calcium levels, 
activation of protein kinase A (PKA) and its recruitment to AQP2 containing vesicles, 
and subsequent phosphorylation of AQP2 at Ser256 (2-4). This phosphorylation is 
essential for the re-distribution of tetrameric AQP2 from intracellular storage vesicles 
to the apical plasma membrane (5). In addition, cAMP also increases AQP2 expression 
via phosphorylation of the cAMP responsive element binding protein (CREB), which 
activates the AQP2 promoter (6;7). Due to the increased plasma membrane expression 
of AQP2, water is able to pass the apical membrane passively along an osmotic
126
Chapter 6
gradient and enters the blood via AQP3 and AQP4 water channels, which are 
constitutively expressed in the basolateral membrane. Once the water balance is 
restored, AVP levels drop and AQP2 is internalized via ubiquitination at Lys270 (8 ). 
Besides AVP, several other hormones regulate the water balance by antagonizing the 
AVP-induced water transport (9), but the underlying mechanism is poorly understood. 
Extracellular purines, ATP and UTP, decrease AVP-induced water permeability, which 
is at least partially mediated via the P2Y2 receptor, located in the basolateral membrane 
of principal cells (10-13), but may also involve P2X2 and P2Y4 receptors (14). 
Moreover, dopamine, carbachol, an acetylcholine analogue, and endothelin-1 inhibit 
the AVP-induced water permeability (15-20).
Intracellularly, the action of these hormones shows overlap, but also differs. ATP/UTP 
and dopamine appear to attenuate the AVP-triggered increase of intracellular cAMP, 
which is thought to be conferred by activation of a counteracting protein kinase C 
(ATP/UTP; (11)), or coupling of the hormone receptor to the inhibitory G (Gi) protein 
(dopamine; (15)). In contrast, carbachol reduced the AVP-induced water transport via a 
PKC-dependent pathway, but did not impair the AVP-induced cAMP production 
(2 0 ;2 1 ).
At present, however, it is unknown whether the reduced AVP-induced water 
permeability induced by these hormones involves AQP2 degradation and, if so, 
whether this occurs via AQP2 ubiquitination, internalization and degradation, as we 
recently reported to occur with forskolin removal or addition of phorbol ester 1 2 - 
tetradecanoylphorbol-13-acetate (TPA), a drug that can activate PKC (8;22). Moreover, 
it is unknown whether any of these hormones employs phosphorylation of AQP2 at any 
other site than Ser256, as it has recently been shown that AQP2 can also be 
phosphorylated at S261, S264 and S269, and that pS261-AQP2 is mainly found in 
intracellular vesicles (23;24).
Therefore, to obtain more insight into the mechanism by which hormones counteract 
the action of AVP on AQP2, we here analyzed in detail the effect and underlying 
mechanism of ATP and dopamine on the AVP-induced AQP2 expression.
Materials and Methods
Chemicals and reagents
[deamino-Cys1, D-arg8]-vasopressin (dDAVP), ATP, dopamine, forskolin, 
cycloheximide and chloroquine were purchased from Sigma (St. Louis, MO, USA). 
dDAVP was administered to the basolateral side only. All other compounds were 
administered to both the apical and basolateral side.
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Ex vivo immunofluorescence
Female Sprague Dawley rats were anesthetized with ether and sacrificed by 
decapitation. Kidneys were quickly removed and sections of approximately 0.5 mm 
were made and divided in four groups. The sections were equilibrated for 10 min in a 
buffer containing 118 mM NaCl, 16 mM HEPES, 17 mM Na-HEPES, 14 mM glucose, 
3.2 mM KCl, 2.5 mM CaCl2, 1.8 mM MgSO4, and 1.8 mM KH2PO4 (pH 7.4). AQP2 
trafficking was stimulated in the same buffer and at 37°C with 1 nM dDAVP for 15 
minutes followed by a 30 minutes incubation with dDAVP alone or in combination 
with either 0.1 mM dopamine or ATP, or 100 nM TPA. Next, the kidney sections were 
overnight fixed in 4% paraformaldehyde at 4°C, infiltrated with 30% sucrose in PBS 
for 24 hours, embedded in Cryomatrix (DDK Srl Milano, Italy) at dry ice and cut with 
a cryostat to obtain 5^m sections.
To stain for AQP2, the kidney sections were washed three times with PBS, blocked 
with 1% PBS-BSA for 1 hour, incubated with our affinity-purified rabbit 1:1000- 
diluted antibodies raised against the 20 amino acids N-terminal of the poly- 
phosphorylated region of human AQP2 (CLKGLEPDTDWEEREVRRRQ; pre-C tail) 
for 2 hours, and washed three times with PBS. After washing, the sections were 
incubated with 1:1000 diluted goat anti-rabbit antibodies coupled to Alexa-488 
(Invitrogen, Milano, Italy), rinsed three times with PBS and mounted in mounting 
medium containing 50% glycerol in 0.2 M Tris-HCl, pH 8.0 in the presence of 2.5% n- 
propyl gallate. Images were obtained with a Leica TCS SP2 (Leica Microsystems, 
Heerbrugg, Switzerland).
Cell culture
MpkCCD cells (clone 14) (25) were grown in a modified defined medium 
(DMEM:Ham’s F12 1:1 vol/vol; 60 nM sodium selenate, 5 mg/ml transferrin, 2 mM 
glutamine, 50 nM dexamethasone, 1 nM triiodothyronine, 10 ng/ml epidermal growth 
factor, 5 mg/ml insulin, 20 mM D-glucose, 2% foetal calf serum, and 20 mM HEPES 
(pH 7.4)).
Cells were seeded at a density of 1.5x105 cells/cm2 on semi-permeable filters 
(Transwell, 0.4 mm pore size, Corning Costar, Cambridge, MA, USA). 1.13 cm2 filters 
were used for immunocytochemistry or imunoblotting, and 4.7 cm2 filters for 
biotinylation experiments. The cells remained in culture for 8  days before being 
analyzed. Cells were treated with 1 nM dDAVP for the last 4 days, to maximally 
induce AQP2 expression (26). Biotinylation was performed as described (27). The 
concentrations of the AVP-counteracting hormones ATP and dopamine were 100 ^M 
and the concentration of TPA used was 100 nM. Each experiment was done in 
triplicate and was repeated at least 3 times.
For the generation of cell lines stably expressing exogenous wtAQP2 or AQP2-K270R, 
the expression constructs pcB6-dBamHI-AQP2 and pcB6-dBamHI-AQP2-K270R (8 ), 
which encode these respective channels, were transfected into mpkCCD cells using the
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calcium phosphate method as previously described for MDCK cells (27). MDCK- 
wtAQP2 have been described (27).
Immunocytochemistry
Immunocytochemistry and confocal laser scanning microscopy (CLSM) of cells grown 
on semi-permeable filters were performed as described (27). For AQP2 detection, the 
filters were incubated with affinity-purified rabbit anti-AQP2 antibodies (1:100; (28)) 
and goat anti rabbit antibodies coupled to Alexa 488 (Molecular Probes, Eugene, OR, 
USA; 1:100).
Immunoblotting
Immunoblotting was performed as described (27). As antibodies, affinity-purified 
rabbit 7 anti-AQP2 antibodies (1:3000; (28)), guinea pig anti-AQP2 (1:4000) 
antibodies, rabbit anti-AQP2-pS261 antibodies (1:2000; kindly provided by Dr. M. A. 
Knepper, Bethesda, USA), mouse anti-ubiquitin (P4D1; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA; 1:1000) or mouse anti-P-actin (Sigma, St. Louis, MO, USA; 
1:25000) were used. As secondary antibodies, goat anti-rabbit, goat anti-guinea pig, or 
sheep anti-mouse antibodies coupled to horseradish peroxidase (HRP; Sigma, St. 
Louis, MO, USA; 1:10000) were employed.
For immunoblotting of kidney sections, this tissue was lysed in a buffer containing 1% 
Triton X-100, 150 mM NaCl, 10 mM NaF, 1mM sodium orthovanadate, 25 mM Hepes 
(pH 7.4) and subjected to immunoblotting studies. Total AQP2 was detected with 
1:1000 dilution of our affinity-purified pre-C-tail antibodies. AQP2-pS261 antibodies 
(1:1000) were purchased from DBA (Segrate, Milano, Italy). As secondary antibodies, 
goat anti-rabbit HRP-coupled secondary antibodies were used.
Quantitative-RT-PCR
MpkCCD cells were grown as described (26) and total RNA was isolated using TriZol 
extraction reagent (Gibco BRL, Life Technologies, Rockville, MD), according to the 
manufacturer’s instructions. To remove potentially contaminating DNA, total RNA 
was treated with DNase (Promega, Madison, WI) in DNase buffer, incubated for 1 hr at 
37 °C, extracted with phenol/chloroform and precipitated using sodium acetate (3M, 
pH 5.2) and 100% ethanol. 1.5 ^g RNA was reverse-transcribed into cDNA using 
MMLV Reverse Transcriptase with random primers (Promega, Madison, WI). SYBR 
Green Real-time quantitative PCR was performed on an iQ5 Real-Time PCR Detection 
System from Bio-Rad by utilizing the SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA), in combination with mouse AQP2 primers (5’- 
CTCCACAACAATGCAACAGC-3 ’ and 5 ’ -GAGCAGCCGGTGAAATAGAT-3’). As 
an internal standard, mRNA of ribosomal 18S was amplified in parallel using the 
primers 5 ’ -GTAACCCGTTGAACCCCATT-3 ’ and 5’-
CCATCCAATCGGTAGTAGCG-3 ’.
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cAMP assay
MpkCCD cells were grown on 0.33 cm2 filters for 8  days, either with or without 
dDAVP for the last 4 days. At the last day, cells grown with dDAVP were incubated 
with culture medium supplemented with 1 nM dDAVP and 250 ^M 3-Isobutyl-1- 
methylxanthine (IBMX; Sigma, St. Louis, MO, USA) for 10 min to prevent cAMP 
degradation by phosphodiesterases, followed by 15 min incubation with the AVP- 
counteracting hormones mentioned above in the presence of dDAVP and IBMX. Cells 
grown without dDAVP were treated with the AVP-counteracting hormones for 8  hours, 
followed by 10 min incubation with IBMX. 15 minutes before harvesting, dDAVP was 
added to the basolateral side. The filters were rapidly excised from their plastic support, 
lysed in 150 ^l of 0.1 M HCl, and incubated for 15 min at room temperature to 
complete lysis. To remove debris, the scraped samples were then centrifuged at 600 x g 
for 5 min at room temperature. Subsequently, 100 ml supernatant was used to determine 
the cAMP levels using a direct cAMP enzyme immunoassay kit (Sigma, St. Louis, 
MO, USA).
Immunoprecipitation
20 ^l protein A agarose beads (Kem-En-Tec A/S, Copenhagen, Denmark) per sample 
were washed three times in lysis buffer (1% Triton X-100, 150mM NaCl, 25mM Hepes 
(pH 7.4)). Per sample, 1 ^l of rabbit anti-AQP2 or guinea pig anti-AQP2 antibodies 
was added to 1 ml lysis buffer with protease inhibitors (1 mM PMSF, 5 ^g/ml 
pepstatin, 5 ^g/ml leupeptin, and 5 ^g/ml a-protinin) and rotated for 4h at room 
temperature. Before use, the antibody-coupled beads were washed three times with 
lysis buffer. Cells were treated as described and lysed in 1 ml lysis buffer containing 
protease inhibitors and 20 mM A-ethylmaleimide (NEM). The samples were 
centrifuged at 1 2 , 0 0 0  x g for 1 0  minutes and the supernatant was incubated for 16 
hours with the antibody-coupled beads at 4°C. The beads were washed four times with 
lysisbuffer, carefully dried and resuspended in 30 ^l of 1x Laemmli buffer with 0.1M 
DTT. Subsequently, the samples were analyzed by immunoblotting for ubiquitin, 
AQP2-phospho-S261, or total AQP2 as indicated.
Statistical analyses
Films were scanned using a GS-690 Imaging Densitometer (Bio-Rad, CA, USA) and 
analyzed using Bio-Rad software. Statistical comparisons were made using one-way 





Effect of ATP and dopamine on AQP2 expression
To study the role of hormones counteracting AVP in vitro, we used the mouse cortical 
collecting duct (mpkCCD) cells as a model, because these cells show an AVP-induced 
expression of endogenous AQP2 (25). To determine whether AVP-counteracting 
hormones did counteract AVP, mpkCCD cells were grown to confluence for 8  days, 
incubated for the last 4 days with dDAVP to generate a steady-state endogenous AQP2 
expression (26), and then treated for the last 8  hours with 100 ATP or dopamine in 
the continued presence of dDAVP. TPA, which is known to decreases AQP2 
expression in mpkCCD cells (8 ), was taken along as a control. Subsequent 
immunoblotting showed that both hormones and TPA decreased AQP2 expression 
(Fig. 1). These data indicated that mpkCCD cells can be used as a model to study the 
mechanism by which ATP and dopamine counteract AVP. Although lower 
concentrations of ATP and dopamine also affected AQP2 expression, the above­
mentioned concentrations of AVP-counteracting hormones gave more consistent 
results and were therefore selected for following experiments.
Figure 1. Effect of TPA, ATP and dopamine on dDAVP-induced AQP2 expression. MpkCCD 
cells were grown for 4 days, incubated with 1 nM dDAVP for an additional 4 days and treated with 
100 nM TPA, 100 ^M ATP, or 100 ^M dopamine in the presence of dDAVP for the last 8 hours. 
Subsequently, the cells were lysed and immunoblotted for AQP2. The signals were semi-quantified 
using densitometry. Samples significantly (P<0.05) different from controls are indicated by asterisk.
Effect of ATP and dopamine on AQP2 internalization
The observed reduction in AVP-induced AQP2 expression in the 8  hours time frame 
can be due to increased AQP2 internalization and degradation, which is a relative fast 
process, and/or reduced AQP2 transcription, which usually is a slow process. To 
determine whether these hormones employ AQP2 internalization, dDAVP-induced 
mpkCCD cells were left untreated or treated with TPA, ATP or dopamine for 2h, and 
subjected to apical cell surface biotinylation assays. Immunoblotting of the biotinylated 
proteins and normalization for the respective total amounts of AQP2 revealed a
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significantly-reduced AQP2 expression in the apical membrane with TPA, ATP and 
dopamine (Fig. 2). As anticipated for the short incubation time, none of the treatments
Figure 2. Effect of TPA, ATP and 
dopamine on AQP2 internalization
MpkCCD cells were grown and treated 
as described in the legend of Fig. 1, 
except that the treatment with TPA, 
ATP and dopamine was for 2 hours.
Subsequently, cells were subjected to 
cell surface biotinylation and lysed. 
Biotinylated proteins were pulled- 
down from the remaining solution and 
immunoblotted for AQP2 (Plasma 
membrane). In addition, total lysates 
were immunoblotted for AQP2 (Total). 
The signals were semi-quantified using 
densitometry. Samples significantly 
(P<0.05) different from controls are 
indicated by asterisk. Triplicate 
samples were analyzed and 
independent experiments were 
performed in threefold, of which a 
representative experiment is shown.
Effect of ATP and dopamine on AQP2 ubiquitination
Recently, we showed that TPA induces short chain ubiquitination of AQP2 in vitro and 
in vivo and that this ubiquitination precedes, and is essential for, AQP2 internalization 
and degradation upon TPA treatment in MDCK-AQP2 cells (8 ). As ubiquitination is 
more readily detectable in MDCK then in mpkCCD cells, we initially reverted to 
MDCK-AQP2 (29) cells for this purpose. Following forskolin treatment for 45 
minutes, these MDCK-AQP2 cells were left untreated (control) or incubated with TPA, 
ATP or dopamine for 15 minutes (optimal period for detecting ubiquitination in these 
cells), lysed and subjected to AQP2 immunoprecipitation. Subsequent immunoblotting 
for ubiquitin revealed the typical strong 43 and 50 kDa and the weaker 58 kDa 
ubiquitinated AQP2 bands in all lanes, which were clearly increased for cells co­
incubated with ATP and dopamine and, to a higher extent, with TPA, as compared to 
control cells (Fig. 3). Detection of immunoprecipitated equivalents with AQP2 
antibodies (Fig. 3; lower panel) revealed that similar amounts of AQP2 were loaded.
To assess the involvement of ubiquitination in the ATP and dopamine-induced 
internalization of AQP2 from the plasma membrane in mpkCCD cells, these cells were
significantly affected the total amount of AQP2.
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stably-transfected with wtAQP2 or the mutant AQP2-K270R, which cannot be short- 
chain ubiquitinated (8 ). As shown in figure 4, treatment with forskolin alone results in 
apical plasma membrane localization of wtAQP2 and AQP2-K270R. In line with the 
biotinylation data above, co-treatment with TPA, ATP or dopamine induced 
internalization of wtAQP2 into vesicles. In contrast, the apical localization of AQP2- 
K270R remained unaffected by any of these compounds, demonstrating that 
ubiquitination of K270 is essential for hormone-induced internalization of AQP2 in 
mpkCCD cells.
Figure 3. Effect of TPA, ATP and 
dopamine on AQP2 ubiquitination.
Confluent monolayers of MDCK-AQP2 
cells were incubated with 5x10-5 M 
forskolin followed by co-incubation with 
100 nM TPA, 100 ^M ATP, or 100 ^M 
dopamine for the last 15 minutes. Cells were 
lysed and subjected to immunoprecipitation 
using rabbit anti-AQP2 antibodies. Samples 
were immunoblotted and blots were 
incubated with mouse anti-ubiquitin (upper 
panel) or guinea pig anti-AQP2 (lower 
panel) antibodies. Protein masses (in kDa) 
are indicated on the left.
Figure 4. Effect of 
TPA, ATP and 
dopamine on the 
subcellular 







cells were grown for 
8 days, incubated 
with 5x10-5 M 
forskolin for 45 
minutes to induce
apical localization of AQP2, and were then left untreated (control), or treated with dDAVP in the 
presence of 100 nM TPA, 100 ^M ATP, or 100 ^M dopamine for 30 minutes. Subsequently, cells 
were fixed and subjected to immunocytochemistry for AQP2. Top view (XY) confocal images and 
their corresponding cross sections (XZ) are shown.
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Figure 5. Effect of 
TPA, ATP and 





wtAQP2 or AQP2- 
K270R cells were 
incubated with 100 
nM dDAVP for 1 h 
45 min, followed by 
co-incubation with 
100 nM TPA, 100 
|uM ATP, or 100 juM 
dopamine for an additional 15 minutes. Cells were 
lysed and subjected to immunoblotting for pS261- 
AQP2 (upper panel) and AQP2 (lower panel). (B) 
Confluent monolayers of mpkCCD cells were 
incubated with 1 nM dDAVP for 4 days and treated 
with 100 ^M ATP, or 100 ^M dopamine in the 
presence of dDAVP for an additional 30 minutes. Cells 
were lysed and subjected to immunoblotting for 
pS261-AQP2 (upper panel) and AQP2 (lower panel).






Effect of ATP and dopamine on Ser-261 phosphorylation
Besides phosphorylation of AQP2 at Ser-256 by PKA, three additional phosphorylation 
sites were identified in the C-terminal tail of AQP2, Ser-261, Ser-264, and Ser-269 
(23;24). Interestingly, whereas AVP treatment increased phosphorylation at Ser-256, 
AQP2-pS261 mainly localized in vesicles and AQP2 phosphorylation at Ser-261 was 
decreased upon AVP incubation (24). To investigate whether the AVP-counteracting 
hormones affect the phosphorylation state of AQP2 at Ser-261 and how this relates to 
ubiquitination of AQP2, mpkCCD-AQP2 and AQP2-K270R cells were left untreated 
or pre-incubated with 100 nM dDAVP, followed by co-incubation with TPA, ATP, or 
dopamine for 15 minutes. Consistent with in vivo data, dDAVP reduced the pS261 29 
kDa signals for wtAQP2 (Figure 5A, top panel, left lanes). Upon co-incubation of 
mpkCCD-AQP2 cells with TPA, ATP, or dopamine two forms of data were obtained. 
Often, TPA, ATP, and dopamine did not change the signal for AQP2-pS261 at 29 kDa, 
but induced the appearance of a signal at 43 kDa (Fig. 5A, upper left panel), a band that 
also appeared in the blot representing total AQP2 (Figure 5A, bottom left panel). In 
other experiments, AQP2-pS261 of 29 kDa was also observed (not shown). For AQP2- 
K270R, the basal level of AQP2-pS261 also decreased upon treatment with dDAVP 
(Fig. 5A, upper right panel). Co-treatment with TPA, ATP, or dopamine neither led to 
an increase of the 29 kDa signal, but also did not result in the appearance of the 43 kDa
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signal as observed for wtAQP2. Total levels of AQP2 protein remained unaltered 
during the experiment (Figure 5A, bottom panels). Interestingly, longer treatment of 
mpkCCD-AQP2 cells did not reveal the 43 kDa AQP2-pS261 band any more, but only 
showed an increased AQP2-pS261 signal at 29 kDa (Fig. 5B). These data indicated that 
hormone-induced phosphorylation of S261 coincides with, and is likely a downstream 
effect of, ubiquitination of AQP2 at K270.
C dDAVP dDAVP
ATP (minutes) Dop (minutes)










■ * 45 -Input Total 
31 -  ___________ AQP2
Figure 5. Continued (C) MpkCCD cells were incubated for 4 days in the presence of dDAVP and, 
subsequently, treated with culture medium supplemented with 1 nM dDAVP and 100 |uM ATP or 100 
|uM dopamine for the indicated time points. Cells were lysed in the presence of de-phosphorylation and 
de-ubiquitination blockers and AQP2 proteins were extracted by immunoprecipitation using guinea pig 
anti-AQP2 antibodies. Samples were analyzed by immunoblotting for ubiquitin, AQP2-pS261, or total 
AQP2 as indicated. Total lysates were blotted for total AQP2 to demonstrate equal AQP2 input levels. 
Protein mass (in kDa) is indicated on the left.
To determine more precisely whether pS261 occurs later than AQP2 ubiquitination, 
native mpkCCD cells expressing steady-state levels of AVP-induced AQP2 were left 
untreated (control) or incubated with ATP or dopamine for 5, 10, 15, 20, or 30 minutes, 
lysed, and subjected to AQP2 immunoprecipitation. Subsequent immunoblotting for 
ubiquitin revealed an increase in ubiquitinated AQP2 of 43 kDa after 5 minutes, with a 
peak in ubiquitination after 10 to 15 minutes (Fig. 5C, top panels), while pS261 signals 
of 29 and 43 kDa AQP2 mainly increased between 10 and 20 after hormone addition 
(Figure 5C, upper middle panel). Please note that the 29 kDa band in the blot for 
ubiquitination is a background band, because it is present in mpkCCD cells not pre-
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treated with dDAVP (see also input, lower panel). As the total levels of 
immunoprecipitated and total AQP2 remained essentially unaltered during the 
experiment (Figure 5C, bottom two panels), these data demonstrate that time-wise 
ubiquitination of AQP2 precedes phosphorylation of AQP2-S261.
Effect of ATP and dopamine on AQP2 degradation
In mpkCCD cells, TPA-induced internalization of AQP2 leads to its degradation via 
the lysosomal pathway, which can be inhibited by chloroquine (8;30). To test whether 
the hormones, besides internalization, also affect AQP2 degradation, dDAVP pre­
treated cells were co-incubated for 8  hours with ATP or dopamine in the presence or 
absence of cycloheximide to block protein synthesis, and in the presence or absence of 
chloroquine. Subsequent immunoblotting showed a significant reduction in AQP2 
abundance when cells were incubated with TPA, ATP, or dopamine, and this reduction 
was prevented by blocking lysosomal protein degradation with chloroquine (Fig. 6 ). 
Therefore, these data indicate that these AVP-counteracting hormones induce 
degradation of AQP2 via the lysosomal pathway.
Together, the data above clearly reveal that ATP and dopamine counteract AVP- 
induced water permeability by increasing the internalization of AQP2 from the plasma 
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Figure 6. Effect of TPA, ATP and dopamine on lysosomal degradation of AQP2. MpkCCD cells 
were grown to confluence, treated with 1 nM dDAVP for 4 days, and then left untreated or incubated 
with 100 ^M ATP, or 100 ^M dopamine with or without 100 ^M chloroquine, dDAVP and 50 ^M 
cycloheximide for 8 hours. Subsequently, cells were lysed and immunoblotted for AQP2 and signals 
quantified using densitometry. Quantified data represents pooled data from triplicate samples of three 
independent experiments. Samples significantly (P<0.05) different from the dDAVP alone control are 
indicated with an asterisk.
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Figure 7. Effect of ATP and dopamine on 
AQP2 mRNA amount. MpkCCD cells 
were grown and treated as described in the 
legend of Figure 6, except that 
cycloheximide was omitted. Cells were 
lysed, mRNA was isolated, and reverse 
transcribed to cDNA using random primers. 
Equal amounts of cDNA were subsequently 
subjected to Q-PCR using primers for mouse 
AQP2 and 18S (internal control). Following 
normalization against the 18S signal, the 
AQP2 mRNA amounts are expressed 
relative to control values.
Effect of ATP and dopamine on AQP2 mRNA abundance
In addition to increased AQP2 internalization and degradation (as shown above), the 
observed reduction in AVP-induced AQP2 expression in the 8  hours timeframe can be 
due to reduced AQP2 production. To determine whether the above-mentioned 
hormones affect AQP2 mRNA levels, cells were treated as above and subjected to 
quantitative RT-PCR. Using equal amount of starting cDNA and following 
normalization for 18S mRNA, ATP gave a nearly 60% reduction in AQP2 mRNA, 
while dopamine showed a 30% reduction (Fig. 7). TPA did not reduce AQP2 mRNA 
levels.
Figure 8. Effect of ATP and dopamine on 
dDAVP-induced cAMP production. MpkCCD 
cells were grown to confluence, treated with 1 
nM dDAVP for 4 days, incubated with 250 ^M 
IBMX for 10 minutes, and then left untreated or 
treated with 100 nM TPA, 100 ^M ATP, or 100 
I^M dopamine for another 15 minutes in the 
presence of dDAVP and IBMX. Then, cells were 
lysed and cAMP levels were determined with a 
control TPA ATP Dop cAMP enzyme immunoassay kit.
Effect of ATP and dopamine on cAMP production
Binding of AVP to its V2R induces an increase in cAMP, which results, via activation 
of CREB, in increased AQP2 gene transcription (6;7). Considering the observed 
reduction in AQP2 mRNA levels with ATP and dopamine (Fig. 7), we tested whether 
the used AVP-counteracting hormones reduce the steady-state cAMP levels induced by
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dDAVP. For this, mpkCCD cells were grown and pretreated with dDAVP as above, 
incubated with the phosphodiesterase inhibitor IBMX for 10 minutes, followed by 
treatment with ATP, dopamine and TPA for 15 minutes in the continued presence of 
dDAVP and IBMX. Subsequent analysis of the cAMP levels revealed that ATP and 
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Figure 9. Effect of TPA, ATP and dopamine on AQP2 localization and S261 phosphorylation in 
vivo. Rat kidney slices were pre-incubated at 37°C with 1 nM dDAVP for 15 min, followed by a 30 
min incubation with dDAVP alone or together with 0.1 mM dopamine, 0.1 mM ATP or 10-7M TPA. 
Then, the kidney sections were (A) stained for AQP2 and subjected to confocal laser scanning 
microscopy, or (B) lysed in a 1% Triton X-100 buffer and subjected to immunoblotting for total AQP2 
and AQP2-pS261. (C) The signals of (B) were semi-quantified using densitometry. Samples 
significantly (P<0.05) different from controls are indicated by asterisk.
Effect of ATP and dopamine ex vivo
To investigate whether TPA, ATP and dopamine also induce AQP2 internalization in 
kidney principal cells and whether this also coincides with increased phosphorylation 
of AQP2  at S261, rat kidneys slices were pre-incubated with 1 nM dDAVP for 15 
minutes, followed by 30 minutes with dDAVP alone or in combination dopamine, 
ATP, or TPA. Consistent to our mpkCCD cell line results, immunohistochemistry
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indeed showed that treatment with dDAVP alone yielded a localization of AQP2 in the 
apical membrane, whereas co-treatment with dopamine, ATP, or TPA revealed 
internalized AQP2 (Fig. 9A). Moreover, immunoblotting indeed revealed that, 
normalized for total AQP2 levels, AQP2-pS261 levels were significantly increased 
upon co-incubation with dopamine, ATP, or TPA (Fig. 9B,C).
Discussion
ATP and dopamine counteract AVP-action by inducing ubiquitin-dependent AQP2 
internalization and lysosomal degradation.
Several studies have demonstrated a role for extracellular purines ATP and UTP, and 
phenetylamine dopamine in the inhibition of AVP-induced water reabsorption 
(10;11;15;16;31;32). Our present study reveals that the mechanism of action by which 
these hormones counteract vasopressin consists of two parts:
The first part involves the short-term ubiquitin-dependent internalization and lysosomal 
degradation of AQP2. Using mpkCCD cells stimulated with AVP to induce total and 
plasma membrane expression of endogenous AQP2, ATP and dopamine induced 
internalization of AQP2 from the apical membrane (Fig. 2), followed by lysosomal 
degradation (Fig. 6 ). Importantly, using kidney slices we could show that these short 
term effects on AQP2 internalization mimicked the in vivo effects of ATP and 
dopamine on AQP2 localization (Fig. 9A). As we have shown for TPA-induced 
internalization of AQP2 (8 ), our data reveal that this internalization of AQP2 by ATP 
and dopamine is dependent on the ability to ubiquitinate AQP2 (Fig. 4). Using MDCK- 
AQP2 cells, we found that both hormones increase AQP2 ubiquitination, resulting in 
two main bands of 43 and 50 kDa, a weaker higher band of around 58 kDa and some 
smear (Fig. 3). This smear may represent glycosylated, K63-ubiquitinated AQP2 or 
possibly K29-poly-ubiquitinated AQP2. Poly-ubiquitination via K29 in ubiquitin is 
thought to be a general mechanism to degrade membrane proteins via the ER- 
associated degradation (ERAD) pathway. These different ubiquitination bands were not 
observed in precipitates of mock-transfected MDCK cells and are consistent with the 
addition of 2-4 ubiquitin moieties onto AQP2 (8 ). Possibly because of increased 
expression of de-ubiquitinating enzymes in dDAVP-induced mpkCCD cells, 
ubiquitinated AQP2 is not readily detectable in mpkCCD cells (see also below). 
However, our finding that wt-AQP2, but not the constitutively-de-ubiquitinated AQP2- 
K270R (8 ), is internalized in mpkCCD cells with both hormones (Fig. 4), shows that 
ubiquitination is an important regulatory mechanism in mpkCCD cells as well and that 
ubiquitination of AQP2 is needed for both hormones to internalize AQP2.
The second part involves the long term effects on AQP2 mRNA expression. As shown 
in figure 8  and consistent with in vivo data using perfused inner medullary collecting 
ducts (11 ;21), ATP and dopamine also significantly reduce the steady state cAMP
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levels. As AQP2 gene expression is increased when the cAMP-regulatory element 
binding protein (CREB) binds to the CRE present in the AQP2 promoter (6;7), the 
reduced AQP2 mRNA levels observed with both hormones (Fig. 7) is likely a 
consequence of the reduced cAMP levels. Interestingly, TPA appears to affect AQP2 
expression via the short term, but not the long term, pathway (see also below).
Short-chain ubiquitination o f AQP2 coincides with phosphorylation at Ser-261, before 
its degradation
While the essentiality of S256 phosphorylation for AQP2 translocation to the apical 
membrane is unchallenged, several data reveal that internalization of AQP2  does not 
necessarily require S256 de-phosphorylation, as activation of PKC by TPA (33), but 
also dopamine and PGE2-induced internalization of AQP2 to intracellular vesicles 
occurred without reducing S256 phosphorylation (34;35). Recently, we have shown 
that TPA-induced AQP2 endocytosis involves its short-chain ubiquitination at K270 
(8 ), but it is unclear if any of the three newly identified additional phosphorylation sites 
in the C-terminal tail of AQP2 may be involved, being Ser-261, Ser-264, and Ser-269 
(23). Interestingly, Hoffert et al. showed that Ser-261 phosphorylation of IMCD AQP2 
was decreased upon AVP incubation (24). Here, we demonstrated that, in line with in 
vivo, dDAVP decreases phosphorylation of AQP2 at Ser-261 (Fig. 5). More 
importantly, however, our data reveal that also internalization of AQP2 with ATP and 
dopamine coincides with an increase in Ser-261 phosphorylation (Fig. 5B).
In mpkCCD cells, stably transfected with AQP2, ATP and dopamine treatment initially 
results in an increased pS261 signal of a 43 kDa band, while the 29 kDa band was not 
increased (Fig. 5A). This pS261-labelled 43 kDa band likely represents AQP2 bound 
by 2  ubiquitin moieties, because its mass is consistent with this (8 ), and the band is not 
observed in ATP or dopamine treated mpkCCD cells expressing AQP2-K270R (Fig. 
5A). Although we cannot exclude the possibility that our pS261 antibodies have a 
higher affinity for ubiquitinated than non-ubiquitinated AQP2 and/or that ubiquitinated 
AQP2 is more prone to S261 phosphorylation than 29 kDa AQP2, these data indicate 
that AQP2  ubiquitination precedes pS261 phosphorylation as an early event in the 
ATP/dopamine-induced AVP-counteracting pathway of AQP2 proteins from the 
plasma membrane to lysosomes. Indeed, the time series experiments with ATP and 
dopamine confirmed that AQP2 ubiquitination precedes pS261 phosphorylation in the 
ATP/dopamine-induced pathway that targets AQP2 proteins for degradation (Fig 5C). 
Recently, the first steps were taken to identify the kinases involved in the 
phosphorylation of AQP2 at Ser-261. Although PKA is responsible for the 
phosphorylation of AQP2 at S256, Hoffert et al. demonstrated that PKA is unable to 
phosphorylate S261 (36). In vitro experiments where synthetic COOH-terminal AQP2 
peptides were incubated with various purified MAP kinases, demonstrated that JNK, 
p38, and CDK5/9 could potentially be involved in the phosphorylation of AQP2 at 
S261 (37). Although JNK, p38, and CDK5/9 are putative candidates, the identity of
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kinases involved in the ATP and dopamine dependent S261 phophorylation of AQP2 
remains to be established.
ATP and dopamine receptors involved in AQP2 degradation
Hormones can inhibit AVP-stimulated water permeability by decreasing cAMP levels, 
but can also exert their effects without affecting cAMP production, depending on the 
receptor subtype and subsequent G protein that is activated. In case the receptor 
couples to Gi, cAMP production will be inhibited, whereas upon Gq coupling, 
phospholipase C is activated and intracellular Ca2+ levels will increase. In AVP- 
stimulated mpkCCD cells, ATP and dopamine both decreased cAMP production (Fig. 
8 ), suggesting that ATP and dopamine activate receptors that couple to Gi. Purinergic 
receptors expressed in the collecting duct include P2Y1, P2Y2, and P2Y4 receptors. 
However, these receptors are considered to be Gq coupled and are therefore not likely 
to be involved in the effects described here. On the other hand, EP receptors might be 
involved in the effects of ATP on AQP2 expression. Extracellular purines have been 
shown to stimulate P2Y2 receptor-mediated release of prostaglandin E2 and 
arachidonic acid (38), which activate the Gi coupled EP receptors EP1 and EP3. This is 
in line with our recent paper, which suggests the involvement of P2Y4 and P2X2 
receptors, in addition to P2Y2, in AQP2-mediated water permeability in mpkCCD cells 
(14). Considering the fact that TPA, which is thought to activate PKCs, does counteract 
vasopressin action through the short term mechanism (AQP2 internalization, 
ubiquitination, lysomal degradation; Fig. 2, 3, and 6 )), but does, in contrast to ATP and 
dopamine, not reduce cAMP levels (Fig. 8 ), may indicate that ATP and dopamine 
indeed use a bimodal mechanism (direct PKC activation through Gq and indirect 
reduction of cAMP through activation of EP1/3 and Gi) to counteract vasopressin 
action.
Of the dopamine receptors, D2, D3 and D4 couple to Gi. Of these, the D4 receptors 
may be most likely to mediate the effect of dopamine on AQP2, since these receptors 
are expressed in the renal collecting duct (15;16).
The identity of the purinergic and dopamine receptors involved and the precise 
mechanism by which activation of these receptors result in reduced cAMP and AQP2 
levels remains to be established.
In summary, we demonstrated that ATP and dopamine counteract AVP-induced water 
permeability by two mechanism, being AQP2 internalization and lysosomal 
degradation in an ubiquitin-dependent and pS261-related manner, and through 
decreased cAMP levels.
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Effect of the cGMP Pathway on AQP2 Expression and Translocation
Abstract
Background. Arginine vasopressin (AVP) binding to the V2 receptor (V2R) in renal 
collecting duct principal cells induces a cAMP signalling cascade resulting in the 
activation of protein kinase A (PKA), translocation of aquaporin-2 (AQP2) to the 
apical membrane and an increase in AQP2 expression. Consequently, concentration of 
urine is initiated. X-linked nephrogenic diabetes insipidus (NDI), characterized by the 
inability to concentrate urine in response to AVP, is caused by mutations in the V2R 
gene. Initiation of AQP2 translocation, while circumventing the V2R-cAMP-PKA 
pathway has been suggested as a putative therapy for these patients. In this respect, the 
activation of a cAMP-independent and cGMP-dependent pathway for AQP2 membrane 
insertion by different cyclic guanosine monophosphate (cGMP) pathway activators, 
such as atrial natriuretic peptide (ANP), L-arginine and 8 -bromoguanosine 3’,5’-cyclic 
monophosphate (8 -Br-cGMP), has been put forward. However, it is unclear whether 
they can increase AQP2 expression.
Methods. Mouse cortical collecting duct (mpkCCD) cells were incubated with ANP, 
L-arginine and 8 -Br-cGMP for 2 h and subjected to immunocytochemistry and cell 
surface biotinylation assays to examine their effect on AQP2  translocation. To test the 
effect of cGMP pathway activators on AQP2 expression, the mpkCCD cells were 
treated with dDAVP, ANP and L-arginine for 4 days, or with 8 -Br-cGMP for the last 
day. AQP2 protein levels were determined by immunoblotting.
Results. ANP, L-arginine and 8 -Br-cGMP induced the translocation of AQP2 in the 
mpkCCD cells. However, in contrast to dDAVP, ANP, L-arginine and 8 -Br-cGMP did 
not increase the expression of AQP2.
Conclusions. Our results suggest that while activators of the cGMP pathway are likely 
beneficial in the treatment of X-linked NDI, their ability to relieve NDI in the patients 
maybe improved when combined with agents stimulating AQP2 expression.
Introduction
In mammals, maintenance of a proper water balance is of vital importance and, 
therefore, is tightly regulated. To maintain this balance, water is reabsorbed from the 
pro-urine by the principal cells of the renal collecting duct, which is under the control 
of the pituitary-derived antidiuretic hormone arginine vasopressin (AVP). In the state 
of dehydration or hypovolaemia, the release of AVP and its binding to the vasopressin 
type 2 receptor (V2R) in the basolateral membrane of principal cells increases 
intracellular cyclic adenosine monophosphate (cAMP) levels through Gs-mediated 
stimulation of adenylyl cyclase (1-3). This increase in cAMP activates protein kinase 
A (PKA), resulting in the phosphorylation of aquaporin-2 (AQP2) water channels and, 
likely, other proteins (2-5). Consequently, AQP2-bearing vesicles translocate to and
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fuse with the apical membrane, rendering the membrane water permeable. Due to an 
osmotic gradient, water will then enter the cells via AQP2 and leave to the interstitium 
via AQP3 and AQP4, which are constitutively present in the basolateral membrane. 
Upon correction of hypovolaemia, blood AVP levels drop and AQP2 is retrieved from 
the apical membrane, resulting in reduced water reabsorption.
In humans suffering from nephrogenic diabetes insipidus (NDI), the ability to reabsorb 
water and concentrate urine in response to AVP is severely disturbed. Congenital NDI 
can be caused by mutations in either the AQP2 gene or the AVPR2 gene. Mutations in 
the AQP2 gene are responsible for the autosomal dominant and recessive form of 
inheritance of NDI (6 ), whereas mutations in the A VPR2 gene, which account for ~90% 
of inherited NDI cases, are inherited as an X-linked recessive trait (7; 8 ).
At present, several approaches are under development to find a treatment for NDI. One 
of these approaches for X-linked NDI is to bypass V2R and the cAMP activation 
pathway by the activation of the cGMP pathway. This approach is based on the 
findings of Bouley et al. that AQP2 insertion could also be accomplished by the 
activation of the cAMP-independent and cGMP-dependent pathway (9-11). Nitric 
oxide (NO) donors, such as sodium nitroprusside (SNP) and NONOate, as well as the 
nitric oxide synthase (NOS) substrate L-arginine, appeared to induce AQP2 
translocation from intracellular vesicles to the apical membrane by increasing cGMP 
levels in rat kidney slices and AQP2-transfected LLC-PK1 cells. In addition, atrial 
natriuretic peptide (ANP), which increases cGMP levels by activating membrane- 
bound guanylyl cyclase, stimulates AQP2 membrane insertion in the principal cell of 
ANP infused rats (11).
In the absence of functional V2R, however, AQP2 expression levels are also reduced, 
because cAMP, generated through the activation of the V2R, stimulates AQP2 
transcription through a cAMP-responsive element in its promoter (12-15). At present, it 
is unclear whether the activation of the cGMP pathway also leads to an increased 
AQP2 expression. In the mouse cortical collecting duct cell line (mpkCCD), AVP 
increases endogenous AQP2 expression (16). Therefore, we used this cell line to 
determine whether the activation of the cGMP-signalling pathway not only induces 
AQP2 translocation, but also increases AQP2 expression.
Materials and methods
Chemicals and reagents
ANP, L-arginine, 8 -bromoguanosine 3’,5’-cyclic monophosphate (8 -BrcGMP), 
forskolin and (deamino-Cys1, D-arg8)-vasopressin (dDAVP) were purchased from 
Sigma (St. Louis, MO, USA). V2R antagonist (SR121463B) was kindly provided by 
Dr C. Serradeil-Le Gal (Sanofi Synthélabo Recherche, Toulouse, France).
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Cell culture
Mouse cortical collecting duct (mpkCCD) cells (clone 14) (16) were grown in a 
modified defined medium [DMEM:Ham’s F12 1:1 vol/vol; 60 nM sodium selenate, 5 
^g/ml transferrin, 2 mM glutamine, 50 nM dexamethasone, 1 nM triiodothyronine, 10 
ng/ml epidermal growth factor, 5 ^g/ml insulin, 20 mM D-glucose, 2% fetal calf serum 
and 20 mM HEPES (pH 7.4)] at 37°C in an air atmosphere of 5% CO2. The medium 
was replaced every 2  days.
Exponentially growing mpkCCD cells (at ~70% confluence) were trypsinized and 
seeded at a density of 1.5 x 105 cells/cm2 on semipermeable filters (Transwell®, 0.4 
^m pore size, Corning Costar, Cambridge, MA, USA). A total of 10 1.13 cm2 filters 
were used for immunocytochemistry or immunoblotting and 4.7 cm2 filters for 
biotinylation experiments. The cells remained in culture for 8  days before being 
analysed. Unless stated otherwise, the cells were treated for the last 4 days with 
dDAVP (1 nM) only on the basolateral side, to maximally induce AQP2 expression 
(16). For internalization of AQP2, the cells were washed three times with a warm 
medium to remove dDAVP after which they were incubated with 1 ^M of the V2R 
antagonist SR121463B for the indicated time points. The affinity of the V2R for 
dDAVP (Ki in relation to AVP around 3 nM [17]) and SR121463B (Ki: 0.54 nM [18]) 
is similar, indicating that with the concentrations used, a 1 0 0 0 -fold excess of the 
antagonists was used. Again after three washes, forskolin (10 ^M), ANP (1 ^M), L­
arginine (10 mM) or 8 -Br-cGMP (100 ^M) were administered to both the apical and 
basolateral sides for the indicated time points. Biotinylation was performed as 
described (19).
Immunocytochemistry
Immunocytochemistry and confocal laser scanning microscopy (CLSM) of the cells 
grown on semi-permeable filters were performed as described (19). To detect AQP2, 
the filters were incubated with affinity-purified rabbit anti-AQP2 antibodies (20) 
(1:100) and goat anti-rabbit antibodies coupled with Alexa 488 (Molecular Probes, 
Eugene, OR, USA; 1:100).
Immunoblotting
Immunoblotting was done as described (21), for which affinity-purified rabbit anti- 
AQP2 antibodies (1:3000; [20]) were employed. Goat antirabbit antibodies coupled 
with horseradish peroxidase (HRP; Sigma, St. Louis, MO, U.S.A.; 1:5000) were used 
as secondary antibodies.
Statistical analyses
Films and blots were scanned using a Bio-Rad (Hercules, CA, USA) 690c densitometer 
and chemidoc XRS, respectively, and analysed using the Bio-Rad software. Statistical
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comparisons were made using one-way analysis of variance (ANOVA) and 
Bonferroni’s post hoc correction. P-value<0.05 was considered significant.
Results
Figure 1. Effects of V2R 
antagonist SR121463B 
on the cellular 
distribution of AQP2 in 
the mpkCCD cells. 
Confluent monolayers of 
the mpkCCD cells were 
stimulated with 1 nM 
dDAVP for 4 days and 
left untreated (a), or 
treated with 1 j^M V2R 
antagonist for 2 h (b), 4 h 
(c), 8 h (d) or 16 h (e). 
Cells were subjected to 
immunocytochemistry, 
using rabbit AQP2 
antibodies, followed by 
Alexa 488-conjugated 
anti-rabbit IgGs.
Horizontal (XY) and 
vertical (XZ) confocal 
images are shown.
AQP2 internalization upon SR121463B treatment in the mpkCCD cells 
To be able to test whether the activation of the cGMP pathway results in increased 
AQP2 expression levels in the mpkCCD cells, it was necessary to test whether this 
activation results in AQP2 translocation. For this, the mpkCCD cells were grown to 
confluency for 4 days and treated with 1 nM dDAVP for an additional 4 days to 
maximize endogenous AQP2 expression (22). As anticipated, the cells stimulated with 
dDAVP showed clear AQP2 expression at the apical membrane (Figure 1a). To be able 
to study the effect of cGMP on AQP2 translocation, AQP2 needed to be internalized. 
Removal of AVP for 2 h or 4 h did not affect the localization of AQP2, but dDAVP 
wash-out for 8  h and 1 6  h resulted in increased intracellular AQP2  staining. However, 
dDAVP removal for 8  h and 16 h also decreased AQP2 expression to a large extent 
(data not shown).
Therefore, we tested whether the V2R antagonist SR121463B could be employed to 
internalize AQP2, while maintaining sufficient AQP2 expression. The dDAVP treated 
mpkCCD cells were incubated with 1 ^M SR121463B for 2 h, 4 h, 8  h or 16 h and
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subjected to immunocytochemistry or immunoblotting. CLSM demonstrated that after 
2 h SR121463B, AQP2 was partially internalized (Figure 1b), which was more 
pronounced after 4 h of treatment (Figure 1c). After 8  h and 16 h, AQP2 appeared to be 
completely internalized, but the number of positive cells seemed reduced (Figure 1d 
and e). To analyse the expression quantitatively, we employed AQP2 immunoblotting, 
followed by semi-quantification (Figure 2A and B). At 2 h, SR121463B did not affect 
AQP2 expression. However, at 4-h and 8 -h treatment, the AQP2 expression levels 
decreased significantly, whereas at 16-h treatment AQP2 expression was almost 
completely abolished. Based on these data, a 4-h treatment with SR121463B was 
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Figure 2. Effects of V2R antagonist SR121463B on the expression of AQP2 in mpkCCD cells. (A)
MpkCCD cells were grown to confluence, treated with 1 nM dDAVP for 4 days, left untreated or 
treated with 1 pM SR121463B for the indicated times and subjected to immunoblotting for AQP2. (B) 
The signals from a were scanned and the amount of AQP2 was semi-quantified in arbitrary units. 
Significant differences are indicated by asterisks.
Effect of activation of the cGMP pathway on AQP2 translocation in the mpkCCD cells 
To test whether the mpkCCD cells also show cGMP pathway-mediated trafficking of 
AQP2, AQP2 was internalized with 4-h V2R antagonist treatment as described above, 
after which the medium was replaced, and the cells were left untreated or stimulated 
with forskolin (10 pM), ANP (1 pM), L-arginine (10 mM) or 8 -Br-cGMP (100 pM) for 
2 h. As mentioned before, the cells treated with SR121463B showed mainly 
internalized AQP2 expression (Figure 3a). Upon forskolin stimulation, AQP2 was 
completely translocated to the apical membrane (Figure 3b). Incubation with ANP 
(Figure 3c), the NOS substrate L-arginine (Figure 3d) and the cell-permeable analogue 
of cGMP, 8 -Br-cGMP (Figure 3e), also induced translocation of AQP2 from 








Figure 3. Effect of the activation of the cGMP pathway on translocation of AQP2 in the 
mpkCCD cells. Confluent mpkCCD monolayers were stimulated with 1 nM dDAVP for 4 days, 
incubated with 1 pM V2R antagonist SR121463B for 4 h, and left untreated (a), or treated with 10 pM 
forskolin (b), 1 pM ANP (c), 10 mM L-arginine (d), or 100 pM 8-Br-cGMP (e) for 2 h. Cells were 
subjected to immunocytochemistry. Horizontal (XY) and vertical (XZ) confocal images are shown.
Figure 4. Effect of the 
activation of the cGMP 
pathway on apical 
membrane expression of 
AQP2 in the mpkCCD 
cells. Confluent monolayers 
of the mpkCCD cells were 
stimulated with 1 nM 
dDAVP for 4 days, 
incubated with 1 pM V2R 
antagonist SR121463B for
4 h, and left untreated, or 
treated with 10 pM 
forskolin, 1 pM ANP, 10 
mM L-arginine, or 100 pM 
8-Br-cGMP for 2 h. Then, 
the cells were subjected to a 
cell surface biotinylation 
assay. Biotinylated proteins were pulled-down and immunoblotted for AQP2 (AQP2). In addition, total 
lysates were immunoblotted for AQP2 (Total AQP2). The signals were scanned and the amount of 
protein was semiquantified in arbitrary units. Significant differences are indicated by asterisks. 
Biotinylation experiments were performed in triplicates in three independent experiments.
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To analyse translocation of AQP2 by the activation of the cGMP pathway 
quantitatively, we treated the mpkCCD cells as mentioned above and performed apical 
cell surface biotinylation assays. As anticipated, immunoblotting of the biotinylated 
proteins revealed that forskolin treatment strongly increased apical membrane 
expression of AQP2  (Figure 4). In addition, incubation with ANP, L-arginine or 8 -Br- 
cGMP significantly increased cell surface expression of AQP2 in these cells, while the 
total amount of AQP2 remained equal (Figure 4). These data demonstrate that the 
mpkCCD cells also exert a cGMP-mediated translocation of AQP2 to the apical 
membrane and that these cells are suitable to analyse the effect of cGMP on AQP2 
expression.
Effect o f the activation o f the cGMP pathway on AQP2 expression in the mpkCCD cells 
To test the effect of cGMP pathway activation on AQP2 expression, the mpkCCD cells 
were grown for a total period of 8  days and incubated with dDAVP, ANP and L­
arginine for the last 4 days or with 8 -Br-cGMP for the last day. As anticipated, 
immunoblotting revealed that dDAVP treatment increased expression of AQP2 
extensively (Figure 5). However, incubation with ANP, L-arginine or 8 -Br-cGMP did 
not change AQP2 expression compared to untreated cells (Figure 5). These data show 
that ANP, L-arginine and 8 -Br-cGMP are not able to induce AQP2 expression in the 
mpkCCD cells. While the compounds activating the cGMP pathway were not able to 
stimulate AQP2 expression by themselves, we also tested whether they would affect 
AQP2 expression in the presence of dDAVP. Following determination of a dDAVP 
concentration that resulted in sub-maximal AQP2 abundance, the mpkCCD cells were 
unstimulated, treated with 1.4 nM dDAVP or with 0.7 nM dDAVP alone or in 
combination with ANP, L-arginine or 8 -Br-cGMP for 4 days, except for cGMP which 
was added again for 1 day. Subsequent AQP2 immunoblotting revealed that neither 
ANP, L-arginine nor cGMP (P = 1) affected dDAVP induced AQP2 expression (Figure
6 A). The increased AQP2 expression with 1.4 nM dDAVP (Figure 6 B) shows that a 
higher expression of AQP2 could be obtained when there would be some activation of 
AQP2 expression by the other compounds.
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Figure 5. Effect of the activation of the cGMP pathway on AQP2 expression in the mpkCCD 
cells. Confluent mpkCCD monolayers were left untreated, treated with 1 nM or 10 nM dDAVP, or 
treated with 1 nM dDAVP together with 1 pM ANP, 10 mM L-arginine (4 days) or 100 pM 8-Br- 
cGMP (1 day). Protein samples were immunoblotted for AQP2 and the blot was coomassie-stained to 
check for equal protein loading. The signals were scanned and the amount of AQP2 normalized for 
total protein amount was semiquantified in arbitrary units. Significant differences are indicated by 
asterisks. The effects on AQP2 expression were determined in triplicate in three independent 
experiments.
A B
dDAVP dDAVP/ANP dDAVP/ L-arg dDAVP/cGMP
Figure 6. Effect of dDAVP 
combined with activators of 
the cGMP pathway on 
AQP2 expression in the 
mpkCCD cells. (A) 
Confluent mpkCCD
monolayers were left 
untreated, treated for 4 days with 0.7 nM alone, or with 0.7 nM dDAVP together with 1 pM ANP, 10 
mM L-arginine (4 days) or 100 pM 8-Br-cGMP (1 day). (B) Confluent mpkCCD monolayers were 
treated for 4 days with 0.7 nM dDAVP or 1.4 nM dDAVP. Subsequently, protein samples were 
immunoblotted for AQP2. Protein samples were immunoblotted for AQP2. The effect on AQP2 
expression was determined in triplicate. Data from three independent experiments are shown.
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Discussion
ANP, L-arginine and 8-Br-cGMP induce translocation o f AQP2 in the mpkCCD cells 
Bouley et al. demonstrated that elevation of cGMP levels by NO donors, such as SNP 
and NONOate, and the NO synthase substrate L-arginine results in membrane insertion 
of AQP2 in AQP2-transfected LLC-PK1 cells and kidney slices (9). In addition, ANP, 
which activates the cGMP cascade, also induces the plasma membrane targeting of 
heterologously-expressed AQP2 in LLC-PK1 cells and ANP-infused rats (9; 11). In this 
study, we show that the mpkCCD cells represent a proper model to study the effects of 
the cGMP pathway on AQP2 functioning, because ANP, L-arginine and 8 -Br-cGMP 
also induced the translocation of AQP2 to the apical membrane of these cells (Figures
3 and 4). The higher potency of forskolin compared to the other agonists may explain 
the increased translocation and plasma membrane expression of AQP2 with this drug. 
It remains to be established whether the translocation of AQP2 through activation of 
the cGMP pathway involves PKA phosphorylation of AQP2 or whether this is 
mediated by another kinase.
For these analyses in the mpkCCD cells, we needed to internalize AQP2 with the V2R 
antagonist SR121463B, because removal of dDAVP for 4 h did not result in clear 
internalization of AQP2, while removal for longer time points (8 , 16 h) resulted in 
reduced AQP2 levels.
ANP, L-arginine and 8-Br-cGMP do not affect AQP2 expression in the mpkCCD cells 
cGMP can replace cAMP in re-distributing AQP2 water channels from intracellular 
storage vesicles to the apical membrane. However, V2R-induced cAMP levels not only 
induce AQP2 translocation, but also increase AQP2 transcription and thus protein 
expression. We demonstrated that, in contrast to dDAVP, ANP, L-arginine and 8 -Br- 
cGMP could not induce AQP2 expression (Figure 5).
Although direct evidence for decreased AQP2 levels in principal cells of NDI patients 
is lacking, several studies suggest that AQP2 expression is reduced in NDI patients. For 
instance, the urinary excretion of AQP2 in patients with NDI is decreased (20;23) and 
patients with central NDI, who lack endogenous AVP, also showed decreased basal 
excretion of AQP2 (23). However, as urinary AQP2 is predominantly derived from 
exosomes, which are released into urine following translocation of AQP2 from storage 
vesicles to the apical membrane, these studies cannot provide an answer whether 
reduced urinary AQP2 levels in urine of NDI-V2R patients is due to a reduced AQP2 
expression, reduced AQP2 trafficking or both.
More information is present from animal models. In pups of mice completely lacking 
the V2R and in adult female mice heterozygous for a deletion of the V2R gene, the 
AQP2 expression levels were not changed (24). These data are in line with the 
knowledge that AQP2 expression is only increased after birth (pups) and that carriers 
of a V2R gene mutation are generally without symptoms. In untreated Brattleboro rats,
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which are AVP-deficient, AQP2 protein levels were found to be ~50% lower than in 
untreated Wistar rats (25). However, treatment of these rats with the V2R-specific 
antagonist SR121463B still reduced the AQP2 protein and mRNA levels considerably 
(40-50%), indicating that the V2R in Brattleboro rats is still active and, as such, is not 
the ideal animal model for NDI patients with non-functional V2Rs. This V2R-mediated 
stimulation of AQP2 expression may be due to the basal activity of the V2R (i.e. low 
level of V2R activity without agonist binding) or, possibly, through activation by 
oxytocin.
In fact, normal or Bratteboro rats treated with V2R antagonists may be more 
appropriate models, as these correspond to ‘functional inactivation’ of V2Rs. While 
normal adult rats treated with the V2R-selective antagonist OPC-31260 showed a 
‘significant’ decrease in AQP2 expression (15), use of the V2R-specific antagonist 
SR121463B in Brattleboro rats thus reduced AQP2 mRNA and protein levels to ~25% 
of the levels observed in normal rat with water ad libitum (50% of 50%) (25). The 
strong reduction in AQP2 levels in animals lacking functional V2R is further supported 
by recent data from Dr Wess and colleagues, who have been able to generate mice 
whose V2R gene can be conditionally knocked out. With excision of the loxP-flanked 
V2R gene at adulthood, these mice developed severe NDI and had only 20% of the 
basal AQP2 expression observed in the non-excised V2R gene littermates receiving 
water ad libitum (J. Wess, NIH, Bethesda, MD, USA, personal communications; 
manuscript under review). Altogether, these data reveal that a lack of functional V2R 
leads to strongly reduced AQP2 expression levels, which may, besides the absence of 
AQP2 translocation, be an additional factor fundamental to X-linked NDI.
In conclusion, our data reveal that the activation of the cGMP pathway does not induce 
AQP2 expression in vitro, but, together with data of others, does induce AQP2 
translocation to the apical membrane in vitro and ex vivo. Assuming similar low AQP2 
levels and translocation of AQP2 with compounds activating the cGMP pathway in X- 
linked NDI patients, our data suggest that the beneficial effect of such compounds to 
relieve NDI may be improved when combined with agents that stimulate AQP2 
expression.
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General Discussion and Summary
Introduction
These days, water management is a hot topic. It is generally believed that, due to the 
changes in the world climate, water will become the world’s biggest problem. Sea 
water levels are rising and floods are the order of the day. Moreover, global warming 
induces long periods of drought in many regions across the world. This is even 
deteriorated by the fact that clean drinking water becomes a scarcity in a substantial 
number of countries. To deal with these problems, more and more measures are taken. 
In the end, it all revolves about controlling this shaky water balance.
This also holds true for the body, which needs to be able to deal with changes in the 
body water balance. An ingenious system controls both water intake and excretion, 
enabling living beings to respond adequately to changes in osmolality and blood 
volume. In states of hypernatremia, specific osmoreceptors in the hypothalamus are 
activated, which results in the sensation of thirst and subsequent water intake (1). In 
addition, the antidiuretic hormone arginine-vasopressin (AVP) is released from the 
pituitary gland into the bloodstream and makes its way toward the kidney where water 
excretion is controlled (2;3). As outlined throughout this thesis, the aquaporin-2 
(AQP2) water channel is one of the key players in regulating renal water excretion. 
Binding of AVP to its type-2 receptor initiates a signal transduction cascade, which 
results in the translocation of AQP2 water channels from intracellular storage vesicles 
towards the apical membrane, allowing water to pass the membrane (4;5). When blood 
AVP levels drop, AQP2 is internalized, leaving the apical membrane watertight again. 
Considering its important role in water homeostasis, it is not surprising that AQP2 is 
involved in several diseases associated with a disturbed water balance, including 
congenital nephrogenic diabetes insipidus (NDI) (6;7). Congenital NDI is characterized 
by impaired AVP-induced water reabsorption, which results in polyuria and polydipsia. 
Although different therapies to treat NDI patients are under development, a satisfying 
treatment is still lacking. Increased knowledge on AQP2 regulation might thus be 
useful to develop a remedy for AQP2-associated pathologies. The results described in 
this thesis focused on gaining more insights in the molecular regulation of AQP2 
trafficking and expression. This chapter will summarize and discuss the findings of 
these studies.
AQP2 regulation by the AQP2-associated protein LIP5
A number of proteins that potentially play a role in the regulation of AQP2 trafficking, 
including signal-induced proliferation-associated protein 1 (SPA-1), actin, heatshock 
protein 70 (Hsc70), myelin, and lymphocyte-associated protein (MAL), have been 
described to bind AQP2 (8-11). In this thesis, Lyst interacting protein 5 (LIP5; also 
known as DRG-1, vta1p, and SBP1) is identified as a novel AQP2-interacting protein
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using a yeast two-hybrid screening (Chapter 2). In the kidney, LIP5 and AQP2 are both 
expressed in principal cells, although LIP5 can also be detected in intercalated cells. 
LIP5 directly binds AQP2, but is unable to interact with AQP3 and AQP4, which are 
also expressed in collecting duct principal cells. Although AQP2 is phosphorylated at 
Ser-256, which is preceded by its translocation to the apical membrane (12-15), the 
phosphorylation state of AQP2 does not affect its binding to LIP5. Similarly, although 
AQP2 is mono-ubiquitinated at Lys-270 upon internalization (16), the interaction with 
LIP5 is independent of this modification. LIP5 is part of a complex protein machinery 
that is involved in the sorting of membrane proteins to the internal vesicles of 
multivesicular bodies (MVBs), from where proteins are targeted for lysosomal 
degradation. Evidence for its role in protein degradation was provided by a LIP5 
silencing study, which demonstrated that lysosomal degradation of epidermal growth 
factor receptor (EGFR) was decreased upon knockdown of LIP5 (17). Chapter 2 
demonstrates that LIP5 binds EGFR and inhibits the degradation of AQP2 upon LIP5 
silencing. These results provide the first evidence of a role for LIP5 in binding 
membrane proteins that are destined for lysosomal degradation.
Chapter 2 already demonstrated that amino acids 230-243 of AQP2 are essential for 
LIP5 binding. In chapter 3 the interaction between AQP2 and LIP5 is further 
characterized. LIP5 encompasses three conserved domains, involved in protein-protein 
interactions, a C-terminal VSL (Vta1/SBP1/LIP5) domain and two N-terminal 
microtubule interacting and transport (MIT) domains (referred to as MIT1 and MIT2). 
Although AQP2 and EGFR are the first cargo proteins to directly interact with LIP5, 
several members of the MVB sorting machinery were demonstrated to bind LIP5 as 
well. The ATPase Vps4, which is recruited to the membrane to disassemble and recycle 
ESCRT complexes that assist in the sorting process, binds the VSL domain of LIP5 
(18). Furthermore, several members of the ESCRT complexes, including CHMP1B, 
CHMP2B, CHMP3, and CHMP5, associate with LIP5 (17;19). For two of these 
members this interaction was shown to occur through the MIT2 domain (20;21). 
Conversely, the interaction between AQP2 and LIP5 is mediated through the MIT1 
domain of LIP5, as described in chapter 3. Within the LIP5 binding region of the AQP2 
C-tail, amino acids 230-243, the leucine residues 230, 234 and 237 are essential for 
binding to LIP5. Secondary structure prediction indicates that the region L230-L237 is 
likely to form a helix, in which Leu 230, 234 and 237 form a hydrophobic patch. 
Similarly, several other AQPs, including AQP0, AQP1, AQP4, AQP5, and AQP6 , 
might also form a helix. However, except for AQP6 , these AQPs lack binding to LIP5. 
Closer examination of the primary structure of these AQPs tells us that the three 
leucines involved in AQP2 binding to LIP5 are present in AQP6 , but not in the other 
AQPs. These results further confirm the importance of these leucines in the AQP C-tail 
for LIP5 association. As both LIP5 (chapter 2) and AQP6  (22) are expressed in 
intercalated cells, it will be of interest to further investigate whether LIP5 plays a role 
in AQP6  degradation as well.
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Chapter 4 describes the localization of LIP5 in various epithelial tissues. LIP5 can be 
detected in a wide variety of tissues as a 42 kDa band, but also additional bands can be 
observed in several tissues, including testis, spleen, thymus, and liver. According to 
AceView, which provides all public mRNA sequences, transcription of the human 
LIP5 gene could produce at least 5 alternatively spliced mRNAs and the program 
supports at least 7 spliced variants for the mouse Vta1 gene. Whether the bands in these 
tissues represent spliced variants needs to be further explored. Exploiting the 
advantages of microarray technologies, which allow the simultaneous analysis of 
thousands of parameters within a single experiment (23), human tissue microarrays 
(TMAs) were used to study the distribution of several AQPs in rare or hard to study 
human tissues (24;25). In chapter 4, we demonstrate that LIP5 is abundantly expressed 
in a number of these human epithelial cells and tissues, including kidney, salivary 
gland, adrenal gland, skin, prostate, seminal vesicles, bronchial epithelium and 
bronchial cartilage, ectocervix, ileum, colon, endometrial glands, oviduct, and testis. 
Additionally, LIP5 is expressed in a number of mouse tissues, including salivary gland, 
eye, brain, liver, stomach, ileum, and bladder. Both AQP5, which is abundantly present 
in salivary gland (26;27), and AQP0 (also referred to as MIP), which is highly 
expressed in the lens fiber cells of the eye (28;29), co-localize with LIP5. Conversely, 
AQP4, which is localized in brain glial cells (30;31) and LIP5 are not detected in the 
same cells. Although AQP0 as well as AQP5 are co-expressed with LIP5 in eye and 
salivary gland respectively, both proteins do not associate with LIP5 (chapter 3). 
Therefore, their co-expression may be co-incidential and without any physiological 
relevance.
Hormonal regulation of AQP2
One of the best studied parts of AQP2 regulation is its translocation from intracellular 
storage vesicles towards the apical plasma membrane upon AVP stimulation. In short, 
AVP binds to the type 2 receptor on the basolateral membrane of principal cells, which 
results in activation of adenylate cyclase, a rise in cAMP levels, and activation of 
protein kinase A (PKA). This is followed by the phosphorylation of AQP2 at Ser-256, 
its translocation, and the fusion with the membrane to enable water reabsorption (1 2 ­
15). When water homeostasis is restored, AVP levels drop, which is followed by 
clathrin-mediated endocytosis and accumulation of AQP2 in intracellular vesicles 
(5;32-34). Besides AVP removal, PKC activation by the phorbol ester 12- 
tetradecanoylphorbol-13-acetate (TPA) also causes AQP2 internalization (12). 
Although AVP withdrawal surely inhibits water flow, several other hormones have 
been reported to diminish AQP2-mediated water transport as well. Extracellular 
purines, ATP and UTP, decrease AVP-induced water permeability (35;36). In chapter 
5, part of the molecular mechanism underlying ATP-induced inhibition of AQP2-
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mediated water reabsorption in mouse cortical collecting duct (mpkCCD) cells is 
elucidated. Co-treatment with AVP and ATP results in internalization of AQP2 from 
the apical membrane and a decreased expression. In addition, AVP induces the 
expression of the P2Xi receptor at the apical domain, and the translocation of P2X2 and 
P2Y2 receptors to the apical and basolateral membrane, respectively. P2Yi and P2Y4 
receptors are expressed in the apical membrane independent of the presence of AVP. 
When ATP is added to either the apical or basolateral medium only, AQP2 is still 
internalized from the apical plasma membrane, although the effect is increased when 
ATP is added to both media. These data indicate that both apical and basolateral P2Rs 
can affect membrane expression of AQP2. Indeed, upon co-expression of different P2 
receptors with AQP2 in oocytes and activation with ATP, oocytes expressing P2 X2, 
P2 Y2 or P2 Y4 receptors display a reduced AQP2-mediated water permeability and 
stability. These results confirm previous findings that activation of basolaterally 
expressed P2 Y2 by ATP can inhibit AQP2-mediated water transport in the collecting 
duct (36-39). Additionally, this study provides first evidence of a role for apical P2 
receptors in inhibition of AVP-induced water reabsorption. One question remaining 
concerns the physiological relevance of this regulation. It is generally believed that 
ATP is released locally upon cell swelling (40). One could therefore speculate that cell 
swelling in states of over-hydration leads to ATP release, which could help to increase 
water excretion by its effect on both basolateral and apical P2 receptors.
Another compound, which inhibits AVP-induced water flow, is carbachol, an 
acetylcholine analogue, and also dopamine, and endothelin- 1  decrease water 
permeability in collecting duct (41-45). Although prostaglandin E2 (PGE2) stimulates 
water permeability in the absence of AVP, it impairs AVP-induced water reabsorption 
(46-48). Chapter 6  describes the pathways involved in the inhibition of the AQP2 water 
channel by these hormones in mpkCCD cells. In line with the studies mentioned above, 
co-treatment with AVP and ATP or dopamine results in internalization and decreased 
abundance of AQP2. The reduction in AQP2 abundance can be blocked by co­
incubation with chloroquine, a lysosomal degradation inhibitor, which indicates that 
these hormones induce lysosomal degradation of AQP2. Previously, it was 
demonstrated that AQP2 internalization and degradation is preceded by its mono- 
ubiquitination at Lys-270 upon AVP removal or PKC activation (16). Similarly, ATP 
and dopamine increased mono-ubiquitination of AQP2. These hormones might inhibit 
AVP-stimulated water permeability by decreasing cAMP levels, but possibly also exert 
their effects without affecting cAMP production, depending on the receptor subtype 
and subsequent G protein that is activated. In AVP-stimulated mpkCCD cells, ATP and 
dopamine both decrease cAMP production. These findings suggest that ATP and 
dopamine activate receptors that couple to Gi. These observations for ATP and 
dopamine are in line with previous findings in perfused inner medullary collecting duct 
(IMCD) (36;49). The receptor subtypes that are responsible for the observed effects in 
mpkCCD cells remain to be explored.
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The importance of Ser-256 phosphorylation in AVP-mediated AQP2 translocation is 
supported by many studies (12;13;50). Internalization of AQP2, however, appeared to 
be independent of Ser-256 phosphorylation (12;51;52). Three additional 
phosphorylation sites, Ser-261, Ser-264, and Ser-269, were identified in the C-terminal 
tail of AQP2 (53). Ser-261 phosphorylation was demonstrated to decrease upon AVP 
incubation and the protein localized subapically, showing a punctuate staining (54). 
Interestingly, upon co-incubation with AVP, ATP and dopamine both increase Ser-261 
phosphorylation of AQP2. The physiological relevance of Ser-261 phosphorylation still 
needs to be further explored. Currently, several attempts are being made to identify the 
kinases involved in Ser-261 phosphorylation. PKA, the kinase responsible for Ser-256 
phosphorylation, is not involved in the phosphorylation of AQP2 at Ser-261 (55). In 
vitro experiments with synthetic COOH-terminal AQP2 peptides, identified JNK, p38, 
and CDK5/9 as putative kinases involved in the Ser-261 phosphorylation. It will be 
interesting to determine whether one or more of these kinases are involved in the ATP 
and dopamine-dependent S261 phosphorylation of AQP2.
AQP2 translocation by the cGMP pathway
Initially, AQP2 translocation was thought to occur upon rising cAMP levels only. 
Nevertheless, various compounds that increase intracellular cGMP levels, including 
atrial natriuretic peptide (ANP), nitric oxide donors, nitric oxide synthase (NOS) 
substrate and cGMP phosphodiesterase inhibitors, have also been shown to stimulate 
AQP2 translocation to the plasma membrane in rat kidney slices and AQP2-transfected 
LLC-PK1 cells (56;57). Seeing that activation of the cGMP pathway can induce 
translocation of AQP2, stimulation of this pathway might potentially be beneficial for 
patients with X-linked NDI. These patients suffer from an inability to concentrate urine 
due to mutations in the A VPR2 gene, encoding the V2R, which prevents activation of 
the V2R-cAMP-PKA-AQP2 pathway upon AVP release. However, because cAMP 
levels, which are generated through AVP-mediated V2R activation, also drive the 
expression of AQP2 through a cAMP responsive element in its promoter, AQP2 
protein expression will be severely decreased in these patients as well (58-61). In fact, 
although several compounds that stimulate the cGMP pathway, including ANP, the 
NOS substrate L-arginine, and 8 -bromoguanosine 3’,5’-cyclic monophosphate (8 -Br- 
cGMP), can cause a translocation of AQP2 towards the apical membrane in mpkCCD 
cells, these compounds can not induce its expression, as described in chapter 7. These 
results indicate that activators of the cGMP pathway might be applicable to treat 
patients with X-linked NDI, but a combination with agents stimulating AQP2 




Tremendous efforts increased our knowledge on both the physiological and patho­
physiological regulation of AQP2 over the last decades. In this thesis, we unravelled a 
small part of the complex regulation of hormone-induced AQP2 trafficking and 
expression. The identification of LIP5 as a novel binding partner of AQP2 contributes 
to our understanding of AQP2 degradation. Besides AVP, also hormones such as ATP 
and dopamine are tightly involved in AQP2 regulation, as they induce ubiquitination, 
internalization, and degradation of AQP2, thereby inhibiting AVP-induced water 
permeability. One of the challenges of the future is to further identify the receptors and 
signalling pathways involved in hormone-induced AQP2 regulation. Furthermore, 
considering the fact that Ser-261 phosphorylation is regulated by AVP, ATP, and 
dopamine, it will be interesting to reveal the exact role of Ser-261 phosphorylation in 
AQP2 regulation. As was shown for the cGMP pathway, full understanding of AQP2 
regulation in health, can also contribute to a potential cure for AQP2-associated 
pathologies, such as congenital NDI.
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Tegenwoordig is het begrip “water management” niet meer weg te denken uit onze 
maatschappij. Het wordt steeds duidelijker dat “water” op weg is om het grootste 
probleem ter wereld te worden. Overal ter wereld is het klimaat aan het veranderen. De 
zeewaterspiegels stijgen en in bepaalde delen van de wereld zijn overstromingen aan de 
orde van de dag. In andere gebieden heeft men juist te maken met langdurig 
aanhoudende droogte. Ook in Nederland hebben we te maken met problemen als 
gevolg van het water. Overstromingen en dijkdoorbraken als gevolg van het stijgende 
rivierwater worden ook hier steeds vaker afgewisseld met perioden van aanhoudende 
droogte. Het is dus een wankel evenwicht dat vraagt om adequaat beheer.
Zo is het ook voor het menselijke lichaam, dat om te kunnen overleven in staat moet 
zijn om zich aan te passen aan steeds wisselende omstandigheden. Het lichaam verliest 
water via de longen (adem), de huid (zweten), de darmen (ontlasting) en de nieren 
(urine) en verkrijgt water uit het glucose metabolisme, via drank en 
voedingsmiddelen. Om de waterbalans in evenwicht te houden beschikt het lichaam 
over een vernuftig systeem dat zowel de inname als de afvoer van water reguleert. 
Veranderingen in natrium concentratie van het bloed worden opgemerkt door 
specifieke osmoreceptoren in de hypothalamus. Activering van deze receptoren leidt 
achtereenvolgens tot een dorstprikkel en de inname van water. Tegelijkertijd wordt het 
hormoon arginine vasopressine (AVP) uitgescheiden door de hypofyse en gaat op weg 
naar de nier waar de uitscheiding van water gereguleerd wordt. Ook veranderingen in 
het bloedvolume, door bijvoorbeeld uitdroging, worden opgemerkt door baro- en 
volumereceptoren, die de afgifte van het hormoon arginine vasopressine (AVP) 
reguleren. In de nieren bindt AVP aan de (vasopressine)V2-receptoren (V2R), gelegen 
aan de basolaterale (interstitiële) zijde van hoofdcellen van de verzamelbuis. Als 
gevolg hiervan wordt een signaaltransductie route geactiveerd, wat leidt tot een 
verplaatsing van Aquaporin-2 (AQP2) waterkanalen vanuit celblaasjes naar de apicale 
membraan (luminale zijde). Water komt via de AQP2 waterkanalen de cel binnen en 
stroomt vervolgens via de AQP3 en AQP4 waterkanalen in de basolaterale membraan 
richting het bloed, hetgeen leidt tot een concentrering van de urine. Als de hoeveelheid 
AVP vervolgens weer afneemt, door bijvoorbeeld het drinken van water of het 
terughalen van water uit pro-urine, verlaagt het bloed AVP niveau en verdwijnen de 
AQP2 waterkanalen van de celmembraan, waardoor water niet langer de cellen kan 
passeren.
Hoewel onze kennis over de hormonaal geïnduceerde translocatie van AQP2 van en 
naar de apicale plasma membraan en de onderliggende moleculaire mechanismen de 
afgelopen jaren enorm is toegenomen, zijn er nog steeds grote delen van de AQP2 
regulatie onopgehelderd. Het belangrijkste doel van dit proefschrift was het verkrijgen 




Voor dit doeleinde hebben we gekeken welke eiwitten binden aan AQP2. Dit 
resulteerde in de identificatie van Lyst interacting protein 5 (LIP5) als nieuw AQP2- 
bindend eiwit (hoofdstuk 2). De aminozuren 230-243 in het C-terminale deel van 
AQP2 zijn essentieel voor de binding met LIP5 en deze binding is onafhankelijk van de 
fosforylatie en ubiquitinering van AQP2, dat meer C-terminaal in het molecuul 
plaatsvindt. LIP5 maakt deel uit van een uitgebreid eiwit complex (ESCRT complex), 
dat een rol speelt bij de insnoering van membraan eiwitten in de blaasjes van 
mutivesicular bodies (MVBs), waarvandaan eiwitten naar de lysosomen worden 
getransporteerd voor verdere afbraak. Het verwijderen van LIP5 uit de cel met behulp 
van shRNA technieken remt de afbraak van AQP2. Deze resultaten wijzen op een rol 
voor LIP5 in de afbraak van AQP2.
LIP5 bezit drie geconserveerde domeinen, welke betrokken zijn bij eiwit-eiwit 
interacties, een C-terminaal VSL (Vta1/SBP1/LIP5) domein en twee N-terminale 
microtubule interacting and transport (MIT) domeinen (MIT1 en MIT2). Vps4, een 
ATPase dat betrokken is bij het ontmantelen en recyclen van het ESCRT complex, 
bindt het VSL domein van LIP5. Een tweetal andere ESCRT eiwitten binden LIP5 
middels het MIT2 domein. In hoofdstuk 3 laten we zien dat AQP2 het MIT1 domein 
van LIP5 bindt. Wanneer één van drie leucines (Leu 230, 234 of 237) in het LIP5 
bindende deel van AQP2 (230-243) wordt veranderd naar een alanine bindt LIP5 niet 
meer. Structuur voorspellingen van het gebied Leu 230-Leu 237 laten zien dat dit deel 
van AQP2 vermoedelijk een helix vormt, waarbij Leu 230, 234 and 237 een hydrofoob 
gedeelte vormen. Hoewel andere AQPs, zoals AQP0, AQP1, AQP4, AQP5 en AQP6 , 
mogelijkerwijs ook een dergelijke helix vormen, bindt alleen AQP6  ook aan LIP5. 
Daarbij is AQP6  de enige andere AQP, naast AQP2, die over drie leucines in het C- 
terminale deel beschikt. Deze bevindingen onderschrijven het belang van deze leucines 
voor de interactie met LIP5.
De lokalisatie van LIP5 in verschillende epitheliale weefsels wordt beschreven in 
hoofdstuk 4. Met behulp van human tissue microarrays (TMAs) kan worden 
aangetoond dat LIP5 volop tot expressie komt in een groot aantal humane epitheliale 
cellen en weefsels, inclusief nier, speekselklier, bijnier, huid, prostaat, zaadblaasjes, 
bronchiaal epithelium en kraakbeen, ectocervix, ileum, colon, endometriale klieren, 
oviduct en testis. Daarnaast komt LIP5 tot expressie in groot aantal muizen weesfels, 
inclusief speekselklier, oog, hersenen, lever, maag, ileum en blaas. Zowel AQP5, het 
waterkanaal dat volop aanwezig is in de speekselklier, als AQP0, het waterkanaal dat 
hoog tot expressie komt in lens fiber cellen van het oog, lijken op dezelfde plaats tot 
expressie te komen als LIP5. Daarentegen komt AQP4, het waterkanaal dat zich in de 
glia cellen van de hersenen bevindt, en LIP5 niet tot expressie in dezelfde cellen. De 




Hoewel een verlaging van AVP niveaus in het bloed de reabsorptie van water 
vermindert, spelen ook andere hormonen, zoals ATP, dopamine, endotheline en 
prostaglandine E2 (PGE), een rol bij het remmen van AQP2-gemedieerd water 
transport. Hoofdstuk 5 beschrijft een deel van het moleculaire mechanisme dat ten 
grondslag ligt aan de door ATP-geïnduceerde vermindering van AQP2-gemedieerde 
water reabsorptie. Voor dit doeleinde hebben we gebruik gemaakt van gepolariseerde 
niercellen, die na stimulatie met AVP endogeen AQP2 tot expressie brengen op de 
apicale membraan (mpkCCD cellen). Gelijktijdige incubatie van deze cellen met AVP 
en ATP resulteert in de internalisatie en verminderde membraan expressie van AQP2. 
Om te achterhalen welke ATP receptoren (P2 receptoren) hierbij mogelijk een rol 
spelen, hebben we de expressie en lokalisatie van deze receptoren in mpkCCD cellen 
bestudeerd. AVP induceert de expressie van de P2 X1 receptor op de apicale membraan 
en de translocatie van P2 Y1 receptoren naar de apicale membraan en P2 Y4 receptoren 
naar de basolaterale membraan. Daarnaast komen P2 Y1 and P2 Y4 receptoren tot 
expressie op de apicale membraan van deze cellen onafhankelijk van de aanwezigheid 
van AVP. Wanneer ATP uitsluitend aan het apicale of basolaterale medium wordt 
toegevoegd, wordt AQP2 nog altijd geïnternaliseerd. Dit wijst erop dat zowel apicale 
als basolaterale P2 receptoren een rol kunnen spelen in ATP-geïnduceerde internalisatie 
van AQP2. Wanneer we verschillende P2 receptoren samen met AQP2 tot expressie 
brengen in oocyten en we deze receptoren vervolgens activeren met ATP, laten oocyten 
die P2 X2, P2 Y2 of P2 Y4 receptoren tot expressie brengen een sterk verlaagde water 
permeabiliteit zien. Deze resultaten onderschrijven eerdere bevindingen dat ATP 
AQP2-gemedieerd water transport kan remmen middels activering van P2Y2 
receptoren op de basolaterale membraan. Daarnaast wijzen deze resultaten tevens op 
een rol voor apicale P2 receptoren in de remming van AVP-geïnduceerd water 
transport.
Hoofdstuk 6  beschrijft de mechanismen waar ATP en dopamine gebruik van maken bij 
het remmen van AQP2-gemedieerd water transport. Zoals beschreven voor ATP in 
hoofdstuk 5, leidt gelijktijdige incubatie van mpkCCD cellen met dopamine eveneens 
tot internalisatie en verminderde membraan expressie van AQP2. Deze vermindering 
van AQP2 expressie kan voorkomen worden door gelijktijdige incubatie met 
chloroquine, een remmer van lysosomale afbraak. Dit wijst erop dat ATP en dopamine 
de cel aanzetten tot lysosomale afbraak van AQP2. Deze afbraak wordt voorafgegaan 
door mono-ubiquitinering van AQP2. Eerder is aangetoond dat zowel verwijdering van 
AVP als activering van proteine kinase C (PKC) mono-ubiquitinering van AQP2 tot 
stand kan brengen. Daarnaast verlagen ATP en dopamine beiden de cAMP productie in 
AVP-gestimuleerde cellen. Deze laatste bevinding suggereert dat ATP en dopamine 
bepaalde receptoren activeren die via het inhiberende Gi eiwit een signaal transductie 
pas op gang brengen. Welke receptoren hier een rol in spelen, is momenteel 
onduidelijk. Behalve effect op de internalisatie, de afbraak, en de mono-ubiquitinering 
van AQP2, hebben ATP en dopamine ook effect op de fosforylatie van AQP2. Al
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jarenlang is bekend dat AVP de fosforylatie van de serine op plaats 256 van AQP2 
teweegbrengt, wat leidt tot de translocatie van AQP2 van de blaasjes naar de 
membraan. Echter, in hoofdstuk 6  wordt beschreven dat ATP en dopamine de serine op 
plaats 261 fosforyleert, één van de drie overige fosforylatie plaatsen van AQP2. Het 
fysiologische belang van deze bevinding dient nog verder onderzocht te worden.
Gezien de belangrijke rol van AQP2 in de regulatie van de waterbalans, is het niet 
verrassend dat AQP2 een rol speelt bij verschillende aandoeningen waarbij de 
waterbalans verstoord is. Één van deze aandoeningen is congenitale (aangeboren) 
Nefrogene Diabetes Insipidus (NDI), waarbij de nieren niet in staat zijn om de urine te 
concentreren in reactie op de afgifte van AVP Dit resulteert in polyurie (frequent 
urineren) en polydipsie (verhoogd drinken) in patiënten met NDI. Congenitale NDI kan 
X-chromosomaal overerven, veroorzaakt door mutaties in het gen dat codeert voor de 
V2R, of recessief overerven, als gevolg van mutaties in het AQP2 gen. Ondanks 
verscheidende ontwikkelingen in de behandeling van NDI, kan deze aandoening nog 
altijd niet genezen worden. Één van de strategieën om een nieuwe therapie voor de X- 
chromosomaal overervende vorm van NDI te ontwikkelen, is het zoeken naar een 
manier om AQP2 op de celmembraan tot expressie te brengen, maar de AVP-V2R- 
cyclisch AMP (cAMP) signaaltransductie route te vermijden. In eerste instantie werd 
gedacht dat men uitsluitend door middel van de activering van het cAMP 
signaaltransductie systeem in staat was om AQP2 vanuit de blaasjes op de membraan te 
krijgen. Onlangs is gebleken dat activering van het cyclisch GMP (cGMP) 
signaaltransductie systeem met behulp van stikstofoxide (NO) donoren, zoals 
natriumnitroprusside (SNP) en NONOate, of met L-arginine, het stikstofoxide synthase 
(NOS) substraat, eveneens een translocatie van AQP2 vanuit de blaasjes naar de 
plasmamembraan teweegbrengt. Ook het atrium natriuretisch peptide (ANP), dat de 
cGMP niveaus in de cel verhoogt door activering van het membraan-gebonden 
guanylyl cyclase, stimuleert de translocatie van AQP2. Echter, hoofdstuk 7 beschrijft 
dat activering van het cGMP signaaltransductie systeem in mpkCCD cellen niet leidt 
tot een verhoging van AQP2 expressie. Aangezien V2R activering de cAMP niveaus in 
de cel doet toenemen en cAMP de transcriptie van AQP2 verhoogt, is de AQP2 
expressie sterk verminderd in de afwezigheid van functioneel V2R. Deze resultaten 
tonen aan dat het gebruik van activatoren van het cGMP signaaltransductie systeem 
mogelijkerwijs toepasbaar zouden kunnen zijn om patiënten met de X-chromosomaal 
overervende vorm van NDI te behandelen, maar dat een combinatie met een middel, 
dat de AQP2 expressie kan verhogen, noodzakelijk zal zijn.
De ontdekking van nieuwe eiwitten, zoals LIP5, die aan AQP2 binden en van invloed 
zijn op het functioneren van AQP2, draagt bij aan onze kennis over de werking van dit 
waterkanaal. Daarnaast blijken vele hormonale factoren, behalve AVP, een aanzienlijke 
rol te spelen in de regulatie van AQP2-gemedieerd water transport. Het verder
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identificeren van de receptoren en onderliggende mechanismen, die hierbij betrokken 
zijn, kan in de toekomst zeker van belang zijn. Zoals beschreven voor het cGMP 
signaaltransductie systeem, kan een beter begrip van de fysiologische regulatie van 
AQP2 bijdragen tot het vinden van een mogelijke therapie voor verschillende 
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